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A/E Attaching and Effacing
AP-1 Activator Protein-1
BF Factor B
CCP Complement Control Protein
CFHR Complement Factor H Related proteins
CSF-1 Colony Stimulating Factor-1
D+HUS  Diarrhoea-associated Haemolytic Ura-
emic Syndrome
DRM Detergent Resistant Membranes
EDTA Ethylenediaminetetra-acetic Acid
EHEC Enterohaemorrhagic Escherichia coli
ECP Escherichia coli Common Pilus
ER Endoplasmic Reticulum
ESC Escherichia coli Secretion Apparatus
ESP Escherichia coli Secreted Proteins
FACS Fluorescence Activated Cell Sorting
FCS Fetal Calf Serum
FITC Fluorescein Isothiocyanide
Gb3 Globotriaosylceramide
GMVECs  Glomerular Microvascular Venous  
Endothelial Cells
HBSS Hanks Balanced Salt Solution
HD Haemodialysis
HEP Heparitinase I
HF1 Factor H
HPTLC  High Pressure Thin-Layer  
Chromotography
HS Human Serum
HSA Human Serum Albumin
HS Heparan Sulfate
HSPG Heparan Sulfate Proteoglycans
HUS Haemolytic Uraemic Syndrome
HUVECs  Human Umbilical Venous Endothelial 
Cells
IEC Intestinal Epithelial Cell
IF  Factor I
IL  Interleukin
LEE Locus of Enterocyte Effacement
LPS Lipopolysaccharide
MAC Membrane Attack Complex
MAPK  Mitogen Activated Protein  
Kinase-system
MCP Membrane Cofactor Protein
NBCS New Born Calf Serum
NF-κB Nuclear Factor Kappa B
PBS Phosphate Buffered Saline
PD Peritoneal Dialysis
PE R-phycoerythrin
PMN Polymorphonuclear leukocytes
RCA  Regulators of Complement  
Activation-locus
RNA Ribonucleic Acid 
SAP Serum Amyloid P
SCR Short Consensus Repeats
SDS Sodium Dodecyl Sulfate
SDS-PAGE  Sodium Dodecyl Sulfate- Poly  
Acrylamide Gel Electrophoresis
SNP Single Nucleotide Polymorphism
STEC  Shiga-like Toxin producing  
Escherichia coli
STP  Serine, Threonine and Proline-rich 
domain
Stx Shiga-like toxin
StxB Shiga-like toxin B-subunit
TCA Trichloroacetic Acid
TGN Trans-Golgi Network
TIR Translocated Intimin Receptor
TNF-α Tumor Necrosis Factor Alpha
TTSS Type Three Secretion System
VWF Von Willebrand Factor
WPbs Weibel Palade bodies
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1.1  General introduction
1.2 Aims & outline of the thesis
The secret recipe of HUS
to exposure of the Thomsen-Friedenreich crypt- 
antigen, resulting in the clinical picture of HUS. 
This thesis is focusing on Escherichia coli O157:H7 
which is a Gram-negative anaerobic micro-organism. 
The most important virulence factor of this bacte-
rium is the synthesis of Shiga-like toxin (Stx). This 
type of Escherichia coli is therefore called: Shiga-
like toxin-producing Escherichia coli (STEC). Other 
important virulence factors are the presence of the 
gene for a specific type of Stx, called Stx2 and the 
intimin-protein encoding eae-gene (10). 
This bacterium can be detected as a normal commen-
sal in the colon of cattle and domestic animals like 
sheep, pigs, goats and dogs. It will reach the human 
food chain from these animal sources, mainly by con-
tamination of meat in slaughter houses (especially 
ground beef) or other food products that could have 
been in contact with animal droppings (dairy prod-
ucts, fruit and vegetables).  But also water can be 
contaminated and person-to-person transmission 
has been described (11). The last break-out in The 
Netherlands was most probably caused by contami-
nated ‘steak tartar’ (12). Recently, Heuvelink et al de- 
scribed the incidence of STEC on petting farms (13). 
The typical course of infection-induced HUS is onset 
of diarrhoea which becomes bloody in 90% of pa-
tients. In 85% there will be spontaneous resolution, 
but 15% will develop HUS (1). This occurs especially 
in younger children and elderly. It is still not clear 
why these age groups have a predisposition. 
 2.2 The toxin
 Stx is an exotoxin consisting of an AB5 structure. 
The A- and B-subunits are non-covalently bound. 
The B-subunits can bind the toxin, whereas the 
A-subunit is the enzymatically active part of the 
toxin (14). The toxin can be internalised into tar-
get cells, after binding to a specific receptor, called 
globotriaosylceramide-receptor (Gb3, or CD77) (15). 
This receptor can be detected in the kidney on 
glomerular endothelial cells and cortical tubules 
and does not vary with age (16).
The A-subunit is cytotoxic because it disables ribo-
somes. It functions as RNA N-glycosidase. In the cy-
tosol, it removes one adenine from the 28S rRNA 
of the 60S ribosomal unit and thereby inhibits the 
elongation factor 1–dependent aminoacyl-tRNA 
binding to the ribosome (17, 18). This will lead to an 
 Chapter 1.1 
 Introduction
 1 The disease
 The haemolytic-uraemic syndrome (HUS) is a clin-
ical trias consisting of micro-angiopathic haemo-
lytic anaemia, thrombocytopenia and acute renal 
failure (1). There are various underlying pathogenic 
mechanisms (2). Two of the most occurring causes 
are infection-induced and disorders of complement 
regulation (non-Stx HUS). Both mechanisms will be 
explained in this introduction. It can also be found 
with defective cobalamine metabolism, quinine-in- 
duced or associated to clinical entities like HIV, ma- 
lignancies, transplantation and auto-immune disea-
ses. 
There are no proven effective therapies to arrest the 
devastating renal damage induced by both inflam-
mation and coagulation. Since specific treatment is 
still lacking, more knowledge is urgently needed. 
Until now, the mechanism of disease is partially ‘a 
secret recipe’. 
 2 Infection-induced HUS
 This cause of HUS is often preceded by (bloody) 
diarrhoea. This clinical feature combined with the 
classical elements of HUS trigger paediatricians to 
consider the diagnosis of infection-induced HUS.
 2.1 The bacteria
 Different pathogens can cause HUS. The most 
abundantly isolated organism in approximately 50% 
of patients with HUS is Escherichia coli with sero- 
type O157:H7 (O: type of LPS and H; type op flagel- 
lum) (3, 4). Manning et al discovered by SNP-analy- 
sis nine different clades (group of micro-organism 
originating from an identical ancestor) of which 
clade 8 has acquired critical factors that contribute 
to more severe disease (5). However, other sero- 
types of Escherichia coli are increasingly identified 
like O26:H11, O91:H21, O103:H2, O111:H8, O113:H21, 
O145:H28/H25 and O157:non-motile (6, 7). This un- 
derlines the rising importance of non-O157:H7 sero- 
types, although patients with O157:H7 serotypes re- 
quire dialysis for a longer time and had bloody diar- 
rhoea more often (8).  Also Streptococcus pneumoniae 
can be the causative micro-organism in HUS (9). 
This pathogen releases neuraminidase which leads 
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a type III secretion system (TTSS) to transfer its 
components to the IEC. This is a multi-component 
organelle assembled by a group of proteins, called 
ESC (Escherichia coli secretion apparatus) (28). 
After the TTSS is fi nished, microbial proteins 
(Escherichia coli-secreted proteins (ESP)) are relea-
sed into it to produce a pore in the IEC. The pore 
will create an easy accessible pathway between 
STEC and IEC. To optimize the attachment, ESP 
are released into the IEC to initiate the A/E lesion. 
This will lead to aggregation of actin and rearran-
gements of the cytoskeleton, forming a pedestal 
and effacing the microvilli. To fi nally attach STEC, 
the translocated intimin receptor (TIR) is transport-
ed over the TTSS and inserted in the IEC. The recep-
tor can bind to intimin which is present on the outer 
membrane of STEC (29). With this binding, STEC 
can closely adhere to the IEC.
The attachment of STEC to IEC is demonstrated in 
fi gure 1.
  Figure 1 Attachment of Stx to IEC and passage 
of Stx
STEC adheres to the IEC. After assembly of the 
TTSS, the bacterium is able to insert microbial prod-
ucts like ESP and Stx into the cell. ESP induces the 
formation of a pedestal to optimize the adherence. 
This pedestal can be seen in B. Both Stx and ESP 
trigger the IEC to produce IL-8 which attracts poly-
morphonuclear leukocytes (PMN). Stx can cross the 
IEC both trans- and paracellular.
work of Newburg et al that reported a lower amount 
of Gb3 on erythrocytes of children with HUS as de-
termined with high-pressure liquid chromatogra-
phy (35). The group of Bitzan et al confi rmed the 
binding of Stx to human erythrocytes in vitro (36). 
However, Robson et al could not fi nd a protective 
role of the Pk-antigen for the development of HUS 
(37). Also, te Loo et al could not measure a binding 
of Stx to erythrocytes (38). Until now, there are no 
indications that Stx uses erythrocytes as a carrier 
to reach the renal endothelium.
 2.3.2.B Platelets
 In patients with HUS, thrombocytopenia caused 
by platelet consumption is present. This indicates 
a role for platelets in the pathogenesis of HUS. If 
Stx can directly bind and activate platelets is ex-
tensively discussed. There are in vitro experiments 
that demonstrate the binding of Stx to platelets 
(39, 40, 41). Platelets were found to carry Gb3-re-
ceptors and Stx can also bind to a glycosphingo-
lipid identifi ed as band 0.03 specifi cally found on 
platelets (39). In the systemic circulation of HUS-
patients, platelets are found to be activated and de-
granulated, and serum from HUS-patients induced 
adhesion and aggregation of normal platelets (42). 
Guessous et al demonstrated the ability of Stx to in-
duce human microvascular endothelial cells to re-
lease chemokines and other factors that stimulate 
platelet function (43). However, other publications 
did not demonstrate a direct binding of Stx to plate-
lets (38, 44).
 2.3.2.C Polymorphonuclear leukocytes
 Another possible carrier for Stx in the circula-
tion is the polymorphonuclear leukocyte (PMN). 
Different groups demonstrated an increased ac-
tivation of PMN in HUS with a damaging effect 
on the endothelium. This was demonstrated by 
changed markers of degranulation (an increase in 
α-1 antitrypsin complexed elastase in serum, de-
creased endothelial cell fi bronectin, CD16- and 
CD11b-expression and intracellular granule content 
in PMN) and functional studies (a reduced degranu-
latory capacity and reactive oxygen species gen-
eration, an impaired antibody-dependent cellular 
cytotoxicity, and a more intense binding of PMN 
to endothelium) in patients with HUS (45, 46, 47, 
inhibition of peptide elongation and consequently 
an overall inhibition of protein synthesis in target 
cells like the renal glomerular endothelial cells (19).
There are two different families of Stx, called Stx1 
(with variants Stx1c and Stx1d) and Stx2 (with vari-
ants Stx2c, Stx2d, Stx2d- and Stx2e). Especially 
STEC producing Stx1, Stx2 and Stx2c can be isola-
ted from HUS-patients (7). However, also Escherichia 
coli O157 strains which did not produce Stx were 
detected in patients with HUS (20). This can be 
inherently Stx-negative strains or strains which 
loose the Stx gene during infection (21). This initi-
ated an intensive search for other non-Stx virulence 
factors that can play a role in the pathogenesis of 
HUS. Discovered candidates are cytolethal disten-
ding toxin (22), EHEC haemolysin (23), and subtilase 
cytotoxin (24). These novel proteins are discussed 
in chapter 5. More research is necessary to under-
stand their role in HUS.
 2.3 The journey of Stx
 STEC is a non-invasive bacterium which has fasci-
nating mechanisms to transport Stx across the in-
testinal barrier and into the circulation in order to 
reach its main target, the renal endothelium.
 2.3.1 Passage of Stx across the intestinal wall
 After surviving the acidity of the stomach, the 
ingested STEC will adhere to intestinal epithelial 
cells (11). It was generally assumed that the colon 
and perhaps also the distal ileum were the prefer-
red sites for colonization. The human intestinal 
epithelial cells (IEC) do not have a specifi c recep-
tor for STEC. Rendon et al demonstrated with ad-
herence assays combined with mutagenesis that 
STEC can use a pilus (polymeric adhesive fi ber) 
called E coli common pilus (ECP) for the facilitation 
of initial attachment and subsequent colonization 
(25). After adherence, STEC H7 fl agellin can inter-
act with Toll-like receptor 5 on IEC which directly 
up-regulates its production of pro-infl ammatory 
chemokines (26). Moreover, the micro-organism 
is able to insert a ‘home-made’ receptor into the 
IEC. To achieve this, STEC must carry the genetic 
information to create attaching and effacing (A/E) 
lesions. Proteins involved in this lesion are encoded 
by genes on a pathogenicity island called the locus 
of enterocyte effacement (LEE) (27). STEC uses 
With the completed TTSS, Stx can be released into 
the IEC. Acheson et al demonstrated that biologi-
cally active Stx1 is capable of moving across intact 
IEC without cellular disruption (30). This occurred 
in an energy-dependent and saturable manner. 
Other data suggested that Stx is not just moving 
passively across the IEC, but also stimulates IEC 
to produce the chemokines like interleukin-8 (31). 
The group of Acheson also described that STEC 
interaction with IEC induces neutrophil recruit-
ment to the intestinal lumen (32). This mechanism 
increases the paracellular permeability which in 
parallel increases the amount of Stx that passes 
into the underlying tissues. This will lead to an in-
creased risk of HUS. It needs to be mentioned that 
the work on the transport of Stx is performed on 
colonic carcinoma cell lines, which carry Gb3-
receptors. This receptor, however, was never de-
tected on normal human colon. But, recent work 
from Schuller et al described experiments showing 
binding of Stx to Paneth-cells in both normal and 
infl amed intestinal tissue (33). These cells contain 
antimicrobial agents like α-defensins and lysozyme, 
and are specifi cally present in the small intestine. 
The presence of Gb3-receptors on Paneth cells could 
be detected with an antibody against Gb3. This new 
fi ndings will need more research to investigate the 
functional aspect and possible involvement in the 
pathogenesis of STEC induced HUS.
 2.3.2 Passage of Stx in circulation
 After Stx reaches the circulation, it has to be 
transported to the renal endothelium. Stx was never 
detected in the blood of HUS-patients. Therefore, a 
carrier was suggested. Many possibilities have been 
discussed in the literature.
 2.3.2.A Erythrocytes
 Erythrocytes are the cells most abundantly 
present in the circulation. These red blood cells also 
carry a Gb3-receptor. Gb3 is the Pk-antigen of the P 
blood group system (15). This antigen is present on 
almost all types of erythrocytes, but can vary in ex-
pression. This indicates that erythrocytes could have 
a protective role in HUS by catching Stx out of the 
circulation. Taylor et al demonstrated that erythro-
cytes from patients with HUS express a weak or 
absent Pk-antigen (34). This was underlined by the 
General introduction
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 2.3.4 Effect of Stx on renal 
 non-endothelial cells
 Since Stx was detected bound to tubular cells in 
renal biopsies of HUS-patients, researchers were 
interested in the effect of Stx on renal cells other 
than endothelial (16). Work of Hughes et al de-
scribed the cytotoxicity of Stx on glomerular epi-
thelial cells which also express the Gb3-receptor 
(70). Furthermore, this group demonstrated a sti-
mulation of cytokine production by these cells (71). 
Recently, Morigi et al reported that Stx induced 
the production of endothelin-1 in murine podo-
cytes, thereby modifying podocyte cytoskeleton 
and formation of intercellular gaps (72). This da-
mage may occur after the primary insult of the en-
dothelial cells. After perturbation of the endothe-
lial cells and increasing the permeability of the re-
nal fi lter, Stx can reach the proximal tubular cells. 
These cells also express Gb3 and urinary markers 
of proximal tubule damage are elevated ear-ly in 
the course of HUS (73). Stx is capable of stimula-
tion of these cells to produce cytokines (IL-1, IL-6 
and TNF-α). 
 3 Disorders of complement regulation
 Last few years, research for HUS resulted in an 
enormous amount of knowledge on non-Stx HUS. 
This form of HUS does not have a prodromal phase 
with bloody diarrhoea, but the clinical picture is 
identical. It can occur both sporadic and in families. 
The prognosis of non-Stx HUS is considered to be 
unfavourable with 50% of patients progressing into 
end-stage renal disease and 25% dying in the acute 
phase (74). 
The extensive search for causes of non-Stx HUS 
resulted in a paper published by Warwicker et al 
in which they described the segregation of non-
Stx HUS to the q32 region of chromosome 1 (75). 
This chromosome contains a region of complement 
control proteins called ‘regulators of complement 
activation-locus (RCA)’.
The complement system is part of the innate 
immunity and is divided in three different path-
ways according to the initiating element (76). 
All pathways have the same goal: the formation of 
the membrane attack complex (MAC; C5b-C9). This 
complex can induce lysis of bacteria and cells. When 
a bacteria needs to be eliminated, this is a very 
 2.3.3 Arrival at target cell and intracellular  
 traffi cking
 The toxin can be internalised after binding to 
its specifi c receptor, Gb3. In earlier work, it was 
described that Stx would enter the cell through 
a clathrin-dependent pathway. However, clathrin-
independent pathways are involved as well (59, 60). 
Interestingly, not every cell carrying a receptor for 
Stx is sensitive for the cytotoxic effect of Stx. In 
monocytes/macrophages, Stx has a stimulating ef-
fect. In these cells, which are totally resistant to the 
cytotoxic function of Stx, the toxin is effectively de-
graded in lysosomes after having activated the cell 
(61). However, in toxin-sensitive cells such as Vero 
cells and cancer cell lines, Stx is able to escape lyso-
somal degradation and can become cytotoxic after 
reaching the cytosol (62). In these cells, Stx follows 
the retrograde transport route. Both intracellular 
pathways are depicted in fi gure 2.
 Figure 2 Intracellular pathways of Stx
Adapted from and reprinted by permission from 
Macmillan Publishers Ltd: Kidney International 
(70, 2049-2051), copyright (2006).
In retrograde transport, Stx will be able to bypass 
the late endosome and thereby degradation. After 
internalizing, Stx is transported from early endo-
somes to the trans-Golgi network (TGN) and Golgi 
apparatus (63). This route is controlled by spe-
cifi c proteins (SNARE, Rab) involved in membrane 
exchange between intracellular compartments 
(64). After reaching the Golgi apparatus, Stx is 
effi ciently transported to the endoplasmic reticu-
lum (ER) (65). Once Stx arrive in this compartment, 
it ‘misuses’ the endoplasmic reticulum-associated 
protein degradation pathway to enter the cytosol 
(66). Yu and Haslam demonstrated a complex con-
sisting of Stx and HEDJ. This protein is a chaperone 
for the transport from the ER to the cytosol (67). 
When Stx will enter the cytosol, the A-subunit is al-
ready cleaved by the enzyme furin. This step is es-
sential for rapid intoxication of the cell (14).
Recent literature on intracellular traffi cking has 
focused on the large variability in the sensitivity for 
Stx in relation to its targeting to one of the above 
mentioned pathways. One hypothesis was that there 
existed a difference in expression of different mole-
cular species of Gb3 on different cell types (15, 68). 
Interestingly, work of Falguieres et al, demonstrated 
the infl uence of detergent-resistant membranes 
(DRM; also called ‘lipid rafts’) on the traffi cking path-
way (54). Evidence was provided that association 
of B-subunits with Gb3-receptors in DRM targeted 
Stx into retrograde transport. A distinct difference 
in presence of Gb3-receptors in DRM between Stx-
sensitive cells like HeLa-cells and Stx-insensitive 
cells like monocytes was demonstrated. This could 
indicate that different molecular species of Gb3 will 
associate with different areas in the cell membrane, 
thereby infl uencing the intracellular pathway of Stx. 
Another interesting fi nding concerning the intracel-
lular traffi cking is that next to endocytosis, Stx acti-
vates Syk and induces rapidly tyrosine phosphoryla-
tion of several proteins in Stx-sensitive cells (69). 
This indicates that next to an inhibitory effect 
on protein synthesis, Stx is also able to activate sen-
sitive cells.
48). This, again, raised the question whether Stx 
did have a direct or indirect effect on PMN. Finally, 
te Loo et al described in their work a selective bind-
ing and transfer of Stx to PMN both in vitro and in vivo 
(38, 49). Also, Brigotti et al could detect Stx bound 
to PMN in the blood of HUS-patients with fl ow cy-
tometry (50).  But in contrast to the work of te Loo 
et al, Fernandez et al were not able to demonstrate 
a direct binding of Stx to PMN (48). Furthermore, 
Holle et al could not determine an activation of PMN 
by Stx in vitro (51). This indicates that the question if 
Stx is bound by PMN does not have a clear answer. 
This will form part of the research in this thesis.
 2.3.2.D Peripheral blood monocytes
 The monocyte is another candidate to be the car-
rier of Stx. Several groups have detected a specifi c 
receptor for Stx on monocytes (52, 53, 54). After 
internalizing, Stx activates the monocytes in con-
trast to its cytotoxic effect in epithelial cells. This 
intracellular pathway will be discussed in chapter 
2.3.3. In short, the activation of monocytes by Stx 
consists of initiation of the mitogen activated pro-
tein kinase-system (MAPK), nuclear translocation of 
nuclear factor-κ B, and secretion of pro-infl amma-
tory cytokines like tumor necrosis factor-α and in-
terleukin-6 (52, 55, 56). Since the binding of Stx to 
monocytes is well-established, it was hypothesized 
to be the transport-mechanism. The performed ex-
periments on this topic are presented in this thesis.
 2.3.2.E Other possible carriers
 Another possible carrier is a neutralizing factor 
for Stx2 in human blood, detected by Kimura et al 
(57). After purifi cation, the protein was identifi ed as 
serum amyloid P (SAP) which is a highly conserved 
normal human plasma protein and not present in 
other species. To investigate the function of this 
binding, Armstrong et al determined the amount 
of circulating SAP in patients with HUS (58). There 
was no difference in concentration of SAP detected 
between patients with HUS and control-patients. 
This indicates that the level of SAP can not predict 
whether an individual will develop HUS.
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effi cient system. But the effi ciency of this system 
depends on a tight control that will prevent non-
specifi c damage to host cells. 
The proteins involved in the pathogenesis of non-Stx 
HUS can be found in the alternative pathway, which 
is activated by components of the bacterial cell wall. 
This will lead to formation of C3 convertase which 
cleaves protein C3 into C3b. Furthermore, in plasma 
there continuously is a spontaneous hydrolysis of 
C3 to C3(H20), which is equal to C3b in functionality. 
C3b is a highly reactive protein. It has two options 
for binding. When it binds to a bacterium, it will in-
teract with circulating complement proteins called 
factor B and factor D. This will lead to the formation 
of the MAC and the bacterium will be destroyed. The 
other possibility is that C3b will bind to a host cell 
like an endothelial cell inducing damage with cell ly-
sis, increased expression of adhesion molecules and 
coagulation factors and the attraction of monocytes 
and PMN. However, because of a polyanionic coating 
on the host cell (like sialic acid or heparan sulfate 
proteoglycans), regulatory complement protein fac-
tor H (HF1) will preferentially bind to C3b instead of 
factor B. Factor H has a higher binding affi nity than 
factor B. Together with other regulatory proteins 
called Membrane Cofactor Protein (MCP) which is 
membrane-bound and the circulating factor I (IF), 
C3b is inactivated. This mechanism is demonstrated 
in fi gure 3.
 Figure 3 Inactivation of C3b
Regulatory proteins factor H, factor I (both soluble) 
and MCP (membrane-bound) are involved in the in-
activation of highly reactive C3b on host cells. 
Since the paper of Warwicker et al, mutations in fi ve 
different proteins involved in complement regula-
tion have been described in patients with non-Stx 
HUS. These defective proteins will induce an inap-
propriate regulation of the alternative pathway 
resulting in excessive damage of host-cells like the 
endothelium.
 3.1 Factor H (HF1)
 Figure 4 Factor H
Factor H consists of 20 short consensus repeats. 
The binding domains for C3b are depicted in light 
blue. The units that can bind to heparan sulfate or 
sialic acids are indicated with an arrow. 
The gene for HF1 is localized on the chromosome 1. 
It consists of 23 exons of which exon 10 is cleaved 
out by alternative splicing. The 22 remaining exons 
encode the protein which consists of 20 units, cal-
led ‘short consensus repeats’ (SCR) (see fi gure 4). 
Exon 1 encodes a leader peptide that is cleaved off. 
SCR2 is constructed from 2 exons. HF1 is a single-
chain serum glycoprotein of 150 kDa (77). HF1 func-
tions as a co-factor in the cleavage of C3b. 
More than 50 different mutations in HF1 have been 
detected in patients with non-Stx HUS (78-85). 
Most of the mutations cluster in the region of SCR 
19 and 20, which is critical for control activation 
of complement on cell surfaces (77). In non-Stx 
HUS, HF1 is rarely decreased in plasma (77). Cap-
rioli et al showed that in a group of 156 patients 
with Non-Stx HUS, 30.1% carried a mutation in HF1 
(86). These mutated proteins demonstrate defec-
tive complement regulation on the endothelial cell 
(87, 88). Also, anti-HF1 auto-antibodies against its C-
terminal recognition function have been described 
in patients with non-Stx HUS (89, 90). 
HF1 has fi ve closely related proteins (complement 
Factor H-related protein (CFHR)), called CFHR1 to 
CHFR5. The genes encoding these proteins are also 
present at chromosome 1. Zipfel et al recently de-
scribed that deletion of CFHR1 or -3, is associated 
with an increased risk of HUS. They demonstrated 
 3.3 Membrane Co-factor Protein (MCP)
 Figure 6 Membrane Co-factor Protein
 Complement control protein repeats
 Serine, threonine and proline-rich domain
 Unknown function
Membrane-bound protein MCP consists of 4 comple-
ment control protein modules connected by a trans-
membrane domain and a cytoplasmic tail
MCP is a membrane-bound protein encoded by a 
gene localized on chromosome 1, position 1q32.  The 
gene consists of 14 exons. The protein is a co-factor 
for IF and is composed of four complement control 
protein (CCP) modules that can bind C3b and C4b. 
CCP 1, 2 and 4 carry an N-bound complex sugar-
group. This part is followed by a serine, threonine 
and proline-rich domain (STP), which is subjected 
to alternative splicing. This area is O-glycosylated. 
Then there is a domain with an unknown function, 
followed by a transmembrane domain and a cyto-
plasmic tail. The protein structure of MCP can be 
seen in fi gure 6. The tail is also alternatively spliced. 
In combination with the STP-domain, this will lead 
with a functional assay that these proteins have 
a regulatory role in complement activation (91). 
Interestingly, Jozsi et al reported that anti-HF1 
auto-antibodies correlated with a defi ciency of 
CFHR1 and -3 (92). Furthermore, a hybrid HF1/CFHR1 
gene (exons 1-21 derived from HF1 and exons 22-
23 from CFHR1) was detected in a family with HUS 
by Venables et al (93).
 3.2 Factor I (IF) 
 Figure 5 Factor I
 FI Membrane Attack
 Scavenger Receptor
 Low-density Lipoprotein Receptor
 Unknown function
 Serine protease
Factor I consists of a heavy and light chain, linked by 
a disulfi de bridge
In contrast to the other complement control pro-
teins, the gene for IF is localized on chromosome 4 
(position 4q25). It contains 13 exons. The encoded 
protein consists of a heavy (amino acids 19-335) and a 
light chain (amino acids 340-583). These two chains 
are linked by a disulfi de bridge (fi gure 5). In the ma-
ture protein, a leader-peptide (amino acids 1-19) and 
a cleavage-site (amino acids 336-339) are cleaved 
out. The light chain is the functional serine protease 
domain which is responsible for the cleavage of C3b 
and C4b. In this soluble protein, six mutations have 
been detected in non-Stx HUS patients until now 
(94, 95, 96). Caprioli et al detected a mutation fre-
quency in non-Stx HUS of 4.5% in IF (86).
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monogenic disease. Multiple factors (genetic and 
environmental) are necessary to initiate the patho-
logical process that results in non-Stx HUS. Also, 
combined mutations in 2 different complement 
control proteins (HF1 and IF) have been described in 
patients with non-Stx HUS (105). 
The carriage of a mutation in complement con-
trol proteins can be considered as a predisposing 
factor since a trigger like an infection is still 
necessary to initiate the complement system. The 
question that still remains is why specifically the re-
nal endothelium is subjected to damage of the dys-
regulated complement system?
to four isoforms that co-exist on the cell-membrane. 
More than twenty different mutations have been de-
tected in patients with non-Stx HUS (97-100). Most 
mutations have been detected in the CCP modules. 
12.8% of non-Stx HUS patients carry a mutation in 
MCP (86).
 3.4 Other involved complement proteins
 All mutations described above result in a de-
creased function of a complement control protein. 
This results in an excessive activation of the alter-
native pathway of the complement system. Recent-
ly, Goicoechea de Jorge et al described the opposite: 
gain-of-function mutations in complement factor B 
(BF) (101). After binding of C3b to a cell surface, BF 
will bind to it. Then factor D will cleave it into two 
fragments of which one will form an active serine 
protease that cleaves additional C3 into C3b (102). 
The mutated proteins enhanced formation of the 
serine protease or increased resistance to inacti-
vation by complement regulator proteins, thereby 
amplifying this pathway of the complement system 
and resulting in non-Stx HUS (101). 
Very recently, another involved complement protein 
was described by Blom et al. They detected in 6 out 
of 166 HUS patients a polymorphism in C4b-binding 
protein (103). This protein is also involved in degra-
dation of C3b and functions as a co-factor for IF. The 
polymorphism decreases the ability of the protein 
to bind C3b and thereby its degradation.
 
 3.5 Implications of a mutation in 
 complement control proteins
 A remarkable feature of the above described 
mutations is that in the majority of cases it involves 
a heterozygous mutation. This indicates that the 
presence of 50% normal protein is inadequate to 
prevent excessive complement activation. Further-
more, the presence of a mutation is not sufficient 
to cause non-Stx HUS. There is incomplete pene-
trance with carriers of a heterozygous mutation 
who do not develop the disease. Esparza-Gordillo et 
al speculated that concurrence of different suscep-
tibility alleles influences the predisposition to non-
Stx HUS (96, 104). Also, unaffected mutation car-
riers may still develop the disease at an older age in 
concomitance with pregnancies or infections (86). 
Thus, it appears that non-Stx HUS is not a simple 
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Stx-sensitive cells like HeLa cells. Chapter 3.1 re-
ports about the intracellular trafficking of Stx in its 
target cells in HUS, the glomerular endothelial cells. 
Also the mesangial cells were included. This essen-
tial knowledge was still lacking. 
The Weibel-Palade bodies (WPbs) are an important, 
endothelium-specific storage organelle. It contains 
important mediators for inflammation and coagu-
lation. Chapter 3.2 describes the effect of Stx on 
these components of endothelial cells. Chapter 3.3 
focuses on the inflammatory process on the en-
dothelial cell induced by Stx. The role of heparan 
sulfate proteoglycans (HSPG) in the increased ad- 
hesion of leukocytes was studied. The last chapter 
on the interaction between Stx and endothelium, 
chapter 3.4, describes the efforts to understand the 
dual effect of the toxin. Besides the well-described 
inhibition of the protein synthesis, Stx can also acti-
vate the endothelial cell. 
Chapter 4 represents the work on the dysregulation 
of the complement system in non-Stx HUS. Chapter 
4.1 is a case-report of a non-Stx HUS-patient with 
a novel mutation in IF. The functional defect of this 
mutation was demonstrated by performing a func-
tional assay for the alternative pathway of the com-
plement system.
In chapter 5, the work of this thesis is summarized 
and put into perspective in the general discussion. 
Interesting possibilities for future research are also 
mentioned.
 Chapter 1.2 
 Aims & outline of the thesis
 For many years our research group has contri-
buted to the knowledge of the pathogenesis of HUS. 
Important findings are the up-regulatory effect of 
TNF-α on the presence of the Gb3-receptor; the ac- 
tivating effect of Stx on human peripheral blood 
monocytes; the effect of Stx on its target cell, the 
renal glomerular endothelial cell; and the binding of 
Stx to human PMN. In this thesis we have continued 
our search for a better understanding of the di- 
sease mechanism of HUS. In recent years, impres-
sive new insights have been gained in non-Stx HUS. 
The discovery of the involvement of complement 
control proteins induced a wave of published arti-
cles on this topic. However, our work is still focused 
on HUS associated with Stx, since the pathogenesis 
is still unclear after many years of research. But 
also one article on non-Stx HUS is included. The 
main questions in our search on HUS remain: (1) 
how does Stx reach the kidney? (2) Why does Stx 
specifically damage the kidney? Chapter 2 presents 
the work on the transport mechanism of Stx in the 
circulation. After passage of the toxin through the 
intestinal epithelial cell, it will reach the circulatory 
system. It is assumed that it will bind to a constitu-
ent of the blood, in order to reach its main target: 
the renal glomerular endothelium. Chapter 2.1 is fo-
cused on the possibilities of PMN as a transporter. 
Work of te Loo et al suggested that PMN are the car-
riers of Stx in patients with HUS (38). As at a later 
stage our group and others could not confirm these 
data, new studies were performed. This chapter de-
scribes our efforts to elucidate the interaction of 
Stx with PMN.
Chapter 2.2 describes the data about the human 
monocyte as a possible carrier. The monocyte is 
not sensitive for the cytotoxic effect of Stx, although 
it carries the specific receptor for Stx. This makes it 
a good candidate for transport. 
The major part of this thesis involves the study of 
the toxic and damaging effect of Stx on the en-
dothelium, especially the glomerular endothelium. 
This work is presented in Chapter 3. Many experi-
ments have been published on the intracellular traf-
ficking pathway of Stx. A new intracellular pathway, 
called ‘retrograde transport’, was demonstrated in 
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  Abstract
 Background
 After gastrointestinal infection with Shiga-like 
toxin (Stx) producing Escherichia coli, the toxin is 
transported from the intestine to the renal micro-
vascular endothelium. This is the main target for 
Stx in humans. Previous studies indicated that poly-
morphonuclear leucocytes (PMN) could serve as 
carriers for Stx in the systemic circulation. As at a 
later stage we could not confirm these data, we per-
formed new studies.
 Methods
The binding of Stx1 to PMN was determined in vitro 
(isolated human PMN and whole blood) and in vivo 
(injection in mice). The specificity of binding of an 
antibody against Stx2 to PMN from patients with 
haemolytic uraemic syndrome (HUS) was determi-
ned. This was compared with binding to PMN from 
healthy controls, and patients on haemodialysis or 
on peritoneal dialysis. Furthermore, PMN were incu-
bated with Stx to study possible activation. 
 Results
No specific binding of Stx1 to PMN could be detec-
ted. After intravenous injection of the toxin in mice, 
it was not associated with PMN. The binding of an 
antibody against Stx2 to PMN was detected in both 
patients with HUS and patients after haemodialysis, 
but not in patients on peritoneal dialysis. Stx was 
not able to activate PMN.
 Conclusions
PMN are not acting as transporter for Stx in the 
pathogenesis of HUS. The interaction of a Stx-anti- 
body with PMN from HUS-patients is not specific 
as it can also be observed in patients after hae- 
modialysis (possibly due to activation of the PMN). 
Therefore, binding of Stx-antibody to PMN is not re-
liable as a diagnostic tool for HUS.
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 Introduction
 Shiga-like toxin (Stx, also called verocytotoxin) 
is an important mediator in the pathogenesis of 
the diarrhoea-associated haemolytic uraemic syn-
drome (HUS). Stx is produced by the pathogen Es-
cherichia coli, of which O157:H7 is the serotype most 
commonly involved in HUS (1). In an earlier study 
of 50 isolates of E. coli associated with HUS in The 
Netherlands, 45 were positive for the Stx2 gene and 
five for both Stx1 and Stx2 (106).
As the renal microvascular endothelium is the most 
important target of the toxin, a transport route from 
the intestine to the kidney is postulated. Stx was 
never found in sera from patients with HUS, but Stx2 
could be detected in kidneys from HUS-patients (19). 
Furthermore, antibodies against Stx2 are found in 
serum from patients with HUS (107). After reaching 
the renal endothelium, Stx will initiate cell damage 
with the formation of thrombi in the glomerular ar-
terioles and capillaries (1). Acute renal failure with 
thrombocytopenia and haemolytic anaemia will oc-
cur, which are the hallmark features of HUS.
Earlier work of te Loo et al suggested that circula-
ting polymorphonuclear leukocytes (PMN) trans-
ported Stx2 in patients with HUS (38). However, 
with a new batch of the same antibody, these results 
could not be reproduced. Therefore, binding studies 
with Stx to PMN in vitro were repeated. Also, addi-
tional binding experiments were performed in vivo 
in mice. The interaction of an antibody against Stx2 
with PMN collected from blood of HUS-patients was 
re-evaluated.  It was hypothesized that the antibody 
could bind aspecifically to activated PMN in these 
patients. Consequently, the capacity of PMN to bind 
the antibody against Stx2 was compared between 
healthy controls, HUS-patients, patients treated by 
haemodialysis (HD) and peritoneal dialysis (PD). It 
is known that PMN originating from patients on HD 
are highly activated (108).
In addition, if no binding of Stx to PMN occurs, it can 
be proposed that Stx has no effect on PMN func-
tion. For this reason, the expression of degranula-
tion markers and cell adhesion molecules (CD66b, 
CD63, L-selectin and CD11/CD18) on PMN were stu-
died after incubation with Stx2. 
 Methods 
 Materials
 Purified Stx1 used for the binding experiments was 
kindly provided by Dr. M.A. Karmali (Public Health 
Agency of Canada, Ontario, Canada). The 125I-Stx1 
B-subunit was a gift from Dr. L. Johannes (Institut 
Curie, Paris, France). The unlabelled Stx1 B-subunit 
was a gift from Dr. L. Brunton (University of Toron-
to, Canada). For the stimulation of PMN, Stx2 was 
purchased from Toxin Technology (Sarasota, United 
States). Ethylenediaminetetraacetic acid (EDTA) 
tubes were ordered from BD Vacutainer (Alphen a/d 
Rijn, The Netherlands). Ficoll-PaqueTM PLUS was 
purchased from Amersham Biosciences (Uppsala, 
Sweden). Human Serum Albumin (HSA; Cealb) from 
Sanquin (Amsterdam, The Netherlands) was used. 
Hanks Balanced Salt Solution (HBSS) was ordered 
from MP Biomedicals (Eschwege, Germany).
Monoclonal antibodies against CD66b (FITC-label-
led) and CD63 (PE-labelled) were obtained from 
Coulter/Immunotech (Marseille, France). Antibodies 
against L-selectin, CD11b/CD18 (both FITC-labelled), 
CD13 (PE-labelled) were purchased from DAKO 
(Heverlee, Belgium), as was the secondary goat-anti- 
mouse FITC and goat serum. HBSS without phenol 
red was obtained from Life Technologies (Paisley, 
Scotland), luminol and 12-myristate 13-acetate and 
horseradish peroxidase were purchased from Sigma 
(St Louis, USA).
The antibody against Stx2 was a kind gift from 
Dr. A. O’Brien (Uniformed Services University of 
Health Sciences, Bethesda, USA). This is a well-
characterized, humanized antibody as described 
previously (109). The secondary antibody (goat-anti-
human FITC) for this antibody was purchased from 
Jackson Immunoreseach (Cambridgeshire, UK). The 
Fc-receptor blocker was ordered from Miltenyi Bio- 
tec (Utrecht, The Netherlands). Mouse serum was 
obtained from the Central Animal Laboratory (Nij-
megen, The Netherlands). Lipopolysaccharide (LPS)
was collected from Sigma (St Louis, USA).
 Isolation of polymorphonuclear leukocytes
 Fresh venous blood was drawn and collected in 
EDTA tubes. Blood was diluted two times with PBS 
and centrifuged (30 minutes 400 xg at 4˚C) over 
Ficoll-PaqueTM Plus. After centrifugation, the pel-
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let containing PMN and erythrocytes was collected. 
Erythrocytes were lysed using ammonium chloride. 
This procedure routinely revealed a PMN population 
of over 95%. 
  Binding of shiga-like toxin to isolated human 
polymorphonuclear leukocytes
 After isolation of PMN from healthy donors (n=7), 
cells were washed with PBS and resuspended in 
HBSS containing 1% HSA at 0˚C. During three hours, 
5 x 105 PMN were incubated with 125I-Stx1. Incuba-
tions were performed with different concentrations 
of Stx1 ranging from 0.3 up till 70 nmol/L. Stx1 was 
radio-iodinated according to the Iodogen method. 
To determine non-specific binding, the same incu-
bation was carried out in the presence of a 25-fold 
molar excess of unlabeled Stx1. After the incubation, 
free 125I-Stx1 was separated from the PMN using Fi-
coll-Paque PLUS and cells were washed. Cell-associ-
ated 125I-Stx1 was determined in a gamma-counter. 
The binding of 125 I-Stx1 to monocytes showed an 
adequate Kd value in the Scatchard plot analysis. 
In the glycolipids extracted from human monocytes, 
125I-Stx is bound to Gb3.
 Binding of shiga-like toxin in whole blood
 EDTA-blood from seven healthy human donors 
was obtained. Whole blood (2-2.5 ml) was incubated 
with 125I-Stx1 B-subunit (0.75 μgr, 3 μCi) during 2.5 
hour at 4˚C. 
In order to up-regulate a possible receptor, blood 
from four donors was pre-incubated with LPS (1 μg/ 
ml) during 2 or 16 hours at 37˚C, before adding the 
125I-Stx1 B-subunit. 
To investigate the amount of binding of Stx1 B-sub-
unit to PMN in the circulation, 9 normal SE mice 
(female, age 10 weeks) were injected intravenously 
with 125I-Stx1 B-subunit. A total amount of 3.5 μg 
protein (1 μCi) was administered intravenously 
through the tail vein. In 5 mice all blood was collec- 
ted after 2.5 minutes. Two of these mice were co- 
injected with an excess of unlabelled Stx1 B-subunit 
(100 μg/mouse), to determine the specificity of the 
binding. The amount of unlabelled Stx1 B-subunit will 
saturate the specific Stx1 B-subunit binding sites in 
vivo. In 4 mice blood was collected after 15 minutes. 
One of these mice received 100 μg unlabelled B-sub-
unit. Blood was collected from the orbital plexus. 
Blood from both mice and men, was centrifuged over 
Ficoll-Paque PLUS (30 minutes, 400 xg at 20˚C). 
The different layers (plasma, interphase, Ficoll-Paque 
PLUS, and the pellet containing PMN & erythro- 
cytes) were separated. The interphase was centri-
fuged twice to remove platelets (10 minutes, 200 
xg). Supernatants were also collected. From each 
layer a fraction was counted in a gamma counter for 
the presence of 125I-Stx1 B-subunit. Subsequently, 
the fraction containing erythrocytes and PMN was 
lysed with ammonium chloride and washed. By this 
means, the presence of 125I-Stx1 B-subunit on the 
PMN could be measured. The 125I activity in each 
fraction was calculated. 
  Analysis of binding antibody shiga-like toxin to 
polymorphonuclear leukocytes
 Blood was collected from healthy controls (n=6), 
patients with HUS (Stx present in faeces) (n=3), 
patients on PD (n=3) and patients on HD (n=14). 
After isolation of PMN, cells were incubated with Fc-
receptor blocker (15 μl for 15 minutes) and blocked 
with 10% goat- and mouse serum. Subsequently, 
PMN were incubated with the antibody against Stx2 
followed by goat-anti human FITC. After the incuba-
tions the cells were suspended in paraformaldehyde 
0.5% and analyzed with FACS analyzer. 
Three other antibodies against Stx2 (2 commercial 
and 1 non-commercial) reacted in a variable degree 
with normal PMN. 
  Stimulation of human polymorphonuclear  
leukocytes with shiga-like toxin 
 One hundred μl whole blood from four healthy 
volunteers was incubated with either LPS 1 μg/ml, 
Stx2 0.1 nM, Stx2 10 nM alone or LPS in combination 
with Stx2 (0.1 nM or 10 nM) for 2 h at room tempera-
ture. Subsequently, erythrocytes were lysed using 
ammonium chloride.  PMN were identified by flow 
cytometry (Coulter® Epics® XL-MCL) using their 
morphological criteria and using CD13-PE as specif-
ic marker.  Monoclonal antibodies against CD63 and 
CD66b were used as markers of degranulation. Also 
monoclonal antibodies against L-selectin and CD11b/
CD18 were used to study the expression of adhesion 
molecules. Antigen expression was measured as 
mean fluorescence intensity of 5000 cells by flow 
cytometry. Data acquisition and analysis were per-
formed using XL-2 software (Coulter).
Furthermore, the superoxide production in PMN of 
eight healthy donors was measured after stimula-
tion with Stx2 0.1 nM, Stx2 10 nM, LPS 1 μM alone 
or LPS in combination with Stx2 0.1 and 10 nM for 
10 minutes, 1 hour and 4 hours, respectively. Phor-
bol 12-Myristate 13-Acetate (PMA) was used as a 
positive control. Immediately after the incubation, 
luminol-enhanced chemilumniscence of proteose-
peptone-elicited PMN was measured on a Victor 
1420 counter (Wallac, Turku, Finland) at 37˚C. The 
measurements were performed in 96-well micro-
plates as described previously (110). Each well con-
tained 2 x 105 PMN, 50 μM luminal, and 4.5 U/ml 
horseradish peroxidase in 200 μl of HBSS without 
phenol red, supplemented with 0.25% HSA. Wilco-
xon signed rank test was used to test significance of 
within-group differences. Differences were consid-
ered significant at P<0.05.
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 Binding of shiga-like toxin in whole blood
 To establish whether PMN in whole blood can 
bind Stx, we incubated blood from healthy donors 
(n=7) with 125I-Stx1 B-subunit. The B-subunit of Stx 
is the binding part of the toxin, whereas the A-
subunit will only stimulate the uptake of the toxin 
and does not affect binding (111).
The experiment was performed with and with-
out previous stimulation of the blood with LPS. 
The major part of the B-subunit can be found in 
the plasma. 71% of total activity was detected in 
plasma, whereas 0.09% was found in the fraction 
containing the PMN (n=3). Pre-incubation with LPS 
did not change the amount of bound toxin (0.09% 
and 0.02% of total activity after respectively 2 and 
16 hours pre-incubation (n=4)).  
To investigate the binding of Stx to PMN in vivo, 125I-
labeled Stx1 B-subunit was injected in mice (n=9). 
After 2.5 and 15 minutes, blood from mice was col-
lected and the distribution of the B-subunit in the 
various blood fractions was determined. Stx1 B-sub-
unit rapidly cleared from the blood as is shown in 
fi gure 1. Subsequently, the different cell populations 
were separated and the 125I-Stx1 B-subunit activity 
in each fraction was determined. The major part of 
125I-Stx1 B-subunit was found in plasma. Only a min-
ute fraction of the activity was found in the PMN 
fraction. The addition of an excess of unlabelled 
Stx1 B-subunit did not reduce the activity (table 1). 
 Results 
  Binding of shiga-like toxin to isolated 
polymor-phonuclear leukocytes
 PMN from healthy donors were isolated and in-
cubated with 125I-Stx1. To test the specifi city of the 
binding simultaneous incubations were done in the 
presence of an excess of unlabelled Stx1. In none of 
the performed experiments (n=7) specifi c interac-
tion of 125I-Stx1 with PMN was found. 
  Figure I The clearance-curve of shiga-like toxin 
in mice
 Vertical: % I25I-Stx1 B-subunit 
 Horizontal: minutes
I25I-Stx1 B-subunit was rapidly cleared from the 
blood of mice. After 5 minutes approximately only 
20% was still present.
  Table I Distribution of 125I-Stx1 B-subunit in 
blood of mice
Time
(min)
2.5
2.5
15
15
Unlabelled 
Stx1-B
-
+
-
+
Number 
of mice
3
2
3
1
Plasma
(% of total)
94.871
90.566
93.302
94.504
Ficoll
(% of total)
3.926
6.912
4.107
3.566
Erythrocyte
(% of total)
1.568
2.942
1.645
1.327
PMN
(% of total)
0.003
0.006
0.006
0.003
Monocycte + 
Lymphocyte
(% of total)
0.040
0.016
0.072
0.025
Platelets
(% of total)
0.373
0.478
0.708
0.660
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  Figure 3 Flow cytometric analysis for detection 
of antibody against shiga-like toxin 2 on poly-
morphonuclear leukocytes of patients on dialy-
sis.
PMN of patients on dialysis were incubated with an 
antibody against Stx2. (A) PMN from a patient on hae-
modialysis. (B) This data represents the PMN from 
a patient on peritoneal dialysis. Binding of the anti-
body can be observed on PMN originating from pa-
tients on haemodialysis. No binding can be found on 
PMN from patients on peritoneal dialysis.
  Binding of antibody shiga-like toxin to polymor-
phonuclear leukocytes
 The specifi city of attachment of the antibody 
against Stx2 was tested with PMN of patients with 
HUS, patients on haemo- or peritoneal dialysis and 
healthy controls. 
In 2 out of 3 blood samples from HUS patients in ac-
tive disease, the antibody did not show any staining 
of the PMN (fi gure 2). Only the PMN of one patient 
showed an attachment of the antibody to the PMN 
during active disease, which disappeared during re-
mission. 
The healthy controls were negative (n=6). In pa-
tients on PD, no attachment of the Stx2 antibody 
to PMN was found. However, if the antibody was 
added to PMN from patients on HD, in 11 out of 16 
experiments positive staining of the PMN with the 
antibody was observed (fi gure 3). In these patients 
no symptoms of HUS could be detected.
  Figure 2 Flow cytometric analysis for detection 
of antibody against shiga-like toxin 2 on polymor-
phonuclear leukocytes from patients with haemo-
lytic uraemic syndrome.
PMN of 2 HUS patients were incubated with an anti-
body against Stx2. 
(A) PMN of patient 1 during active disease. (B) PMN 
of patient 1 during remission. (C) PMN from patient 
2 during active HUS. 
Binding of the antibody can only be observed in 
panel A, showing the PMN of patient 1 during active 
disease. 
Control    Anti-body 
Stx2
A
B
C
Control    Anti-body 
Stx2
A
B
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  Stimulation of polymorphonuclear leukocytes 
with shiga-like toxin
 Incubation of PMN with different concentrations 
Stx2 did not cause any changes in the expression of 
degranulation markers (CD66b and CD63) on PMN 
(fi gure 4). Similar results were obtained with the ad-
hesion molecules. Stx2 did not induce signifi cant 
changes in the expression of CD11b/CD18 and shed-
ding of L-selectin (fi gure 4).
Incubation of PMN from healthy donors did not 
show an increase of superoxide production whereas 
LPS induced a small increase (data not shown). 
  Figure 4 (A, B, C, D) Expression of degranu-
lation markers and cell adhesion molecules 
on polymorphonuclear leukocytes
 Vertical values: 
 A > % PMN positive for CD11b/CD18 expression 
 B > % PMN positive for L-selectin expression 
 C > % PMN positive for CD66b expression 
 D > % PMN positive for CD63 expression 
PMN from healthy donors were stimulated with 
Stx2 (0.1 or 10 nM) or with LPS alone or in combi-
nation with Stx2 (0.1 or 10 nM). After stimulation, 
the expression of degranulation markers and cell 
adhesion molecules was determined. (A and B): The 
expression of cell adhesion molecules (L-selectin and 
CD11b/CD18 respectively) on PMN is not infl uenced 
by incubation with Stx2. (C and D): Also, the degran-
ulation markers (CD66b and CD63 respectively) are 
not affected by Stx2. However, after incubation with 
LPS or LPS + Stx2 there is a signifi cant change in ex-
pression. P<0.05 is considered to be signifi cant (*).
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 Discussion
 In a previous study, we have demonstrated specifi c 
binding of 125I-Stx1 to freshly isolated, non-stimula-
ted human PMN. Also a rapid binding of FITC-labelled 
Stx1 to PMN was detected when incubated in whole 
blood (38). In the current study we were unable to 
reproduce these results. Neither in isolated PMN nor 
in whole blood a specifi c binding of Stx1 to PMN was 
observed. Fernandez et al (112) also studied the bin-
ding of Stx to PMN. PMN from healthy adults and chil-
dren were incubated with different concentrations 
of Stx1 or Stx2 for different time intervals. The bin-
ding of Stx to PMN was determined by fl ow cytometry 
using specifi c anti-Stx antibodies, and by quantifi ca-
tion of the remnant Stx, evaluating the cytotoxicity 
of the supernatants on verocells. Neither of the two 
approaches revealed a positive binding of Stx to 
PMN surface in any of the conditions assayed. We 
also evaluated a possible binding of 125I-Stx1 B-
subunit after intravenous injection in mice. In vivo 
no specifi c interaction of Stx1 with PMN could be 
detected. Some caveats should be noted. It is not 
allowed to extrapolate data obtained in mice to 
the human. It is also possible that labelled toxin is 
detached from cells during the experimental pro-
cedure (centrifugation on Ficoll). We have no ex-
perience with erythrocytes, but labelled Stx on the 
surface of monocytes at a constant temperature is 
not released by centrifugation.
A lack of specifi c binding of Stx to PMN suggests 
the absence of a direct effect of Stx on PMN func-
tion. Stx2 did not stimulate superoxide production 
in PMN and was unable to induce the expression 
of degranulation and activation markers CD63, 
CD66b and CD11b/CD18. Similar results were repor-
ted by Aoki et al and Holle et al (113, 51).
However, Stx2 also has an inhibitory effect on spon-
taneous neutrophil apoptosis. Surprisingly, this ef-
fect is only partially inhibited by anti Stx2 antibody 
(114). Could Stx2 interfere with triggering factors for 
spontaneous apoptosis?
How to reconcile these data with the fl ow cytome-
tric detection of Stx on PMN from HUS patients by 
us and recently by Brigotti et al (50)? Using fl ow 
cytometry, in 13 out of 20 children with HUS they 
showed binding of anti-Stx mouse monoclonal anti-
body to PMN. In our last three investigated patients 
with a proven HUS, PMN from only one patient 
were clearly positive for the antibody against Stx2 
and became negative at remission. A possible ex-
planation is the exposure of altered plasma mem-
brane structures on activated PMN. In D+HUS chil-
dren, PMN have been found to adhere more avidly 
to endothelium and induce endothelial injury, asses-
sed morphologically by degradation of endothelial 
cell fi bronectin (45). α1-antitrypsin complexed elas-
tase is raised in HUS-patients refl ecting PMN acti-
vation and degranulation (46). Fernandez et al show-
ed a reduced degranulatory capacity in response to 
cytokines and a decreased intracellular granule 
content indicating a preceding process of activation 
(48). To underpin our hypothesis, we have tested 
the interaction of the antibody against Stx2 with 
PMN activated by HD and compared it with PMN 
obtained from patients treated by chronic perito-
neal dialysis. Degranulation of PMN appears to be 
an ongoing process during HD, starting directly 
after the initiation (115). In the majority of patients 
on HD, the activated PMN collected after a HD ses-
sion showed a binding of the antibody against Stx2. 
This was not seen in PMN from patients treated by 
chronic peritoneal dialysis.
From these experiments, we hypothesize that in 
activated PMN membrane changes take place that 
cause binding of the Stx2-antibody. The characteris-
tics of these binding sites are still unknown. There-
fore, a reliable diagnosis of HUS patients demon-
strating the presence of Stx on the surface of PMN 
by anti-Stx2 is doubtful.
It remains an unsolved issue how Stx is transported 
in the circulation. Recently, the acute phase protein 
human serum amyloid P has been suggested by 
Kimura et al as a possible neutralizing factor (57). 
But if it can also target Stx to the glomerular endo-
thelium needs to be elucidated.
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Since a specific 
treatment for HUS 
is still lacking, 
more insight in the 
transport of this 
toxin might lead to 
new intervention 
strategies.
 Introduction
 The haemolytic uraemic syndrome (HUS) is a clini- 
cal syndrome consisting of three characteristic 
features: haemolytic anemia, thrombocytopenia 
and acute renal failure (1).  In the new classification 
of HUS, infection due to Shiga-like toxin (Stx) pro-
ducing bacteria belong to the category of ‘etiology 
advanced’ (2). This work is focusing on the form 
in which Stx producing Escherichia coli is the most 
common pathogen (1). It can produce several types 
of Stx of which Stx1, Stx2 and Stx2c are most as-
sociated with HUS (3, 6). Stx plays a crucial role in 
the pathogenesis, because of its cytotoxic effect 
on the renal endothelium. Both renal tubular epi-
thelial cells and glomerular visceral epithelial cells 
(podocyctes) are also sensitive to the toxic effect of 
Stx (72, 116). It can inhibit the protein synthesis of 
these cells after specifically damaging the riboso-
mal RNA (17). However, the question how this toxin 
is targeted mainly to the kidney remains unsolved. 
Stx was never detected in the serum of patients, but 
it was detected in renal biopsy material of patients 
with HUS (19). Since a specific treatment for HUS 
is still lacking, more insight in the transport of this 
toxin might lead to new intervention strategies.
After oral ingestion of the bacteria through con-
taminated food or water, the non-invasive bacte-
ria will adhere to the intestinal epithelial cells of 
the distal small bowel and colon. This will lead to 
a re-arrangement of the morphology of the cells 
and initiate inflammation (11, 117). Bacterial flagel-
lin plays an important role in this process (26). Stx 
can probably reach the circulation because of ac-
tive transport in these cells and also passively after 
damage to the intestinal cells (30). Subsequently, 
it has to be transported in the circulation to reach 
its primary target, the renal endothelium.
It is very tempting to look at the blood cells as a 
carrier for the toxin. Stx can bind to a specific re-
ceptor which is a globotriaosylceramide (Gb3, Pk 
Antigen, CD77) (15). This receptor is present on re-
nal endothelial cells, but also on blood cells. Binding 
of Stx has been described on red blood cells (36), 
B lymphocytes (118) and platelets which also have 
an additional binding possibility (glycolipid, band 
0.03) (39). Several groups showed the existence 
of a specific binding of Stx on monocytes (52, 53, 
 Abstract
 The cytotoxic effect of shiga-like toxin (Stx; produ- 
ced by certain Escherichia coli strains) plays a cen-
tral role in typical haemolytic uraemic syndrome. 
It damages the renal endothelium by inhibiting the 
cellular protein synthesis. Also the monocyte has a 
specific receptor for Shiga-like toxin, but is not sen-
sitive for the cytotoxic effect. In this work, mono-
cytes are studied as a potential transporter for Stx 
to the renal endothelium. 
Co-incubations of isolated human monocytes loa-
ded with Stx and target cells (vero-cells and human 
umbilical vascular endothelial cells) were perfor- 
med. Transfer was determined by measuring the pro- 
tein synthesis of target cells and by flow cytome- 
try. Furthermore, the effect of a temperature-shift 
on loaded monocytes was investigated.
Stx loaded monocytes reduced the protein synthe-
sis of target cells. After adding an antibody against 
Stx, incomplete recovery occurred. Also, adding only 
the supernatant of co-incubation was followed by in- 
hibition of the protein synthesis. Stx detached from 
its receptor on the monocyte after a change in tem-
perature and no release was detected without this 
temperature shift.
Although the monocyte plays an important role in 
the pathogenesis of HUS, it has no role in the trans-
fer of Stx.
 
54). After binding to its receptor, Stx can be inter-
nalized. Whereas in epithelial cells the toxin follows 
the retrograde transport route and becomes cyto-
toxic, in monocytes it is targeted to the lysosomes 
and will get degraded (54). During this transport, 
the monocyte becomes activated. This will lead to 
an increase of transcription factors like NF-κB and 
AP-1 and an up-regulated production of cytokines 
like IL-1β, TNF-α, IL-6 and IL-8 (52, 55). These events 
will have a pro-inflammatory effect. 
We postulated that, since the monocyte has a spe- 
cific receptor, it might also function as a carrier to 
transport Stx to the renal endothelium. To inves-
tigate this hypothesis, Stx was loaded to isolated 
monocytes from healthy donors and co-incubated 
with target cells (vero-cells and human umbilical 
cord venous endothelial cells (HUVECs)). The level 
of transfer was determined by measuring the pro- 
tein synthesis of these target cells and by mea- 
suring the transfer of FITC-labelled B-subunit of Stx1 
with flow cytometry. 
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confluence on a gelatine-coated 24-wells plate (121). 
Every two days fresh medium was added to the cells. 
In contrast to vero-cells, HUVECs were 24 hours pre- 
incubated with TNF-α (10 ng/ml) to up-regulate the 
expression of CD77. 
 Isolation of monocytes and loading with Stx2
 Fresh venous blood (20 ml) from fourty healthy 
donors was collected into EDTA tubes. Monocytes 
were isolated by negative selection using antibody-
labelled beads (CD3, CD7, CD16, CD56 and CD123). 
After centrifugation of blood over Ficoll (20 min 
400 xg without brake, at room temperature), the in- 
terphase (containing monocytes, lymphocytes and 
platelets) was collected. Platelets were removed 
by centrifugation (200 xg, 10 min at room tempera- 
ture) before adding the beads. The purity of mono- 
cytes after the magnetic isolation is (as determi- 
ned by flow cytometry) 80-85%.
After the isolation the monocytes were resuspen- 
ded in HBSS with 1% HSA and placed on ice. In 
every experiment, monocytes from one donor were 
used. To load the monocytes with Stx2, the toxin 
was added to a concentration of 10 nM during a 
time period of 3 hr (52). The cells remained on ice. 
After proper washing to remove all unbound Stx2, 
the cells were resuspended in vero-cell or HUVECs-
medium (in which HS and NBCS are substituted by 
FCS). Monocytes stayed viable after this loading, as 
determined by trypan blue exclusion.
 Co-incubation Stx2-loaded monocytes and  
 target-cells
 These experiments were performed in two dif-
ferent experimental settings; with transfer of loa-
ded monocytes from 4 to 37 degrees, and without 
change of temperature. To start with the first set- 
ting, the Stx2-loaded monocytes were added to a 
monolayer of target-cells (HUVECs (n=10) or vero-
cells (n=9)) in a concentration of 1x106 per well. 
This was performed during 24 hr at 37˚C. For com-
parison, also monocytes without Stx were used. To 
determine the specificity of the effect of Stx2, the 
loaded monocytes were pre-incubated with a well-
characterised antibody against Stx2 (TMA-15, 1 μg/
ml, approximately 150 times excess). All experiments 
were performed in duplicate. To measure the trans-
fer of Stx2 from the monocyte, the protein synthe-
 Methods 
  Materials
 Stx2 was kindly provided by Dr. M Karmali (Public 
Health Agency of Canada, Ontario, Canada). Stx1 B- 
subunit labeled FITC and 125I-Stx1 B-subunit were 
a gift from Dr. L. Johannes (Institut Curie, Paris, 
France). Stx1 B-subunit is a useful tool for study- 
ing binding in monocytes (53). It is the binding part 
of the toxin, whereas the enzymatic A-subunit will 
only stimulate the uptake of the toxin and does not 
affect binding (111).
Vero-cel medium consists of M199 (Gibco; Paisley/UK), 
fetal calf serum (FCS, Greiner Bio-One; Krems-mun-
ster/Austria), penicillin/streptomycin (Gibco, Paisley/ 
UK) and glutamine (MP Biomedicals; Eschwege/ 
Germany).
HUVECs medium is made of M199, human serum (HS; 
Cambrex; Walkersville/USA), new born calf serum 
(NBCS; Gibco, Paisley/UK), penicillin/streptomycin, 
glutamine, heparine (Leo Pharma BV, Breda/The 
Netherlands) and endothelial cell growth factor (119). 
EDTA-tubes were purchased from BD Vacutainer 
(Alphen aan de Rijn/The Netherlands). The MACS-kit 
for negative selection of monocytes was provided 
by Miltenyi Biotec (Bergisch Gladbach/Germany). 
Hank’s balanced salt solution (HBSS) was ordered 
from MP Biomedicals (Eschwege/Germany). Human 
serum albumin (HSA) from Sanquin (Amsterdam/
The Netherlands) and porcine gelatine from Fluka 
(Neu-Ulm, Germany) was used. Trichloroacetic acid 
and TNF-α was obtained from Sigma-Aldrich Chemie 
B.V. (Zwijndrecht/The Netherlands). The antibody 
against Stx2 (TMA-15) is well-characterised (120). It 
was a kind gift from Dr. Yamagami from the Depart-
ment of Biomedical Research from the Teijin Insti-
tute, Tokyo, Japan.  3H-leucine and Ficoll-paque PLUS 
was purchased from Amersham Biosciences (Upp-
sala, Sweden). Culture plates were ordered from 
Corning Inc (Corning, USA).
 Culture of vero-cells and HUVECs
 Vero-cells (renal epithelial cells of the African green 
monkey) were grown to confluency on a 24-wells 
plate (ordered from ATCC; Middlesex, UK). These 
cells have a high basal expression of Stx-recep- 
tor CD77.
HUVECs were isolated and these cells were grown to 
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sis of the target-cells was determined by adding 3H-
leucine (0.67 μCi/ml). Subsequently, intracellular 
proteins were precipitated by treatment with TCA 
and the radioactivity was measured in a liquid scin-
tillation counter.
In the other experimental setting, monocytes were 
loaded in a similar way with Stx1 B-subunit FITC- 
labelled. 1x106  loaded monocytes were co-incubated 
with 1.25 x 105 vero-cells in suspension during 3 hr 
at 4˚C (n=5), meanwhile continuously rotating. At 
this temperature, bias due to internalisation of the 
toxin could be avoided (54, 122). After 3 hr, the 
presence of Stx1 B-subunit FITC on the vero-cell 
was determined by flow cytometry. For every exper-
iment at least 1000 cells were measured.
 Study of supernatant Stx-loaded monocytes
 To study the effect of the supernatant of Stx2-loa- 
ded monocytes, it was collected after 16 hrs of co-in- 
cubation on vero-cells (n=11). The supernatants 
were centrifugated to remove possible monocytes 
and added again to fresh vero-cells. The protein syn- 
thesis was measured by adding 3H-leucine and 
measuring the incorporation after 24 hrs of incu- 
bation at 37˚C. Also, the antibody against Stx2 was 
used to determine a possible effect of free Stx2. 
Furthermore, monocytes were loaded with 125I-
Stx1 B-subunit to investigate whether it could be 
released after a change in temperature from 4 to 
37˚C (n=3). For each experiment, between 3 and 
4x106 monocytes are loaded with 200 nM Stx1 B- 
subunit (3600 cpm/ng protein). After loading, un- 
bound Stx1 B-subunit was removed by centrifuga-
tion. Subsequently, the monocytes were placed at 
37˚C for 2 hr. Monocytes were centrifugated, and 
cells and supernatant were measured separately 
for the presence of 125I-Stx1B with a gamma-coun- 
ter. This was compared to the amount of bin- 
ding to the monocytes before the temperature 
change. The experiment was performed in dupli-
cate.
 Statistics
 All data represented are expressed as a range with 
the median. Significance of increase or decrease of 
protein synthesis compared to controles was ana-
lyzed using Wilcoxon Signed Ranks Test. The statis-
tical level of significance was defined as P<0.05. 
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  Figure I Co-incubation of Stx2 loaded mono-
cytes with target cells (vero-cells and HUVECs)
 Vertical: % protein synthesis
 **: P<0.01  
To investigate if monocytes can transfer Stx2, toxin-
loaded monocytes were co-incubated with vero-cells 
(n=9) and HUVECs (n=10).  This leads to an inhibition 
of the protein synthesis as can be determined with 
the incorporation of 3H-leucine. The co-incubation 
with unloaded monocytes is used as a control and 
set at 100%.
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  Figure 2 Effect of the addition of an antibody 
against Stx2
 Vertical: % protein synthesis
 Horizontal: Donors
The monocytes of 5 healthy donors were co-incuba-
ted with vero-cells (Stx2-loaded monocytes, white-
bar; Stx2-loaded monocytes with Stx2 antibody, 
dark blue. The addition of the antibody against Stx2 
leads to partial recovery of protein synthesis in 4 
donors and complete recovery in one donor. The co-
incubation with unloaded monocytes is used as a 
control and set at 100%.  
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 Results
  Co-incubation Stx2-loaded monocytes and 
target-cells
 To investigate whether monocytes can transfer 
Stx2 to target-cells (vero-cell and HUVECs), Stx2-
loaded monocytes were added to a monolayer of 
these cells. After the co-incubations, the protein 
synthesis of vero-cells and HUVECs was measured. 
If the Stx2 is transferred to the target-cells, there 
will be inhibition of the protein synthesis, since 
this is the biological effect of Stx2 in both types 
of target-cells. 
After 24 hours of co-incubation at 37˚C, in both cell 
types there is an inhibition of the protein synthesis 
(fi gure 1). In vero-cells, more reduction of the pro-
tein synthesis can be measured than in HUVECs. Di-
rectly adding 10 nM Stx2 to vero-cells reduced the 
protein synthesis to 5.5% (data not shown). When 
an antibody against Stx2 was added to the mono-
cytes before co-incubation with vero-cells, the in-
hibition of protein synthesis is partly re-stored 
(fi gure 2). Only in one out of 5 experiments, there 
was a complete recovery. 
In equal experiments performed with HUVECs (n=3), 
TMA-15 also partly prevented the inhibition of pro-
tein synthesis (data not shown).
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 Study of supernatant Stx-loaded monocytes
 Because the addition of an antibody against Stx2 
was not suffi cient for complete recovery of protein 
synthesis in four out of 5 tested donors, we inves-
tigated the possible presence of an additional inhi-
bitor in the supernatant after 16 hours of co-incu-
bation. This was performed by re-adding the super-
natant of co-incubated Stx2-loaded monocytes and 
a monolayer of vero-cells, to new vero-cells. Figure 3 
shows that this incubation again leads to an inhibi-
tory effect on the protein synthesis of the vero-cells, 
in contrast to the supernatant of unloaded mono-
cytes. But this reduction is less than with direct 
co-incubation. The effect can be partly blocked by 
adding the antibody against Stx2. This means that 
there is unbound Stx2 present in the supernatant. 
Next, we investigated if the temperature change 
of the Stx-loaded monocytes from 4 to 37˚C could 
lead to release of the toxin. For this reason, we 
loaded the monocytes with 125I-Stx1 B-subunit. The 
amount of radio-activity on or inside the monocytes 
was measured before and after the incubation of 
the cells for 2 hr at 37˚C (table 1). Vero-cells were 
used as a control.  Both in vero-cells as in mono-
cytes, the toxin is released from its receptor after 
the incubation. 
  Table I Amount of 125I-Stx1 B-subunit on cells 
after change of temperature
 cpm= counts per minute 
  Figure 3 Addition of supernatants co-incuba-
tion to vero-cells
 Vertical: % protein synthesis
 **: P<0.01  
After co-incubations of Stx-loaded and unloaded 
monocytes, supernatants were collected and re-ad-
ded to fresh vero-cells (n=11). The supernatant from 
the toxin-loaded monocytes induced again an inhi-
bition of the protein synthesis. This inhibition could 
be partially restored with a Stx2-antibody (AB). The 
incubation of supernatant with unloaded monocytes 
was used as a control and set at 100%.
  Transfer of Stx to target-cells without change 
in temperature
 A change in temperature from 4 to 37˚C, released 
Stx from its receptor on the monocyte. To study 
again the possibility of transfer of Stx from mono-
cyte to target-cells, we loaded isolated monocytes 
with Stx1 B-subunit labelled with FITC. A co-incuba-
tion of these monocytes with vero-cells in suspen-
sion without a change in temperature, did not result 
in a transfer of the B-subunit to the vero-cells (n=5, 
fi gure 4).
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Stx-loaded cells
Vero-cells
Monocytes donor 1
Monocytes donor 2
Monocytes donor 3
Before 4 > 37 C (cpm)
1034383
1437
1070
1121
After 4 > 37 C (cpm)
671060
427
374
677
  Figure 4 Transfer Stx-loaded monocyte to 
vero-cell without temperature shift
 Horizontal: intensity FITC
 Vertical: amount of cells
(light blue: normal monocytes; dark blue: Stx-loa-
ded monocytes and blue: vero-cells). The x-axis re-
presents the intensity of the FITC-signal, the y-axis 
represents the amount of cells.
Panel A: Stx1 B-subunit FITC-labelled was bound to 
monocytes from a healthy donor showing an in-
crease in intensity. B: Co-incubation of vero-cells 
and unloaded monocytes. Notice the high basal sig-
nal of vero-cells. 
C: After 2 hr co-incubation with vero-cells in suspen-
sion at 4 oC, there is no transfer of the FITC-signal. 
The cells remain at their position.
A
B
C
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 Discussion
 After co-incubation of Stx2-loaded monocytes 
with target-cells (vero-cells and HUVECs), an inhibi-
tion of the protein synthesis could be detected. Since 
the biological effect of Stx is the inhibition of pro-
tein synthesis, a transfer was expected. This effect 
can not be due to the presence of monocytes, be-
cause it is well-described that Stx does not have an 
inhibitory effect on peripheral blood monocytes (52). 
However, the addition of an antibody against Stx 
could only partly restore the inhibition. We hypo-
thesized that in parallel to transfer of Stx2, also a 
possible additional inhibiting factor was present 
in the supernatant during the experiment. To fur-
ther investigate this possibility, the supernatant of 
this co-incubation was re-added to fresh vero-cells. 
Again there was an inhibition of the protein synthe-
sis, which could partly be decreased by blocking 
with the Stx2-antibody. The conclusion was made 
that there is indeed another inhibitory factor pres-
ent (possibly released by activated monocytes), but 
also unbound Stx2 was present (123).
Apparently, Stx1 B-subunit is released from its re-
ceptor when there is shift of temperature from 4 to 
37˚C as shown in this paper and also by Ramegowda 
& Tesh (53). This fi nding underlines the caution 
that has to be taken, in drawing conclusions from 
in vitro experiments performed at 4˚C. In fi gure 5 all 
fi ndings are schematically summarized.
Since these in vitro experiments are not suitable to 
investigate a possible transfer, experiments were 
performed without a change of temperature. No 
transfer of the binding part of the toxin could be 
detected in this setting. Experiments can not be 
performed at 37˚C because the toxin will be inter-
nalised by the monocyte during 3 hours of incuba-
tion. 
Because of these in vitro experiments, we believe 
that the monocyte can not function as a transport-
er for Stx in the circulation. However, monocytes 
still seem to play an important role in the patho-
genesis. As a component of the innate immune 
system, they play a central role in immunity and 
infl ammation.  Fernandez et al showed that patients 
in the acute period of HUS have monocytes with 
phenotypic (reduced expression of CD14, CD64 and 
CD11b) and functional differences (decreases LPS-
induced TNF-α production and Fcγ-dependent cyto-
toxicity) compared to healthy children and acute 
uremic children (124). 
Some unanswered questions remain. What is the 
inhibitory factor released by monocytes after load-
ing with Stx? And why is there still unbound Stx2 
present in the supernatant after 16 hours of co-in-
cubation? It is surprising that Stx2 is not completely 
bound and internalised by the numerous receptors 
on the monocytes and the vero-cells. And also the 
question how Stx is transported in the circulation 
remains unsolved. Kimura et al described that serum 
amyloid P (SAP) can bind Stx2 and function as a 
neutralizing factor (57). However, in humans there 
was no correlation between circulating SAP and the 
development of HUS (58). 
Since renal endothelial damage is already present 
after the occurrence of clinical symptoms of HUS, it 
is very important to develop effi cacious early pre-
vention. Understanding the mechanism in which 
the toxin is specifi cally targeted to the kidney, can 
lead to novel intervention strategies.
  Figure 5 Schematic summary of performed 
experiments
A: Monocytes loaded with Stx at 4˚C. 
B: After shifting Stx-loaded monoytes to target-cells 
at 37˚C, Stx will be released from its receptor. This 
will lead to inhibition of protein synthesis of target 
cells. But, transport can not be excluded (but this 
was performed in experiments without a shift in 
temperature). Probably, some toxin will be internali-
sed and monocytes become actived. This can lead 
to production of cytokines and proteases (possible 
cytotoxic factors).
C: When the supernatant is re-added to new target-
cells, there are released Stx and secreted products 
present. This will induce again an inhibition of the pro-
tein synthesis.
A B C
4 > 37˚C supernatant
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The transport 
route of Shiga- 
toxin/Stx-1 was 
never investigated 
in primary renal 
cells, the main  
target for Stx-1 in 
humans.
 Abstract
 This study has determined the intracellular trans-
port route of Shiga-like toxin (Stx) and the highly re-
lated Shiga toxin in human glomerular microvascular 
endothelial cells (GMVECs) and mesangial cells. In ad-
dition, the effect of tumor necrosis factor-α (TNF-α), 
which contributes to the pathogenesis of haemoly-
tic-uraemic syndrome, was evaluated more profound. 
Establishing the transport route will provide better 
understanding of the cytotoxic effect of Stx on re-
nal cells. For our studies, we used receptor-binding 
B-subunit (StxB), which is identical between Shiga 
toxin and Stx1. The transport route of StxB was stu- 
died by immunofluorescence microscopy and bio-
chemical assays that allow quantitative analysis of 
retrograde transport from  plasma membrane to the 
Golgi apparatus and the endoplasmic reticulum (ER). 
In both cell types, StxB was detergent-resistant 
membrane associated and followed the retrograde 
route. TNF-α up-regulated Gb3 expression in me-
sangial cells and GMVECs, without affecting the ef-
ficiency of StxB transport to the ER. In conclusion, 
our study shows that in human GMVECs and me-
sangial cells, StxB follows the retrograde route to 
the Golgi apparatus and the ER. TNF-α treatment 
increases the amount of cell-associated StxB, but 
not retrograde transport as such, making it likely 
that the strong TNF-α-induced sensitization of me-
sangial cells and GMVECs for the toxic action of Stx 
is not due to a direct effect on the intracellular traf-
ficking of the toxin. 
 
 Introduction
 Shiga-like toxins (Stx) play a key role in the patho-
genesis of the diarrhoea-associated haemolytic- 
uraemic syndrome (HUS). Stx, produced by bacteria 
like Escherichia coli and Citrobacter freundii, are exo- 
toxins that have damaging effects on the endothe-
lial cells in the glomeruli and arterioles of the kidney 
(11). This injury leads to cell death and the initiation 
of the coagulation cascade. Consequently, the three 
classical features of HUS will occur: acute renal fail-
ure, thrombocytopenia, and haemolytic anemia. It is 
not yet known why Stx have a specific effect on the 
renal endothelium. 
Stx are highly similar to Shiga toxin from Shigella 
dysenteriae. These toxins are all composed of a cat-
alytic A-subunit, and a receptor-binding homopen-
tameric B-subunit (StxB) that can bind to a specific 
functional receptor. The A-subunits of Stx-1 and Shi-
ga toxin differ in only one amino acid, whereas the 
amino acid sequences of the respective B-subunits 
are totally identical. In the following, both toxins will 
be considered as equivalent molecular entities. The 
receptor of Shiga toxin/Stx-1 is a glycosphingolipid, 
called globotriaosylceramide, Gb3 or CD77 (125). 
After binding to this receptor, it is suggested that 
Shiga toxin/Stx-1 can enter cells via both clathrin-
dependent and –independent endocytosis (59, 68, 
126, 127). 
Shiga toxin/Stx-1 induces different biological effects 
in various human cell types on which its functional re-
ceptor is present. In monocytes/macrophages, Shiga 
toxin/Stx-1 has a stimulating effect that consists of 
activation of the mitogen activated protein kinase-
system (MAPK), nuclear translocation of nuclear 
factor-κ B, and secretion of cytokines like tumor ne- 
crosis factor-α (TNF-α and interleukin-6 (52, 56). 
In these cells that are totally resistant to the cyto-
toxic function of Shiga toxin/Stx-1, the toxin is ef-
fectively degraded in lysosomes after having acti-
vated the cell (54). This transport route can also 
be demonstrated in bovine intestinal epithelial cells 
(128). However, in toxin-sensitive cells such as can-
cer cell lines, Shiga toxin/Stx-1 is able to escape lyso-
somal degradation and can become cytotoxic (62). 
In these cells, Shiga toxin/Stx-1 follows a recently 
described pathway, termed the retrograde trans-
port route.
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Retrograde transport permits Shiga toxin/Stx-1 to 
bypass the late endocytic pathway by trafficking di-
rectly from early/recycling endosomes to the trans-
Golgi-network (TGN) (63). This step is dependent on 
Rab6a’, SNARE complexes around the heavy chain 
soluble N-ethymaleimide-sensitive factor attach-
ment proteins (SNAREs), syntaxin 16 and -5 (64, 129), 
the tethering molecule golgin97 (130), dynamin, 
clathrin (126, 127), and the potential clathrin adap-
tor epsinR (127). A correlation has also been descri-
bed between the retrograde trafficking of Shiga tox- 
in/Stx-1 at the early/recycling endosomes-TGN inter-
face and its association with detergent-resistant 
membranes (DRMs). When Shiga toxin/Stx-1 is found 
in the DRM fractions, for example in HeLa cells, the 
protein is targeted into the retrograde route. In 
monocytes/macrophages, Shiga toxin/Stx-1 is not 
associated with DRMs, and retrograde transport 
is inefficient (54). From the TGN, Shiga toxin/Stx-1 
is transported to the endoplasmic reticulum (ER) 
using a KDEL-receptor and coatomer protein com-
plex I (COPI)-independent pathway (131). After reach- 
ing the ER, Shiga toxin/Stx-1 most likely uses the cel-
lular retrotranslocation machinery to transfer the 
catalytic A-subunit to the cytosol (66, 67).
The A-subunit functions as RNA N-glysosidase. In 
the cytosol, it removes one adenine from the 28 -S 
rRNA of the 60S ribosomal unit and thereby inhibits 
the elongation factor 1–dependent aminoacyl-tRNA 
binding to ribosomes (17, 18). This will lead to an in-
hibition of peptide elongation and consequently an 
overall inhibition of protein synthesis.
The transport route of Shiga toxin/Stx-1 was never 
investigated in primary renal cells, the main target 
for Stx-1 in humans. In this study, we used quantita-
tive StxB-based trafficking tools and immunofluo-
rescence to analyze whether Shiga toxin/Stx-1 was 
targeted to the retrograde route in human glomeru-
lar and mesangial cells. Both cell types are known 
to express Gb3, which can be up-regulated by cyto-
kines like TNF-α (132, 133, 134). This cytokine can be 
found elevated in serum of HUS-patients (135). Also, 
Harel et al found a kidney-specific induction of the 
TNF-α synthesis after the injection of mice with Stx-1 
(136). Therefore, we have studied the influence of 
TNF-α on the trafficking of StxB. As expected, we 
found that TNF-α increases Gb3 expression and 
thus, the quantity of cell-associated toxin. However, 
TNF-α does not affect StxB association with DRMs 
and the efficiency of retrograde StxB transport to 
the ER.
 
was done according to the manufacturer’s instruc-
tions (GE Healthcare). After washing with cold (4˚C) 
culture medium, the cells were incubated with warm 
(37˚C) complete culture medium (containing 20% 
fetal calf serum (FCS) instead of 10% new born calf 
serum (NBCS) and 10% human serum (HS)) for 4 or 
24 hr at 37˚C. Cells then were washed with phos- 
phatebuffered saline, fixed at room temperature 
for 15 min in 4% paraformaldehyde, quenched 
with ammonium chloride, permeabilized with 1% 
saponine, incubated with the indicated primary 
(the antibody against Golgi-marker CTR433 was 
a kind gift from Dr. M Bornens, Institut Curie, 
France; calnexin-anti-body is purchased from BD 
Transduction Laboratories, Erebodegem, Belgium) 
and secondary anti-bodies (anti-mouse FITC; pur- 
chased from Jackson Immunoresearch, West Grove, 
USA), mounted, and viewed by confocal micro- 
scopy (Leica Microsystems, Mannheim, Germany).
  Iodination and detergent resistant membrane 
isolation
According to the manufacturer’s instructions for 
iodination, 150 μg of purified StxB-Glyc-KDEL was 
treated with 1 mCi iodine-125 (>15 Ci/mg, GE Health-
care) on a single IODO-BEAD (Pierce Biotechnol-
ogy, Rockford, IL, USA). Non-incorporated iodine 
was removed on PD10 gel filtration columns (GE 
Healthcare). StxB-Glyc-KDEL was labeled to a spe-
cific activity of about 5000 cpm/ng. DRMs were 
isolated on Optiprep (Sigma-Aldrich, St Louis, MO, 
USA) gradients, as published (54). The DRMs were 
found at the 5/30% interface. 
 Glycosylation assay
 To obtain quantitative information on retro-
grade transport of StxB to the ER, a modified ver- 
sion of StxB, StxB-Glyc-KDEL, was used (puri- 
fied as published, (54,137)). Confluent GMVECs, me-
sangial cells and HeLa cells were preincubated with 
or without TNF-α (100 ng/mL) for 24 hours. Binding 
of [125I]-labeled StxB-Glyc-KDEL (50 nM) was per-
formed for 30 minutes on ice in complete medium 
containing 20% fetal calf serum. After incubation at 
37˚C for the indicated periods of time in the same 
culture medium, cells were washed with phosphate-
buffered-saline and lysed in SDS sample buffer 
(187,5 mM Tris/HCl pH 6.8, 6% SDS, 30% glycerol, 
 Materials & Methods 
 Cells and cell culture 
 Isolation of glomeruli, as well as purification, char-
acterization and cell culture of human GMVECs and 
human mesangial cells was performed as described 
by Van Setten et al (132, 133). HeLa cells were cultur-
ed as previously described by Johannes et al (137). 
Cells were used for maximal 12 passages. All experi-
ments in this manuscript were performed at least 
three times on human GMVECs or mesangial cells 
obtained from at least two different donors. The 
cells were preincubated with a 100 ng/mL dose of 
TNF-α (Roche, Basel, Suisse). This dose effectively in- 
duced expression of Gb3 on GMVECs without af-
fecting the viability of the cells (132). The human 
monocytes were obtained from blood of healthy do-
nors with their prior consent according to published 
procedures by Faradji et al (138). Monocytes were 
differentiated into macrophages using CSF-1, as 
described by Falguieres et al (54).
  Glycolipid extraction and thin-layer  
chromatography (TLC)
 Lipid extraction was performed as described by 
Falguières et al (54) according to the method of 
Bligh and Dyer (139). The isolated glycolypids were 
spotted on high-performance thin-layer chroma-
tography (HPTLC) plates (Science Inc., Agton Hights, 
IL, USA) and separated with chloroform: methanol: 
water (65:25:4). The plates were dried and incuba- 
ted with STxB, polyclonal anti-STxB (obtained as 
previously described (54)), and alkaline phospha-
tase coupled antibodies (Jackson Immunoresearch, 
West Grove, PA, USA). Reactive bands were revealed 
with the use of ECF (Amersham Pharmacia Biotech, 
Little Chalfont, United Kingdom) and quantified 
with a PhosphorImager (GE Healthcare, Bucking-
hamshire, UK) using a standard Gb3 preparation as 
reference.
 Immunofluorescence methods
 Human GMVECs and mesangial cells were grown 
on gelatine-coated glass coverslips and preincu-
bated or not with TNF-α (100 ng/mL) for 24 hr. The 
cells were placed on ice and incubated with Cy3-StxB 
or Cy3-StxB-Glyc-KDEL (obtained as previously de-
scribed, (54)) for 30 minutes. Cy3 labeling of StxB 
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0,03% Phenol Red). Lysates were analyzed by 10-
20% gradient SDS-PAGE gels, and autoradiographs 
were quantified by PhosphorImager analysis (GE 
Healthcare) using ImageQuant software (GE Health-
care). The percentage of glycosylated over total cell- 
associated StxB-Glyc-KDEL was determined. 
 Sulfation assay
 A variant of StxB, StxB-Sulf2, was used to obtain 
quantitative information on the passage of StxB into 
the Golgi apparatus (purified as published (54, 63)). 
Briefly, after 24 hr of preincubation with or without 
TNF-α (100 ng/ml), GMVECs, mesangial cells, and 
HeLa cells were sulfate starved for 90 minutes. Af-
ter binding of StxB-Sulf2 to cells for 30 minutes on 
ice, the sulfate starved cells were incubated for 4 
hr at 37˚C in 35SO4
2- containing medium (400 μCi/
ml). The cells were lysed in lysis buffer (1% Triton in 
phosphate-buffered saline containing Protein Inhi-
bitor Cocktail), and a post nuclear supernatant was 
prepared. StxB-Sulf2 was immunoprecipitated with 
monoclonal anti-StxB antibody 13C4 (obtained as 
previously described, (54)) and protein-G agarose 
beads. Washed precipitates were boiled in SDS sam-
ple buffer, loaded on Tris-Trycine gels and analyzed 
by autoradiography. Sulfation of StxB-Sulf2 was 
quantified by PhosphorImager analysis (GE Health-
care) using ImageQuant software (GE Healthcare). 
Global sulfation of endogenous proteins and pro-
teoglycans was determined by trichloracetic acid 
precipitation of the immunoprecipitation super- 
natant. The precipitate was retained on GF/C glass 
fiber filters (Whatmann, Maidstone, United King-
dom) and radioactivity was counted in a liquid scin-
tillation counter.
more overlap between the Golgi-marker CTR433 
(green) and Cy3-StxB-Glyc-KDEL (red) was observed 
in GMVECs or mesangial cells. The observed stain-
ing pattern only partially overlapped with the ER 
marker calnexin (not shown), and the exact identity 
of the compartment in which StxB accumulated af-
ter 24 hours remains to be identifi ed.
To confi rm that StxB is transported to the Golgi ap-
paratus, a biochemical population-based approach 
was used. The StxB-Sulf2 variant contains a tandem 
of protein sulfation sites that are recognized by 
TGN-localized sulfotransferase, which catalyzes the 
post-translational transfer of sulfate from the me-
dium onto these sites (54). After binding on ice and 
internalization at 37˚C of StxB-Sulf2 for 4 hr in [35S]
sulfate containing medium, StxB-Sulf2 was immuno-
precipitated and sulfated protein was analyzed by 
autoradiography. Radiolabeled StxB-Sulf2 could be 
detected in GMVECs and mesangial cells (fi gure 2). 
HeLa cells were used as positive control and human 
monocyte derived macrophages, in which retro-
grade transport cannot be detected, as a negative 
control (54). Stimulation of GMVECs and mesangial 
cells by TNF-α increased the sulfation signal, refl ec-
ting the increased Gb3 expression under these con-
ditions (see table 1).
  Table I Quantifi cation of Gb3 expression
After extraction of neutral glycolipids, Gb3 was de-
tected by overlay and quantifi ed on TLC plates.
Standards were run in parallel.
 Figure 2 Sulfation analysis of StxB transport  
 to Golgi apparatus in human GMVECs and
 human mesangial cells
TNF-α   -     +
GMVEC
Mesangial cells
Macrophages
Hela cells
Cells were preincubated with or without TNF-α. After 
binding StxB-Sulf2 was internalized into GMVECs, 
mesangial cells, macrophages and HeLa cells in the 
presence of radioactive sulfate. Then cells were ly-
sed, StxB was immunoprecipitated and analyzed 
by gel electrophoresis. Radiolabeled StxB-Sulf2 was 
revealed by autoradiography. Sulfated, i.e. TGN as-
sociated StxB-Sulf2 was detected in HeLa cells, 
GMVECs and mesangial cells. 
  Figure 3 Glycosylation analysis of StxB 
transport to the ER
 1, 4 & 24: Incubation time (hr) 
Cells were incubated with or without TNF-α. After bin-
ding of iodinated StxB-Glyc-KDEL on ice, the protein 
was internalized into human mesangial cells (A), hu-
man GMVECs (B) and HeLa cells (C) for 1, 4 or 24 
hours. Then cells were lysed and lysates were ana-
lyzed by gel electrophoresis. The arrow indicates 
the glycosylation product, i.e., ER associated StxB. 
The middle band is non-glycosylated Shiga toxin. 
The lower bands are proteolytic cleavage products.
 Results
 Gb3 extraction 
 To confi rm the presence of Gb3 on human GMVECs 
and mesangial cells, neutral glycolipids were extrac-
ted from unstimulated or TNF-α stimulated cells, se-
parated by thin-layer chromatography, and Gb3 was 
specifi cally detected using an overlay technique (9, 
22, 23). The amount of Gb3 was quantifi ed by Phos-
phorImager (table 1). As expected, GMVECs and me-
sangial cells expressed Gb3. Expression levels in 
unstimulated mesangial cells were comparable to 
HeLa cells, and about two fold higher than those 
found in unstimulated GMVECs. Pretreatment with 
TNF-α resulted in a two-fold increase of Gb3 levels in 
mesangial cells, and a fi ve-fold increase in GMVECs. 
Thus, after treatment with TNF-α, GMVECs and me-
sangial cells expressed similar Gb3 levels.
 Transport to the Golgi apparatus
 In HeLa cells, StxB traffi cs to the Golgi appara-
tus by retrograde transport (54). To determine if 
StxB has access to the retrograde route in human 
GMVECs and mesangial cells, immunofl uorescence 
experiments were performed with or without pre-
treatment of the cells with TNF-α. After binding and 
4 or 24 hr of internalization of Cy3-labeled StxB or 
StxB-Glyc-KDEL, respectively, the cells were fi xed, 
quenched, permeabilized, and incubated with an 
antibody against the Golgi marker CTR433. The in-
tracellular distribution of StxB was similar in TNF-α 
stimulated and unstimulated cells, and in the follow-
ing, only the immunofl uorescence data on unstimu-
lated cells are shown.
After 4 hr of internalization of Cy3-STxB, a signifi cant 
overlap between the Golgi-specifi c marker CTR433 
(green) and the StxB (red) was observed in GMVECs 
and mesangial cells (fi gure 1), strongly suggesting 
that after 4 hr, StxB was targeted to the Golgi appa-
ratus. Immunofl uorescence experiments were also 
performed after 24 h of internalization. For this con-
dition, a KDEL-tagged variant of StxB was used. The 
KDEL peptide does not increase the effi ciency of 
StxB transport to the ER, but rather improves the 
ER retention of the protein (137). Consistently, other 
studies showed that interfering with KDEL-receptor 
function did not affect retrograde transport of Stx 
to the ER (140). After 24 hr of internalization, no 
  Figure I* Immunofl uorescence analysis of StxB 
transport to the Golgi apparatus in human 
mesangial cells and GMVECs
*  To see fi gure in full colour, see Appendix
A. Cy3 labeled StxB (red) was internalized for 4 hours 
in human GMVECs or in human mesangial cells. 
Cells were fi xed and stained for the Golgi marker 
CTR433 (green). StxB and CTR433 colocalize (yel-
low) in both human GMVECs and human mesangial 
cells. B. Cy3 labeled StxB-Glyc-KDEL (red) was inter-
nalized for 24 hours, and then fi xed and stained for 
the Golgi marker CTR433 in human GMVECs or me-
sangial cells. No more accumulation of StxB in the 
Golgi region is observed. Similar fi gures were obtain-
ed after 24 hr incubation with Cy3 labeled StxB 
(data not shown).
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Cell types
HeLa cells
Mesangial cells
Mesangial cells + TNF-α
GMVECs  
GMVECs + TNF-α
Gb3 (μg/106 cells)
0.94
1.15
2.00
0.50
2.90
A: TNF-α 
B: TNF-α  
C: TNF-α  
+        /        -
1
+        /        -
1
+        /        -
1
+        /        -
4
+        /        -
4
+        /        -
4
+        /        -
24
+        /        -
24
+        /        -
24
 Transport to the ER
 In HeLa cells, StxB reaches the ER by retrograde 
transport (54, 63, 137). To determine if StxB is also 
transported to the ER in human GMVECs and me-
sangial cells, a modifi ed version of StxB, StxB-Glyc-
KDEL, was used. StxB-Glyc-KDEL contains a N-glyco-
sylation site at the C-terminus, which is glycosylated 
by ER-localized oligosaccharyl transferase, allowing 
to monitor and quantify arrival in this compartment 
(54, 137). As discussed above, the KDEL tag ensures 
effi cient retention in the ER. Iodinated StxB-Glyc-
KDEL was bound to and internalized into GMVECs, 
mesangial cells, and HeLa cells as a positive control. 
After 1, 4, or 24 hr, glycosylated StxB-Glyc-KDEL was 
detected and quantifi ed by autoradiography after 
SDS-PAGE as the percentage of total cell associated 
StxB-Glyc-KDEL. It is important to indicate that this 
assay system measures the glycosylation effi ciency 
independently of variations in receptor numbers, 
and thus, allows comparison of the glycosylation ef-
fi ciency – refl ecting retrograde transport to the ER 
– between different experimental conditions.
Figure 3 shows representative gels from all 3 cell 
types that were analyzed after preincubation or 
not with TNF-α. The uppermost band, indicated by 
an arrow, represents the glycosylation product, and 
the lowermost band is a proteolytic cleavage prod-
uct. All bands are visible in all conditions. Quantifi -
cation of the glycosylation bands is shown in table 
2. In HeLa cells, glycosylation increases from 1.1% 
over 6.4% to 24.9% after respectively, 1, 4, or 24 hr. 
These fi gures reproduce previously reported val-
ues (137), and refl ect the initial observation that 
glycosylation of StxB-Glyc-KDEL is slower than its 
morphologically detected arrival in the ER ((137): 
immunofl uorescence studies; (141): electron micros-
copy studies). This is likely due to ineffi cient recog-
nition by oligosaccharyl transferase of folded StxB-
Glyc-KDEL and possibly also to partial targeting of 
StxB-Glyc-KDEL to the smooth ER (142). In mesan-
gial cells, glycosylation effi ciency is systematically 
lower than in Hela cells, even at the earliest time 
points. This difference becomes particularly strik-
ing after 24 hr (table 2). In GMVECs, the glycosyla-
tion effi ciency is comparable to Hela at the earlier 
time points, even though some decrease is already 
apparent after 4 hr. After 24 hr, the glycosylation 
values observed on GMVECs are almost as low as 
ResultsChapter 3 - Effect of Shiga-like toxin on endothelium
58 59
 DRM association
 It has previously been shown that effi cient retro-
grade transport of StxB correlates with effi cient 
DRM association (54). To determine whether in me-
sangial cells and GMVECs, StxB is also associated 
with DRMs, iodinated StxB-Glyc-KDEL was bound to 
TNF-α treated or control cells on ice. Cells were lysed 
in Triton X-100 buffer, DRMs were fl oated on gradi-
ents, which were fractionated. DRMs were found at 
the 5/30% interface, as described before (54). 26% 
or 35% of cell-associated StxB was found in DRMs 
in mesangial cells or GMVECs, respectively (fi gure 
4), similar to the 30% that were DRM associated 
in HeLa cells (not shown). After preincubation with 
TNF-α for 24 hr, no signifi cant change in percen-
tages of StxB in the DRM fraction was observed.
  Figure 4 Analysis of StxB association with 
DRMs
 Vertical: Stx/StxB (% of total) 
 Horizontal: Fractions
After 24 hours preincubation with (blue) or without 
(white) TNF-α, iodinated StxB-Glyc-KDEL was bound 
to human GMVECs (A) or human mesangial cells (B) 
on ice. The cells were washed, lysed in 1% Triton 
X-100 buffer, and DRMs were fl oated in Optiprep 
step gradients. The gradients were fractionated and 
fractions were counted in a gamma counter. StxB 
was readily detected in the DRM fraction 2 in both 
cell types.
in mesangial cells (table 2). Separated experiments 
showed lack of glycosylation of StxB-Glyc-KDEL in 
human monocyte-derived macrophages.
Strikingly, 24 hr stimulation with TNF-α did not in-
crease retrograde transport effi ciency in any of the 
analyzed cell types at any of the analyzed time 
points (table 2). 
  Table 2 Quantifi cation of STxB retrograde 
transport to the ER.
After 24 hours of preincubation with or without 
TNF-α , iodinated STxB-Glyc-KDEL was bound to 
GMVECs, mesangial cells and HeLa cells for 1, 4, or 
24 hours. Then cells were lysed and lysates were 
analyzed by gel electrophoresis. Arrival in the ER 
was quantifi ed through the detection of STxB’s gly-
cosylation. Data given as means ± SEM (number of 
experiments in parentheses).
Incubation 
time
1 hour
 
4 hours
24 hours
Cell type
GMVECs
mesangial cells
HeLa cells
GMVECs
mesangial cells
HeLa cells
GMVECs
mesangial cells
HeLa cells
Glycosylation 
(%)
Control
1.6 ± 0.9 (4)
0.6 ± 0.1 (3)
1.1 ± 0.8 (3)
5.5 ± 3.5 (3)
3.8 ± 3.3 (3)
6.4 ± 1.5 (4)
9.2 ± 2.8 (6)
7.4 ± 1.2 (5)
24.9 ± 1.6 (6)
TNF-α
1.5 ± 0.6 (2)
0.5 ± 0.2 (2)
0.6 ± 0.1 (2)
5.0 ± 1.1 (3)
1.9 ± 0.6 (3)
6.9 ± 1.0 (3)
10.3 ± 3.0 (4)
7.2 ± 1.7 (5)
23.7 ± 1.9 (5)
1 2 3 4 5 6 7
40
A GMVEC
30
20
10
0
1 2 3 4 5 6 7
40
B Mesangial cells
30
20
10
0
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 Discussion
 During the development of HUS, most extensive 
tissue damage occurs within the kidney (143). Proxi-
mal tubular cells are exquisitely sensitive to Stx, 
undergoing apoptosis even without prestimulation 
with TNF-α or lipopolysaccharide (LPS) (144). Ne- 
vertheless, it is generally accepted that Stx medi-
ated endothelial cell damage is the major event 
triggering the development of HUS (143, 145). It has 
been shown that cytokines can up-regulate the ex-
pression of Gb3 in both mesangial cells and GMVECs 
(132, 133, 134). These findings have been confirmed 
in our experiments with TNF-α. Stx does not affect 
mesangial cell viability under basal conditions or 
after preincubation with TNF-α, whereas protein 
synthesis is inhibited (133, 134). In unstimulated 
GMVECs, Stx does not inhibit cell viability and pro-
tein synthesis, but GMVECs become highly sensitive 
for Stx after stimulation with TNF-α (132).
In this study, we have demonstrated that the recep-
tor binding B-subunit of Shiga toxin/Stx-1 follows the 
retrograde route in TNF-α stimulated and unstimu-
lated mesangial cells and GMVECs. The B-subunits 
are organized in a pentameric form (146). The pres-
ence of the Shiga toxin A-subunit of cell surface-
bound toxin stimulates clathrin-dependent uptake 
of the toxin (111). However, the trafficking route of 
the B-subunit and the holotoxin is the same (62). 
Although the expression of Gb3 is up-regulated af-
ter incubation with TNF-α, and TNF-α-treated cells 
bind more Shiga toxin/Stx-1 than unstimulated cells, 
no change in the retrograde transport efficiency 
of Shiga toxin/Stx-1 is observed. TNF-α therefore 
seems to increase cytotoxicity of Shiga toxin/Stx-1 
without affecting the efficiency of the toxin’s intra-
cellular trafficking. The relative transport rate of 
Shiga toxin/Stx-1 remains unchanged. Interestingly, 
it has also been shown that Stx-1 does not influence 
the viability of mesangial cells and unstimulated 
GMVECs (132, 133), despite its retrograde transport 
in these cells, as shown in this study. We conclude 
that whether or not a cell is sensitive to Shiga toxin/
Stx-1 does not only depend on retrograde transport 
(see below), but also on additional factors. One of 
these might be the amount of Shiga toxin/Stx-1 that 
reaches the cytosol. Gb3 expression of unstimula-
ted GMVECs is much lower than the expression of 
Gb3 on mesangial cells. When both are stimulated 
with TNF-α, Gb3 expression of GMVECs increases 
more and reaches higher levels as in mesangial 
cells (table 1). Under these conditions, a threshold 
level of Shiga toxin/Stx-1 may be reached in the ER 
that permits a cytotoxic amount of Stx to be trans-
ported to the cytosol. Cellular processing of the un-
cleaved toxin by the enzyme furin has also a role in 
this toxicity (132).  It cannot be excluded, however, 
that TNF-α has additional cellular effects that also 
contribute to efficient intoxication of cells, such as 
for example increasing retrotranslocation of toxin 
to the cytosol.
When a toxic dose of Shiga toxin/Stx-1 reaches the 
cytosol of a cell, ribosomes are inactivated and pro-
tein synthesis is massively inhibited which leads 
to cell death (132). Classically, it was thought that 
this was the only relevant biologic activity of Shiga 
toxin/Stx-1 (17, 132, 133). It is only recently that re-
search in this domain has focused on what is called 
the ‘ribotoxic stress model’. When Shiga toxin/Stx-1 
reaches the cytosol in a subtoxic dose, e.g. as in 
mesangial cells or unstimulated GMVECs, only part 
of the ribosomes are inactivated. The intact ribo-
somes are able to keep up with protein synthesis so 
that cell viability is not affected. This Shiga toxin/
Stx-1-mediated damage to ribosomes may gener-
ate a cellular-stress signaling response leading to 
production of new ribosomes and proinflammatory 
cytokines (56, 117, 147). In human umbilical vein en-
dothelial cells (HUVECs), which are comparable to 
GMVECs in that they are only sensitive to Shiga 
toxin/Stx-1 after preincubation with TNF-α (148), 
stimulation with a subtoxic dose of Stx-1 leads to ex-
pression of genes that encode for chemokines and 
cytokines (149). This response is also described in 
a monocytic cell line (56) and intestinal epithelial 
cells (31, 117). The ribotoxic stress model might be 
applicable to renal cells, and thus contribute to the 
pathogenesis of HUS.
In conclusion, we describe that in human GMVECs 
and mesangial cells, Shiga toxin/Stx-1 is transported 
via the retrograde route to the Golgi apparatus and 
ER. This study thereby closes one of the remain-
ing gaps in the understanding of the pathological 
process of HUS: it describes the transport route of 
Shiga toxin/Stx-1 in its physiological target cells, i.e. 
human glomerular endothelial and mesangial cells. 
Our study shows that TNF-α induced sensitization 
of renal cells must result from higher amounts of 
cell-associated toxin rather than from stimulation of 
retrograde transport as such, and thus, makes an 
important contribution to the understanding of the 
cellular mechanisms of HUS.
In conclusion, we 
describe that in 
human GMVECs 
and mesangial 
cells Shiga toxin/
Stx-1 is transported 
via the retrograde 
route to the Golgi 
apparatus and ER.
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Since WPbs contain 
regulators for both 
haemostasis and 
inflammation, we 
evaluated whether  
stimulation of  
primary human  
endothelial cells  
(HUVECs and  
GMVECs) with a 
subtoxic dose of 
Stx could trigger  
exocytosis of 
WPbs.
activator), induce vasoconstriction (endothelin-1, 
endothelin converting enzyme), and inflammation 
(P-selectin, eotaxin-3, IL-8, angiopoietin-2, CD63, 
α1,3-fucosyltransferase VI, osteoprotegerin) (152). 
With all these different components the endothelial 
cell is capable of a rapid response to changing con-
ditions. This is in contrast to the slower response 
with de novo synthesis.  
Many inducers of exocytosis of WPbs have been 
described, but in this work we investigated if Stx 
could also trigger its release. Since WPbs contain 
regulators for both haemostasis and inflamma-
tion, we evaluated whether stimulation of primary 
human endothelial cells (HUVECs and GMVECs) 
with a subtoxic dose of Stx could trigger exocytosis 
of WPbs. For this purpose, we have determined the 
effect of Stx on the quick release of the haemostatic 
VWF. The effect on another component of the WPbs, 
angiopoietin-2 (ANG) was included. 
 
 
 Abstract
 Diarrhea-associated haemolytic-uraemic syndro-
me (D+HUS) is associated with the presence of 
exotoxin Shiga toxin (Stx). In plasma of patients 
with D+HUS, levels of von Willebrand factor (VWF) 
are elevated as a result of renal endothelial da-
mage. In endothelial cells, VWF is stored in secre-
tory granules called Weibel-Palade bodies (WPbs). 
The aim of this study is to examine the possible trig-
gering effect of Stx1 on the endothelial cells, with 
particular reference to the exocytosis of WPbs.
Cultured human primary endothelial cells (HUVECs 
and GMVECs) were stimulated by thrombin and Stx1 
in static conditions as well as in flow. The amount 
of secreted VWF in the supernatant as well as the 
remaining intracellular fraction was determined. 
In static conditions, Stx could not induce a signi-
ficant exocytosis of WPbs in HUVECs as shown 
by both methods. On the contrary, stimulation of 
HUVECs by Stx in flow resulted in a significant de- 
crease in the amount of intracellular VWF. No ef- 
fect of Stx on HUVECs in flow was observed. In 2 
out of 4 investigated GMVECs the amount of in-
tracellular VWF was decreased by Stx during flow. 
Stx might contribute via an effect on WPbs to an 
increased exocytosis of VWF in flow.
 Introduction
 The exotoxin Shiga toxin (Stx), originating from 
specific serotypes of Escherichia coli, is the central 
virulence factor in diarrhoea-associated haemoly-
tic-uraemic syndrome (D+HUS). D+HUS is the most 
important cause of acute renal failure in children. 
In the new classification of HUS, infections due to 
Stx- producing bacteria, belong to the category of 
‘etiology advanced’ (2). The underlying pathogenic 
mechanism is the endothelial damage of the glo-
meruli and arterioles in the kidney by Stx (1). This 
damage leads to the formation of thrombi and ini-
tiation of an inflammatory response. Since coagula-
tion plays an important role in this disease, much 
research has been performed to elucidate possible 
disturbances in this system. Von Willebrand Factor 
(VWF) antigen was found in an increased level in 
serum of patients in the acute phase of D+HUS. A 
loss of large multimers and in increase of small mul-
timers was observed. This may be due to abnormal 
shear stress in the microvascular circulation (150). 
VWF is involved in direct adhesion and aggrega-
tion of platelets on damaged endothelium, whereas 
it also functions as a chaperone for coagulation 
factor VIII. Wagner et al discovered that VWF was 
stored in endothelium-specific storage vesicles, 
called Weibel-Palade bodies (WPbs) (151). The WPbs 
are rod-shaped cytoplasmic structures with a tubu-
lar composition. After perturbation of the endothe-
lial cell, WPbs can be exocytosed through two dif-
ferent mechanisms (152). One pathway is activated 
by an increase on intracellular calcium and will lead 
to both exocytosis of the WPbs and the formation 
of stress fibers with loss of endothelial cell barrier 
function. For an example, thrombin uses this mech-
anism. The other pathway is regulated by cAMP and 
will also lead to exocytosis, but in contrast, improves 
the endothelial cell barrier function. Possible ago-
nists of this route are vasopressin and epinephrine. 
The work of Ikeda et al described that Stx increased 
calcium in Vero cells, which are highly sensitive to 
its effect (153).
Many different components of the WPbs have been 
identified, and these indicate the key role that WPbs 
play in many important physiological processes in 
endothelial cells. Its constituents are involved in 
haemostasis (VWF and tissue-type plasminogen 
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Ingerslev et al (154). 96 wells-plates (Nunc, Rosk-
ilde, Denmark) were coated with rabbit anti-human 
VWF polyclonal antiserum (Dako A/S: Glostrup, 
Denmark). Test samples were diluted 1:100 and 
added to the ELISA plate. Pooled plasma (10 μg/
ml) was used as standard. After incubating for 2 
hours at room temperature, the plate was washed 
and rabbit anti-human VWF peroxidase conjugate 
(Dako A/S, Glostrup, Denmark) was added.  Again, af- 
ter 2 hours the plate was properly washed and 
substrate solution (ortho-phenylenediaminetablets 
(Dako A/S, Glostrup, Denmark) and H2O2) was ad- 
ded to each well. The reaction was stopped after 30 
minutes with H2SO4 and the extinctions were mea-
sured at a wavelength of 492 nm in a BioRAD plate 
reader.
 Quantification of intracellular VWF and ANG 
 in endothelial cells
 Endothelial cells were cultured as described in 
the above section. Stimulation was performed in 
both flowing and static conditions. In both set-ups, 
cells were exposed to thrombin (1 U/ml), Stx1 (10 
nM) or PMA (phorbol 12-myristate 13-acetate (Fluka: 
Neu-Ulm, Germany); 100 ng/ml) during 15 min-
utes (flowing conditions) or 1 hour (static condi-
tions) in EBM-2 with single quots (Lonza, Brussels, 
Belgium) and M199 with 0.5% BSA. Before the ex-
periment, cells were kept overnight with EBM-2 + 
single quots and 5% FCS. To apply shear stress, 
cells were incubated with the stimulants in a par-
allel Focht flow perfusion chamber with well-de-
scribed characteristics (155). A coverslip with a 
monolayer of endothelial cells was assembled in 
the flow chamber, which was mounted on an in-
verted phase-contrast microscope stage (Axio-
vert 35M, Zeiss, Germany). The stimulus was pre-
warmed to 37˚C and aspirated from a reservoir 
through the perfusion chamber with a withdrawal 
syringe pump (Harvard apparatus, Holliston, MA, 
USA; ANTEC, Leiden, The Netherlands). The com-
plete system was present in a 37˚C incubator. Tem- 
perature fine-tuning was performed by the Biop-
techs FCS2 controller. The applied shear stress 
was 1 dyne/cm2 similar to Nolasco et al (156). After 
the incubation with the stimulants, the cells were 
lysed according to Michaux et al (157). After rins-
ing the cells once with PBS, lysis buffer (M199 with 
 Methods
 Culture of endothelial cells
 Human umbilical venous endothelial cells (HU-
VECs) were harvested after collagenase (Worthing-
ton: NJ, USA) treatment as previously described 
(121). HUVECs in passage 2-4 were used. Glomerular 
microvascular endothelial cells (GMVECs) were ob-
tained from human kidneys (collected after informed 
consent). Glomeruli were isolated under sterile con-
ditions using a gradual sieving procedure followed 
by digestion with collagenase (132). GMVECs in pas-
sage 7-10 were used. Cells were grown confluent on 
tissue culture plastic plates coated with 1% porcine 
gelatine (Fluka: Neu-Ulm, Germany). Medium (M199; 
Gibco: Paisley, UK) with addition of 10% human se-
rum (Cambrex: Walkersville, USA), 10% newborn calf 
serum (Gibco: Paisley, UK), 1% 200 mM L-glutamine 
(MP Biomedicals; Eschwege/Germany), 1% penicil-
lin-streptomycin (Gibco: Paisley, UK), growth factor 
(extracted from bovine brains (119)) and 0.1% hepa-
rin (Leo Pharma BV: Breda The Netherlands) was 
refreshed every two days. 
 Quantification of VWF in supernatant 
 endothelial cells
 To study the exocytosis of WPbs in the super-
natant of endothelial cells, the cells were grown 
to confluency in 24 wells plates (Corning Incorpo-
rated: Schiphol-Rijk, The Netherlands).  During 5, 10 
and 15 minutes, the cells were incubated with throm- 
bin (5 U/ml; Organon Technika, Turnhout, Belgium) 
or Stx1 (10 nM; Stx1 was kindly provided by Dr. M. 
Karmali, Toronto, Canada) which was endotoxin- 
free as determined with a Limulus-assay, at 37˚C. 
Cells remained viable during this incubation, as 
determined with a 3H-leucine incorporation as- 
say (data not shown). The stimuli were dissol- 
ved in M199 with 2.5% fetal calf serum (Greiner 
Bio-One; Kremsmunster, Austria). Cells were rin- 
sed once with M199 before adding the stimuli. 
After the incubation the supernatant was removed, 
centrifuged at 2000 xg and stored immediately at 
–20 ˚C. 
The amount of released VWF in the supernatant 
from endothelial cells was measured by ELISA. All 
experiments were performed in duplicate.
The ELISA for VWF was performed according to 
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0.2% BSA and 0.1% Triton X-100 (Sigma-Aldrich, 
Zwijndrecht, The Netherlands)) containing pro-
tease inhibitors (aprotinine 30 μl/ml, PMSF, 20 μl/ 
ml, ortho-vanadate 100 mM 10 μl/ml) was added 
at 4˚C during 30 minutes. Afterwards, lysates was 
centrifuged during 5 minutes at 10000xg at -4˚C. 
For imaging, cells were fixed in the flow chamber 
immediately after the experiment (flow conditions) 
or in a 24-well plate (static conditions).
The lysates were then analysed for the presence 
of VWF and ANG. VWF was detected with an ELISA 
as described above for the supernatants. Also, 
ANG was determined with an ELISA-procedure. A 
96-wells plate was coated over night with a mono-
clonal antibody against ANG (R&D systems, Oxon, 
United Kingdom) at room temperature. After wash-
ing with PBS/Tween, the wells were blocked with 
PBS containing 1% BSA, 5% sucrose (Fluka: Neu-
Ulm, Germany) and 0.05% sodiumacetate (Fluka: 
Neu-Ulm, Germany) for 1 hour at room temper- 
ature.  After blocking, the samples were added to 
the wells during 2 hours at room tempera-ture. Bi-
otinylated anti-human ANG (R&D systems, Oxon, 
United Kingdom) in 1% heat inactivated mouse se-
rum was used during 2 hours at room temperature. 
After rinsing, streptavidin HRP (R&D systems, Oxon, 
United Kingdom) was applied for 20 minutes at 
room temperature followed by OPD. Subsequently, 
extinctions were determined with a plate reader.  
Furthermore, cells were prepared and analysed by 
confocal laser scanning microscopy as described 
by Romani-de Wit et al (158). Cells were stained for 
VWF using monoclonal antibody CLB-RAg20 (159) 
and for CD31 using monoclonal antibody CLB-HEC-
75 (160). Alexa 594 and-633 conjugated secondary 
antibodies were from Invitrogen (Breda, the Nether- 
lands). Laser Scanning Confocal Microscopy was 
performed using a Zeiss LSM510 and results were 
analyzed using Zeiss LSM510 version 4.0 software.
 Statistics
 All data presented are expressed as a range with 
the median. Significance of the quantitative data 
was analyzed using the Wilcoxon signed ranks test. 
The statistical level of significance was defined as 
P< 0.05.
Methods
   Figure 2 Intracellular VWF and ANG in HUVECs 
and GMVECs
 Vertical: % of control
HUVECs and GMVECs were incubated with thrombin 
(T) and Stx1 in static conditions. After the incuba-
tions, the intracellular amounts of VWF and ANG 
were calculated. 
Thrombin is capable of decreasing the intracellular 
amount of VWF and ANG in HUVECS, whereas it 
does not have a signifi cant effect in GMVECS. Stx1 
signifi cantly decreases ANG in HUVECs. No effect 
of Stx1 is detected in GMVECs. The asterisk (*) indi-
cates a signifi cant effect (P<0.05).
Figure 1 presents the data on the level of VWF in 
the supernatant determined with ELISA. The results 
are expressed as percentage of the negative con-
trol. Thrombin was able to induce a signifi cant re-
lease of VWF after 5, 10 and 15 minutes in HUVECs. 
Only after ten minutes of incubation of HUVECs 
with Stx, there is a small but signifi cant increase 
of VWF (median control value 100% versus 125% 
with Stx). In the small number of investigated 
GMVECs, neither thrombin nor Stx1 caused a signifi -
cant release of VWF.
 Results
 Quantifi cation of VWF in the supernatant of  
 endothelial cells
 To study the possible exocytosis of WPbs from hu-
man endothelial cells after incubation with a sub-
toxic dose of Stx, the presence of VWF in the super-
natant of stimulated endothelial cells (HUVECs and 
GMVECs) was determined. Thrombin was used as a 
positive control.
  Figure 1 VWF in supernatant of HUVECs and 
GMVECs after incubation with thrombin or Stx1
 Vertical: VWF of control (%)
 Horizontal: Incubation time (min) 
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 Quantifi cation of intracellular VWF and ANG in  
 endothelial cells
To determine the level of intracellular VWF after 
incubation with Stx1, cell lysates were analysed by 
ELISA. If Stx1 is able to induce exocytosis, the 
amount of VWF should be decreased compared to a 
negative control. Also, the presence of ANG was de-
termined, since this is also a constituent of WPbs.
Figure 2 represents the data of the experiments 
performed in static conditions. HUVECs stimulated 
by the positive control, thrombin, contain a clear 
decreased level of VWF and ANG. In contrast, Stx-1 
was not able to exocytose VWF although a small 
decrease of ANG in HUVECs is observed. GMVECs 
are not sensitive for the effect of Stx in static condi-
tions. No decrease in VWF or ANG could be detected 
in this small study. To illustrate this, fi gure 3 dem-
onstrates confocal images of GMVEC after incuba-
tion with thrombin and Stx1. Thrombin decreases 
the amount of WPbs, whereas Stx1 does not have 
an effect.
Experiments were also performed in fl owing con-
ditions since it approaches more the in vivo situ-
ation. Figure 4 represents our data of HUVECs 
incubated with thrombin or Stx1 in fl ow (n=5). In 
this set-up, Stx1 is triggering the endothelial cells 
into a signifi cant decrease of VWF. ANG is also de-
creased, but non-signifi cantly. Table 1 demonstra-
tes our data gathered after incubation of GMVEC 
in fl ow. 4 GMVECs donors were used. Donors 1 and 
3 respond with a decrease of VWF and ANG after 
incubation with both PMA and Stx1. Only in these 
experiments PMA was used as a stimulus. Throm-
bin had a similar but less pronounced effect. How-
ever, donors 2 and 4 did not respond adequately 
to the positive control. This suggests that if the 
donor is sensitive for the positive control, it will 
also respond by the release of VWF and ANG. But 
not every donor of GMVECs is sensitive for the posi-
tive control. This is also demonstrated in fi gure 5 
that demonstrates 2 different GMVECs-donors of 
which donor A responds to the positive control and 
donor B does not. 
Results
HUVEC
vWF (n=6) Ang-2 (n=8)
T TStx1 Stx1
150 150
125 125
100 100
75 75
50 50
25 25
0 0
*
*
*
GMVEC
vWF (n=3) Ang-2 (n=3)
T TStx1 Stx1
150 150
125 125
100 100
75 75
50 50
25 25
0 0
5
T S
10
T S
15
T S
800
600
400
200
0
*
*
*
*
HUVEC
5
T S
10
T S
15
T S
800
600
400
200
0
GMVEC
HUVECs (n=7) and GMVECs (n=4) were incubated with thrombin or Stx1 for respectively 5, 10 and 15 min-
utes. Negative control was set at 100%. Thrombin clearly triggers secretion of VWF in HUVECs, whereas 
Stx1 does not induce a release. In GMVECs both thrombin and Stx do not induce a signifi cant effect. The bar 
depicts the median. The asterisk (*) indicates a signifi cant effect (P<0.05). 
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  Figure 5* Confocal microscopy of GMVECs 
incubation with thrombin or Stx1 in fl ow 
conditions
*  To see fi gure in full colour, see Appendix
GMVEC donor A and B were incubated in fl ow with 
thrombin and Stx1. Cells were fi xed and stained for 
VWF (blue) and CD31 (light blue). The merge of fl uores-
cent signals is shown.  GMVECs B show less effect of 
thrombin than GMVECs A. A noticeable effect can 
be detected in both donors after exposure to Stx.
  Figure 3* Confocal microscopy of GMVECs for 
VWF after incubation with thrombin or Stx1 in 
static conditions
*  To see fi gure in full colour, see Appendix
GMVECs was incubated under static conditions with 
thrombin and Stx1 (A= control; B= thrombin; C= Stx). 
Cells were fi xed and VWF was stained using mono-
clonal antibody CLB-Rag20. Z-stack images were 
made and projections are shown. Confocal imaging 
showed the same amount of WPbs after incubation 
with Stx1 compared to the control. Thrombin in-
duced a clear effect.
  Figure 4 Intracellular VWF and ANG in HUVECs 
in fl ow
 Vertical: % of control
 
HUVECs were incubated with thrombin (T) and Stx1 
in fl owing conditions. After the incubations, the in-
tracellular amounts of VWF and ANG were calcula-
ted. Stx1 is capable of decreasing the intracellular 
amount of VWF, whereas thrombin has a smaller 
and non-signifi cant effect. However, thrombin sig-
nifi cantly decreases ANG. Stx1 can not produce a 
signifi cant effect on ANG. The asterisk (*) indicates 
a signifi cant effect (P<0.05).
control
GMVEC A
GMVEC B
trombin Stx
A B C
HUVEC
vWF (n=5) Ang-2 (n=5)
T TStx1 Stx1
150 150
125 125
100 100
75 75
50 50
25 25
0 0
*
*
PMA
Stx1
Donor
1
75
82
2
99.1
104
3
65
88.9
4
99.3
93.3
median
87.1
91.1
p-value
0.068
0.144
Donor
1
76.4
82.6
2
84
112.3
3
83.8
93.1
4
95.8
102.2
median
83.9
97.7
p-value
0.068
0.715
VWF (% of control) ANG (% of control)
Stimulus statistics statistics
Table I VWF and ANG in GMVECs incubated in fl ow
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Discussion
 Discussion
 In this paper, the effect of Stx1 on the exocytosis 
of the WPbs was studied. The components of the 
WPbs play a central role in coagulation and inflam-
mation of endothelial cells. Stx1 is a key virulence 
factor in D+HUS. The pathogenesis of this disease 
is based on the damage of the glomerular endothe-
lium with well-described consequences on the co-
agulation and inflammation. If Stx1 proved to be an 
inducer of exocytosis of WPbs, this can contribute 
to our insight in the pathogenesis of D+HUS.
As a marker for exocytosis of WPbs, we have mea-
sured the presence of VWF in the supernatant of 
HUVECs and GMVECs. The remaining intracellular 
fractions of WPBs-constituents VWF and ANG were 
also determined after the incubations. In HUVECs, 
there is a clear effect of thrombin and also Stx1 in-
duces a small release of VWF after 10 minutes in 
the supernatant. Since this effect is quick, it can be 
attributed to the release of WPbs. The intracellular 
content of VWF was not decreased by Stx1. This con-
firms the work of Kaye et al (161) which describes 
the positive effect of TNF-α on the release of WPbs, 
whereas a four-hour incubation of HUVECs with Stx 
did not induce any release. WPbs were detected 
with immunofluorescence microscopy using anti-
bodies against VWF.
We would like to stress that in our experimental 
settings, especially in working with primary GMVECs 
and HUVECS, we have experienced donor variability 
for the sensitivity of Stx and thrombin. 
To approach the in vivo situation, we have perform- 
ed equal experiments with exposure of the endothe-
lial cells to shear stress. Especially, since Nolasco et 
al described the secretion of ultra-large multimeric 
strings of VWF after stimulation of endothelial cells 
with Stx in flow conditions similar to our experi-
ments (156). Also, Galbusera et al published an ar-
ticle in which they describe the stimulating effect of 
prolonged exposure to high shear stress on the re-
lease of VWF (162). HUVECs and GMVECs were incu-
bated with a positive control (thrombin or PMA) and 
Stx1 in flow. After these incubations, the intra-cel-
lular amount of VWF and ANG was measured. With 
these conditions of shear stress, HUVECs could be 
triggered into a significant decrease of VWF by Stx1. 
Interestingly, the GMVECs donors that responded to 
the positive control, were also able to respond to 
Stx1 as can be seen in table 1. This donor variability 
is also demonstrated in figure 5. 
Some important conclusions can be drawn from 
these experiments; 1) Thrombin can induce the re- 
lease of WPbs in HUVECs; 2) In HUVECs, Stx1 ap- 
pears to have a significant effect on WPbs in flow 
condition, and not in static conditions; 3) There is 
a possible influence of flow on the effect of Stx on 
GMVEC.
Further studies under flow conditions will reveal 
new insight in the pathogenesis of HUS, which can 
not be obtained under static conditions. 
Further studies 
under flow condi-
tions will reveal 
new insights in the 
pathogenesis of 
HUS, wich can not 
be obtained under 
static conditions.
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The performed  
experiments al- 
low us to evaluate 
the effect of Stx  
on firm leukocyte-
adhesion under  
dynamic flow  
conditions and 
whether HSPG  
are involved.
roll over the endothelial cells, and get into con-
tact with endothelial HS-bound chemokines, which 
in their turn activates integrins on leukocytes like 
MAC-1. Subsequently, leukocytes will adhere more 
firmly, which is in part mediated by the HS-MAC-1 
interaction. Finally, the leukocytes will transmigrate 
through the endothelium to the extracellular ma-
trix. 
Recently, Wang et al described a reduced neutro-
phil infiltration in an experimental peritonitis in ge-
netically engineered mice with low sulfation of en- 
dothelial HSPG (166). Furthermore, Rops et al have 
demonstrated that HS on mouse glomerular en-
dothelium activated by TNFα, is crucial for the num-
ber of rolling and firmly adhering leukocytes (167). 
In this study, we focused on the inflammatory pro-
cess induced by Stx in HUS. The performed experi-
ments allow us to evaluate the effect of Stx on firm 
leukocyte adhesion under dynamic flow conditions 
and whether HSPG are involved. Since application 
of shear stress changes the phenotypic appearance 
of endothelial cells, these experiments approach 
the in vivo situation (168). Endothelial cells from um-
bilical origin and glomerular endothelial cells were 
used. The latter were selected as being the primary 
target of shiga toxin.
 
 Abstract
 Background
 Shiga toxin (Stx) is the main pathogenic factor in 
the haemolytic-uraemic syndrome (HUS). Stx da- 
mages the renal endothelium which leads to inflam-
mation and coagulation. Endothelial heparan sul- 
fate proteoglycans (HSPG) and in particular hepa- 
ran sulfate, play an important role in the inflam- 
matory process by acting as a ligand for L-selec- 
tin. Furthermore, leukocytes are able to interact 
with chemokines bound to HSPG (examples are IL-8, 
RANTES and MCP-1). This leads to an activation of 
integrins on leukocytes and results in more stable 
leukocyte-endothelial wall adhesion.
In this study, we have evaluated the effect of a sub-
toxic dose of Stx1 and -2 on the HSPG and its role in 
adhesion of leukocytes. 
 Methods
 Primary human umbilical venous endothelial cells 
(HUVECs) and primary human glomerular micro-
vascular endothelial cells (GMVECs) were incubated 
for 24 hours with a subtoxic dose of Stx1 or -2. Then, 
cells were treated with heparan sulfate-degrading 
enzyme heparitinase I or left untreated, followed by 
determination of binding leukocytes to endothelial 
cells in a parallel plate flow chamber.  
 Results
 In both cell types, Stx increased the amount of 
firmly adherent leukocytes. After removal of en-
dothelial heparan sulfate, the number of adhering 
leukocytes decreased. 
 Conclusions
 HSPG have a distinctive role in adhesion of leuko-
cytes to endothelial cells stimulated by a subtoxic 
dose of Stx. 
 Introduction
 Haemolytic-uraemic syndrome (HUS) is a form of 
acute renal failure in children, combined with throm- 
bocytopenia and haemolytic anaemia. Although 
new insight has been gained in the pathogene- 
sis of genetic variants of HUS, the underlying me- 
chanism in infection-related HUS is still not un-
derstood (163). The most important pathogen in 
infection–related HUS is Escherichia coli O157:H7, 
which produces Shiga toxin (Stx) (1). There are 
two different variants, Stx1 and -2, which share 
50% homology and have a similar biological 
effect. This toxin has a cytotoxic effect on the 
renal endothelium. It internalises after binding to 
a specific receptor (CD77; Gb3), and disables the 
ribosome (163). This undermines the protein 
synthesis of the cells and will ultimately lead to 
cell death. Because of this damage, two diffe- 
rent biological cascades are initiated: coagula-
tion and inflammation. Renal biopsies of patients 
with HUS show occluded glomerular arterioles 
and deposition of inflammatory cells (163). 
During the last decade it has become evident that 
heparan sulfate proteoglycans (HSPG) are crucial 
for leukocyte-endothelium trafficking (164, 165). 
These negatively charged structures are ubiqui-
tously expressed on cell surfaces, blood cells and 
in the extracellular matrix (164, 165). HSPG is a 
macromolecular structure consisting of a protein 
backbone covalently carrying heparan sulfate (HS) 
chains. HS belongs to the family of glycosamino-
glycans that comprises the highly sulfated heparin 
and non-sulfated hyaluronan. The HS chain shows 
a high diversity in structure, which is dictated by 
combinations of possible modifications such as sul- 
fation patterns. This allows HSPG to interact 
with many different proteins like cytokines, chemo-
kines and cell-adhesion molecules. HSPG on endo-
thelial cells play an important role in tethering, 
rolling, firm binding and transmigration of leuko-
cytes to the extracellular matrix (164, 165). After 
an inflammatory insult, endothelial cells will ex- 
press more cell adhesion molecules (E- and P-se- 
lectin), which will bind to leukocytes that express 
ligands such as P-selectin glycoprotein ligand-1. 
During the rolling phase, endothelial HS will serve 
as a ligand for L-selectin on leukocytes. They will 
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 Material & Methods
 Culture of endothelial cells
 Human umbilical venous endothelial cells (HU-
VECs) were harvested after collagenase treatment 
(Worthington: NJ, USA) and cultured according to 
a previous described method (121). HUVECs from 5 
donors (passage 2-4) were used. Glomerular micro-
vascular endothelial cells (GMVECs) were obtained 
from human kidneys and cultured as described pre-
viously (132). GMVECs from 3 donors in passage 7-10 
were used. Every donor was used once in the ex-
periments. For the adhesion experiments, cells were 
seeded on plastic coverslips (Thermanox; Nunc Inc., 
Naperville, USA). Growth medium of both cell types 
consisted of M199 (Gibco: Paisley, UK) with addition 
of 10% human serum (Cambrex: Walkersville, USA), 
10% newborn calf serum (Gibco: Paisley, UK), 1% 
200 mM L-glutamine (MP Biomedicals; Eschwege/
Germany), 1% penicillin-streptomycin (Gibco: Paisley, 
UK), growth factor (extracted from bovine brains 
(119)) and 0.1% heparin (Leo Pharma BV: Breda, The 
Netherlands). Medium was refreshed every two days. 
 Isolation of leukocytes
 Leukocytes were isolated from fresh human 
venous blood collected from healthy volunteers 
after informed consent as described previously 
(169). Briefly, after dilution of the blood with cold 
saline, it was centrifugated at 200 xg for 10 min-
utes at 4˚C. Subsequently, the cell pellet was gently 
put on 4 volumes of Emagel (Boehringwerke AG; 
Marburg, Germany) in order to sediment the eryth-
rocytes. This was performed for 45 minutes at 4˚C. 
The supernatant was removed and centrifugated 
at 4˚C for 10 minutes at 500 xg and the pellet was 
washed twice by centrifugation with saline. Then 
ammonium chloride was added for lysis of the re-
maining erythrocytes. After new washing steps with 
saline, cells were resuspended in culture medium at 
a concentration of 1 x 106 cells per ml. For every ex-
periment the leukocytes of 1 donor were used.
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 Incubation and manipulation  
 of endothelial cells 
 Endothelial cells were incubated for 24 hours with 
a subtoxic dose (50 pM) of Stx1 (kindly provided by 
Dr. M. Bielaszewska, Munster, Germany). This dose 
does not exert a cytotoxic effect, which was con-
firmed with trypan blue exclusion. 50 pM of Stx1 was 
free of lipopolysaccharide (LPS) as assessed with a 
Limulus-assay (detection limit 0.006 ng/ml). Stx2 
(Toxin Technology Inc, Sarasota, USA) was also used 
in a subtoxic dose (50 pM), since this toxin was able 
to increase the adhesion of leukocytes as demon-
strated by the work of Zoja et al (170). As the experi-
ments were performed in the same laboratory, the 
toxin was produced equally as described by Zoja et 
al (12). It contains 117 pg LPS/μg Stx2, which is 0.41 
pg/ml LPS at a dose of 50 pM Stx2. This is below 
the detection limit of the Limulus assay. This indi-
cates that LPS does not influence the final effects 
observed in the cells after stimulation with Stx1 and 
Stx2.
After incubation with Stx, HS was cleaved off by the 
HS-degrading enzyme heparitinase I (Seikagaku Co; 
Tokyo, Japan). This enzyme cleaves the alpha-N-
acetyl-D-glucosaminidic linkage in heparan sulfate, 
producing disaccharides. Briefly, the enzyme was 
dissolved in 0.5 U/ml in binding buffer (10 mmol/l 
HEPES, 137 mmol/l NaCl, 4 mmol/l KCl, 11 mmol/l D-
glucose and 0,1% bovine serum albumin (BSA), pH 
7,4), and incubated for 30 minutes at 37˚C. 
The efficacy of the enzyme was evaluated with im-
munofluorescence and FACS-analysis with antibo-
dies directed against heparan sulfate (primary anti-
body: mouse anti-human heparan sulfate 10E4 (US 
Biological, Swampscott, USA); secondary antibody: 
goat anti-mouse FITC conjugated (Jackson Immu-
noresearch, West Grove USA). For FACS-analysis, 
cells were detached by using EDTA 10 mM.
 Adhesion assay under dynamic  
 flow conditions
 A parallel-plate flow chamber was used to apply 
shear stress. This system is described in the arti-
cle of Morigi et al (169). In short, cover slips with 
a monolayer of endothelial cells were placed in the 
flow chamber. First, cell-free medium with 0.5% 
BSA was flowed over the cells during 2 minutes at 
0.6 dynes/cm2 for equilibration. Then, the leukocyte 
suspension was perfused through the chamber with 
1.5 dynes/cm2 during 10 minutes to approach the 
level of shear stress in glomerular arterioles. This 
was followed by again cell-free medium at 3 dynes/
cm2 during 5 minutes. At this higher level of shear 
stress, the number of firmly adhering leukocytes 
can be analyzed. The experiment was visualized 
and recorded with a video recording system con-
nected to an inverted phase-contrast microscope. 
The number of firmly adhering cells was calculated 
in 10 random equal fields by 2 observers.  
 Statistical analysis
 Results are expressed as mean ± SD. Data was an-
alyzed with student’s T-test. Statistical significance 
level was defined as P<0.05.
Figure 4 Number of fi rm adherent leukocytes on 
GMVECs 
 Horizontal: Incubation
 Vertical: cells/mm2
GMVECs (n=3) was incubated for 24 hours with Stx1 
or -2. Furthermore, they were treated with hepari-
tinase I (HEP) or remained untreated. The number 
of fi rmly adhering leukocytes was calculated. Stx 
increased the amount of adherent leukocytes. Re-
moval of HS can decreased this effect.
* <P0.05; **<P0.01
 Flow experiments
 After incubation of both endothelial cells with Stx1 
and -2, there clearly was an increased number of 
fi rmly adhering leukocytes to HUVECs (range: Stx1 
13-55; Stx2 38-70) (fi gure 3) or GMVECs (range: Stx1 
52-60; Stx2 51-62) (fi gure 4). Removal of HS from 
endothelial cells that were not incubated with Stx, 
did not have a signifi cant effect on fi rm leukocyte 
adhesion. However, treatment of the Stx-incubated 
endothelial cells with heparitinase I clearly revealed 
a decreased number of fi rmly adhering leukocytes 
(range: HUVEC Stx1 18-35; HUVEC Stx2 28-63; 
GMVEC Stx1 34-37; GMVEC 32-39) (fi gure 3 and 4). 
Taken together, removal of HS from Stx-incubated 
endothelial cells decreased the number of fi rmly ad-
hering leukocytes. 
Figure 3 Number of fi rm adherent leukocytes on 
HUVECs
 Horizontal: Incubation
 Vertical: cells/mm2
HUVECs (n=5) was incubated for 24 hours with Stx1 
or -2. Furthermore, they were treated with hepari-
tinase I (HEP) or remained untreated. The number 
of fi rmly adherent leukocytes was calculated. Stx in-
creased the amount of fi rmly adhering leukocytes. 
Removal of HS decreased this effect.
* <P0.05; **<P0.01 
 
  Figure 2 Effi ciency of heparitinase I treatment 
determined with FACS analysis
 
 Vertical: counts
 Horizontal: FL1-H
The amount of HS on HUVECs was analyzed after 
treatment with heparitinase I. The plot in light blue 
represents the cells without treatment of hepari-
tinase I. The dark blue plot represents the cells after 
treatment with heparitinase I.
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 Results
 Cleavage of HS from endothelial cells
 To evaluate the effi cacy of the HS-cleaving en-
zyme, the amount of HS after treatment with hepa-
ritinase I was estimated with immunofl uorescence 
and FACS-analysis.
The immunofl uorescence staining of endothelial 
cells by the anti-HS antibody 10E4 is shown in fi g-
ure 1A. Removal of HS by heparitinase I revealed 
a complete abolishment of staining (fi gure 1B). To 
quantify these results, we repeated this analysis 
by FACS. This confi rmed the immunofl uorescence 
staining, since treatment of the cells with the en-
zyme strongly reduced the staining (fi gure 2). 
  Figure 1* Effi ciency of heparitinase I treatment 
determined by immunofl uorescence staining 
*  To see fi gure in full colour, see Appendix
Removal of HS on HUVECs was determined by im-
munofl uorescence staining with the anti-HS anti-
body 10E4. HS on HUVECs was stained without (A) 
and after (B) treatment with heparitinase I. 
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 Discussion
 We showed that HS play an important role in the ad-
hesion of leukocytes to endothelial cells after treat- 
ment with a subtoxic dose of Stx. After removal of 
endothelial HS from Stx-incubated endothelial cells, 
the number of firmly adherent leukocytes is clearly 
decreased. 
Since Stx is considered a cytotoxic toxin, our results 
are very interesting. The increase in adhesion of 
leukocytes indicates that there must also be a 
stimulatory effect, besides inhibition of the protein 
synthesis. Several mechanisms for our results can 
be suggested. One possibility is an increased ex-
pression of HSPG after incubation with a subtoxic 
dose of Stx. Another option is an increase in bound 
chemokines on endothelium-HSPG after treatment 
with Stx. This will result in more adhering leuko-
cytes. The basal level of HSPG present on endothe-
lial cells will be sufficient to bind additional released 
chemokines. Zoja et al described an NF-κB depen-
dent up-regulation of mRNA from IL-8 and MCP-1 
by Stx and inhibition of leukocyte adherence after 
the application of antibodies against IL-8 and MCP-1 
(170). The work of Matussek et al confirmed the up-
regulation of mRNA of pro-inflammatory proteins 
by Stx (149). When released chemokines bind to 
HSPG on endothelial cells, they are protected from 
proteolysis, and are able to rapidly induce activa-
tion of integrins on leukocytes (164).
By using the parallel-flow chamber, we have ap-
plied shear stress to the endothelial cells, which 
mimics the in vivo situation. It is possible that the 
combination of Stx exposure and shear stress will 
increase the biological effect of Stx on endothelial 
cells. Moreover, during the development of HUS in 
patients, leukocytes like neutrophils and monocytes 
will become activated (112, 171). This will lead to in-
creased serum-levels of different cytokines. In our 
experiments, leukocytes from healthy donors in se-
rum-free medium were used. Possibly, in vivo there 
will be a much stronger effect of Stx in combination 
with cytokines from activated leukocytes.  
The residual number of firmly adhering leuko-
cytes after removal of HS from Stx-incubated en-
dothelial cells, indicate that also HS-independent 
factors are involved in the increased adhesion 
of leukocytes. Fractalkine could be such a fac-
tor, since Ramos et al demonstrated a selective 
depletion of mononuclear leukocytes expressing 
the receptor for fractalkine (172). Furthermore, 
fractalkine-receptor positive leukocytes were ob- 
served in renal biopsies of patients with HUS.
In conclusion, our data show that Stx can increase 
the number of firmly adhering leukocytes to en-
dothelial cells, which can be partially blocked by re-
moval of HS. These findings strongly suggest a role 
for endothelial HS in the inflammatory process in 
the renal vasculature during HUS. However, it can 
not explain the preferential damage of glomerular 
endothelial cells observed in HUS patients. 
As possible therapeutic options for future treat-
ment, the use of N-desulfated heparin, which inhi-
bits leukocyte adhesion and transmigration with low 
anticoagulant activity, or blocking of chemokine-re-
ceptors can be considered (173, 174).
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In this work we 
have examined in 
more detail the  
effect of a subtoxic 
dose of Stx on the 
transcription and 
translation in Stx-
sensitive cells.
  Abstract
 Shiga-like toxin (Stx) is produced by Escherichia 
coli bacteria. It may damage the human renal endo- 
thelium and result in the haemolytic-uraemic syn-
drome. Endothelial cells internalise the toxin which 
destructs ribosomes, leading towards inhibition of 
protein synthesis. Recently, data is emerging that 
Stx can also stimulate cells to produce pro-inflam-
matory proteins. We have studied the effect of a 
subtoxic dose of Stx1 (without inhibition of the over-
all protein synthesis) on the protein synthesis of en-
dothelial cells. 
Human umbilical venous endothelial cells were in-
cubated with a subtoxic dose of Stx1 or a positive 
control (TNFα or LPS). Different techniques (RT-
PCR, ELISA, FACS-analysis, Western Blot) were used 
to analyse its effect on protein synthesis.  
Stx1 was capable of increasing the mRNA of ICAM-1 
and IL-8. This did not result in increased expression 
of ICAM-1 on the cell surface. However, the intra- 
cellular level of ICAM-1 increased slightly. But it did 
not approach the effect of LPS, although the amount 
of mRNA was equally up-regulated.
This indicates that a subtoxic dose of Stx1 may sti-
mulate primary endothelial cells into protein syn-
thesis with adequate transcription. Since only a 
small increase of intracellular ICAM-1 is noticeable, 
an effect of Stx1 on posttranslational modifications 
can not be excluded.
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 Introduction
 The cytotoxic effect of Shiga-like toxin (Stx) has 
been well-described (14). Its damage of the ribosom-
al RNA in the endothelial cells of the renal glomeruli 
and arterioles is one of the hallmark-features of the 
pathogenesis of the haemolytic-uraemic syndrome 
(HUS). After binding to its specific glycosphingolipid 
receptor (globotriaosyl-receptor, Gb3, CD77), the 
toxin is internalised and transported in a retrograde 
direction to the endoplasmic reticulum (175).  By 
means of this pathway, Stx is subjected to cleavage 
into its binding (B-) and the enzymatically active A-
subunit (14). The A-subunit can leave the endoplas-
mic reticulum towards the cytoplasm by ‘mis-using’ 
the cellular retro-translocation machinery (67). 
Subsequently, the toxin reaches its target, the ribo-
some, which leads to disabling the translation from 
mRNA to proteins. 
However, Gb3-receptors have also been detected on 
cells which are insensitive to the toxic effect of Stx. 
For example, the protein synthesis is not decreased 
after incubation with Stx in peripheral blood mono-
cytes, cell lines for monocytes/macrophages and 
intestinal epithelial cells (52, 53, 176). It has been 
demonstrated that these cells direct the toxin to-
wards the lysosome where it becomes degraded 
without damaging the ribosomes (54).  During this 
pathway, cells are being activated resulting in the 
production of cytokines and chemokines (52, 55). In 
contrast to damaging the protein synthesis, there is 
a stimulating effect. This indicates that Stx seems to 
have a dual effect in different cell types, with the fi-
nal effect depending on the amount of Stx reaching 
the ribosome. Tesh and his co-workers have stud-
ied this activating mechanism of Stx on monocytes/
macrophages. They have described in increase of 
activity of transcription factors NF-κB and AP-1, and 
also a higher level of phosphorylation of intracellu-
lar kinases JNK1 and -2 and P38 (56, 177). 
A question arising is whether also Stx-sensitive cells 
become primarily activated after internalising the 
toxin. When the gene-expression of human umbili-
cal endothelial cells (HUVECs) incubated with a sub-
toxic dose of Stx was studied, an up-regulation of 
transcripts could be detected (149). These were pre-
dominantly transcripts of cyto- and chemokines. 
In this work we have examined in more detail the 
effect of a subtoxic dose of Stx on the transcription 
and translation in Stx-sensitive cells. All experiments 
were performed in HUVECs. As we want to evaluate 
the effect of Stx on transcription factor NF-κB, cell 
adhesion molecule ICAM-1 and chemokine IL-8 were 
studied. The mRNA level of ICAM-1 and IL-8 was de-
termined. Furthermore, the expression of ICAM-1 
was determined both on the cell surface and intra-
cellularly.
 Materials & Methods
 Culture and incubation of endothelial cells HUVECs 
were harvested after collagenase (Worthington: NJ, 
USA) treatment of human umbilical cords. HUVECs 
from 16 donors in passage 1-3 were used. Cells were 
grown confluent on tissue culture plastic plates 
coated with 1% porcine gelatine (Fluka: Neu-Ulm, 
Germany). Medium (M199; Gibco: Paisley, UK) with 
addition of 10% human serum (Cambrex: Walkers-
ville, USA ), 10% newborn calf serum (Gibco: Pais-
ley, UK), 1% 200 mM L-glutamine (MP Biomedicals; 
Eschwege, Germany), 1% penicillin-streptomycine 
(Gibco: Paisley, UK), growth factor (extracted from 
bovine brains) and 0.1% heparin (Leo Pharma BV: 
Breda The Netherlands) was refreshed every two 
days.
Cells were stimulated with different subtoxic con- 
centrations Stx1 (10 nM, 1 nM and 50 pM; Stx1 was 
kindly provided by Dr. M. Karmali, Toronto, Cana-
da). Stx1 was endotoxin-free as determined with 
a Limulus-assay. Cells stayed viable during this 
stimulation, as was tested with 3H-leucine incorpo- 
ration. Other used stimuli are TNFα (10 ng/ml; 
Roche: Woerden, The Netherlands) and LPS (1 ug/ml; 
Sigma-Aldrich:  Zwijndrecht, The Netherlands). These 
stimuli are known to have a stimulatory effect on 
endothelial cells. Stimuli were dissolved in M199 
+ 20% fetal calf serum (FCS; Greiner Bio-One; 
Kremsmunster, Austria). Before adding the stimuli, 
cells were rinsed with M199.
 RT-PCR for ICAM-1 and IL-8
 RNA from HUVECs was isolated using the RNeasy 
kit (Qiagen Benelux BV; Venlo, The Netherlands) ac-
cording to the manufacturer. HUVECs were incubat-
ed during 24 hours. To remove genomic DNA, the 
RNA samples were treated with 1u DNase (Invitro-
gen; Breda, The Netherlands) per 5 ml RNA for 15 min 
at RT. The reaction was stopped by adding 1 ml 25 
mM EDTA and incubated at 65˚C for 10 min. Reverse 
Transcriptase superscript III (Invitrogen) was used to 
transcribe the RNA into cDNA (5 min. 25°C, 60 min 
37˚C and 10 min 94˚C). The reaction mixture was 
prepared with 2 ml 0.1 M DTT, 0.6 ml 12.5 mM dNTP’s, 
0.4 ml Oligo dT, 0.5 ul 40u/ml RNAsin and 0.5 ml 
RTsuperscript III (Invitrogen) diluted in 5x reaction 
buffer. cDNA was diluted 1/50 and stored at -20˚C. 
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All primers were synthesized by Isogen lifesciences 
(Maarsen, the Netherlands). cDNA levels were de-
termined using SYBR green fluorescence with the 
Abi-Prism 7000 (Applied Biosystems, Nieuwekerk 
a/d IJssel, the Netherlands). Expression levels were 
evaluated as the number of cycle difference from gly- 
ceraldehydes-3-phosphate dehydrogenase (GAPDH). 
Data is represented as times increase compared 
to unstimulated cells.
 Cell-ELISA
 HUVECs were grown confluent on 96-wells cul-
ture plates (Corning; Schiphol-Rijk, The Nether-
lands) coated with 1% gelatine (n=10). After in-
cubation of the cells with Stx1, LPS or TNFα for 
various time points, the stimuli were removed and 
cells were rinsed with pre-warmed M199. Then 
cells were fixed with cold glutaraldehyde for 10 min 
at room temperature. After fixing, the cells were 
washed 3 times with phosphate-buffered saline 
(PBS). Cells were then incubated with primary an-
tibodies against cell adhesion molecules (ICAM-1, 
kindly provided by Dr Westphal, Nijmegen, the 
Netherlands; VCAM, Dako, Glostrup, Denmark; E- 
selectin, Santa Cruz, Heidelberg, Germany) during 
one hour at 37˚C dissolved in M199+8% FCS. After 
washing 5 times with PBS/Tween 0.05%, the second 
antibody was exposed to the cells (goat-anti-mouse 
peroxidase; Dako). This was performed in a dilution 
of 1:1000 for 30 min at 37˚C. Ortho-phenylenediami- 
ne was added as a substrate for 30 min. 2M H2SO4 
was added to arrest the reaction. Extinction was de-
termined with a plate-reader at 492 nm. Data are 
presented as percentage of unstimulated cells. Also, 
experiments were performed to determine the pres-
ence of interleukin-8 in the supernatant. However, 
the positive control did not result in a measurable 
level (data not shown).
 FACS
 HUVECs were grown confluent on 24-wells cul-
ture plates (Corning) coated with 1% gelatine (n=3). 
After incubation of the cells with LPS, Stx1 in M199 
with 20% FCS during 4, 14, 24 and 48 hr, the cells 
were rinsed with PBS and incubated with a FITC-la-
belled primary antibody against ICAM-1 (Dako). This 
was performed in M199 with 8% FCS for 60 minutes 
at 4˚C. After this incubation, cells were washed with 
cold PBS and detached. After detachment, the cells 
were fixated with 0.5% paraformaldehyde. Cells 
were analyzed with a FACS analyzer. Data is pre-
sented as percentage positive cells. 
 Western blot
 HUVECs were grown confluent on 6-wells culture 
plates (Corning) coated with 1% gelatine. After incu-
bation of the cells with stimuli for 24, 48 and 72 hr, 
cells were harvested and immediately centrifuged at 
200 xg at -4˚C. Then cells were dissolved in a RIPA- 
buffer mixed with protease-inhibitors (30 μl/ml apro-
tinin: Sigma-Aldrich; 10 mg/ml PMSF: Sigma-Aldrich; 
10 μl/ml 100 mM sodium orthovanadate). After 30 
min on ice followed by centrifugation, supernatants 
were stored at -20˚C. From cell lysates 1 μg protein 
was run on 7.5% SDS-polyacrylamide gels by elec-
trophoresis and then electrophoretically transferred 
to a nitrocellulose membrane. After blocking the 
membrane with PBS/Tween 0.5%/5% Protifar Plus 
(Nutricia: Zoetermeer, The Netherlands), it was in-
cubated with a mouse monoclonal antibody against 
ICAM-1 (Santa Cruz: Heidelberg, Germany). An anti-
body against GAPDH was used as a loading control. 
A peroxidase-labelled antibody (Dako) was used as 
a secondary antibody before staining the mem-
brane.
 Results
  Stx1 is not able to inhibit protein synthesis of 
endothelial cells without pre-incubation with 
TNFα
 When HUVECs were incubated with Stx1 10 nM or 
1 nM, no inhibition of the protein synthesis could be 
detected with 3H-leucine incorporation. Only after 
pre-incubation with TNFα, which increases the Gb3-
receptor for Stx1, Stx1 was able to decrease the pro-
tein synthesis of HUVECs (178).
  Figure 1 mRNA of ICAM-1 and IL-8 after 
incubation with LPS or Stx1
 Vertical: 
 A: Times increase mRNA ICAM-1
 B: Times increase mRNA IL-8
 Horizontal: Stimuli
HUVECs (n=3) were incubated with LPS or different 
concentrations of Stx1 (10 nM, 1 nM and 50 pM) .The 
level of mRNA from ICAM-1 (A) and IL-8 (B) was mea-
sured. LPS increases the level of both ICAM-1 and 
IL-8 after 4 hours. Stx1 10 nM also increases mRNA 
of ICAM-1 and IL-8, but after 24 hours.
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  The level of mRNA increases after incubation 
with Stx1
 Figure 1 represents the data concerning the le-
vels of mRNA for ICAM-1 and IL-8 after incubation 
with different concentrations of Stx1, or LPS which 
is the positive control (n= 3 HUVECs donors). LPS 
is able to up-regulate the level of mRNA of both 
proteins after 4 hours of incubation. At this time-
point, no effect of Stx can be detected. However, 
after an incubation time of 24 hours, it is evi-
dent that also Stx increases the mRNA of ICAM-1 
and IL-8, while the effect of LPS has already dimin-
ished.
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  The expression of ICAM-1 on the cell surface 
does not change after incubation with Stx
 To study the effect of the up-regulation of mRNA, 
the expression of ICAM-1 on the cell surface of 
HUVECs was determined (n=3). Also, the expression 
of cell adhesion molecules VCAM and E-selectin 
were measured. Figure 2 demonstrates that TNFα is 
capable of increasing the expression of all three dif-
ferent cell adhesion molecules after 4 hours. How-
ever, incubation with Stx1 does not alter the amount 
of expressed ICAM-1, VCAM and E-selectin at any 
time point. Experiments with different concentra-
tions of Stx1 (10 nM, 1 nM, 100 pM, 10 pM, 1 pM, 100 
fM, 10 fM) at different time points showed no dos-
age effect of Stx1 (data not shown). Furthermore, 
four donors of HUVECs were incubated with Stx1 10 
nM for 48 hours, since the level of mRNA after incu-
bation with Stx increased after 24 hours. Again, no 
effect of Stx1 could be detected on the expression of 
ICAM-1 (fi gure 3). 
Another technique, FACS-analysis, was performed 
to evaluate these confl icting results (fi gure 4). 
These results confi rm that there is no clear effect 
of Stx after 48 hours of incubation, whereas the 
effect of LPS is obvious.
 
 Vertical: 
 A: % ICAM of control
 B: % VCAM of control
 C: % E-selection of control
 Horizontal: Incubation (hours)
HUVECs (n=3) were incubated with TNFα (10 ng/
ml) or Stx1 (10 nM) during various time points. The 
expression of ICAM, VCAM and E-selectin was deter-
mined with cell-ELISA. TNFα is able to increase the 
expression of all three cell adhesion molecules. Stx1 
does not have an effect.
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  Figure 3 Effect of a prolonged incubation with 
Stx1 on the expression of ICAM-1 
  TNF 
  LPS
  Stx 1
 Vertical: % extinction of control
 Horizontal: Incubation (hours)
HUVECs (n=4) were incubated with LPS, TNFα or 
Stx1 10 nM for 48 hours. Again, no up-regulation of 
ICAM-1 by Stx1 could be detected. LPS and TNFα 
are able to increase the expression of ICAM-1. The 
error-bar represents the standard-deviation.
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  Figure 2 Effect of Stx on expression of ICAM-1, VCAM and E-selectin
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 Donor 1
 Donor 2
 Donor 3
 Horizontal: % positive cells
HUVECs (n=3) were incubated for 4 (panel A), 14 
(panel B), 24 (panel C) and 48 hours (panel D) with 
Stx1 (10 nM and 10 pM) or LPS (1 ug/ml). The ex-
pression of ICAM-1 was analysed with FACS. LPS can 
up-regulate the amount of expressed ICAM-1. Stx1 
does not have a clear effect.
  The intracellular level of ICAM-1 is increased at 
72 hours of incubation with Stx
 To analyze the possibility that Stx up-regulates 
ICAM-1 without an expression on the cell surface, we 
have performed Western blots. Whole cell lysates 
were used. Figure 5 demonstrates a blot represen-
tative of the performed experiments (n=3). After 24 
hours of incubation with LPS there is an evident up-
regulation of ICAM-1. However, a small increase of 
ICAM-1 can be detected at 72 hours of incubation 
with Stx1.  
 Figure 5 Western blot of ICAM-1
ICAM - 1 
GAPDH 
HUVECs (n=3) were incubated with LPS and Stx1 for 
24, 48 and 72 hours. GAPDH was used as a loading 
control. Whereas LPS increases ICAM-1 already af-
ter 24 hours, Stx1 gives a small raise of ICAM-1 after 
72 hours of incubation. This blot is representative of 
the performed experiments.
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  Figure 4 FACS analysis of ICAM-1 expression on HUVECs 
line, after 12 hours of stimulation with a subtoxic 
dose of Stx TNFα mRNA was raised together with 
an increase in TNFα production (177). In the ma-
crophage, TNFα mRNA peaked at 6 hours, while 
TNFα production was optimal at 12-15 hours (182).
For the interpretation of the action of Stx in HUS, 
not only the effect of a toxic dose, but also the 
effect of a subtoxic dose has to be considered.
 Discussion
 A subtoxic dose of Stx1 was able to induce mRNA 
for ICAM-1 and IL 8 in HUVECs, although at a later 
time than observed after LPS. In bovine aortic endo- 
thelial cells a subtoxic dose of both Stx1 and Stx2 
induced an increase of pre-proET-mRNA levels which 
was evident as early as 4 hours, with maximal ef-
fect at 12-24 hours. Nuclear transcription and acti- 
nomycin D chase experiments indicated that Stx in- 
creased the half-life of pre-proET-mRNA transcripts 
2.5 fold without an increase in synthesis rate (179). 
Matussek et al performed micro-array analysis and 
found that the main changes elicited by sub-inhi- 
bitory concentrations of Stx concerned changes 
in gene expression mainly for genes encoding che- 
mokines and cytokines (149). The gene expression 
of IL-8 (at 4 and 24 hours) by both Stx1 and Stx2 
and of ICAM-1 (at 24 hours by Stx1 and at 4 and 24 
hours after Stx2) was increased. The transcription 
factor NFκB is involved in the stimulation of mRNA 
for IL-8 and MCP in human endothelial cells (170).
Newly synthesized mRNA passes through the nu-
clear membrane into the cytoplasm, where it be- 
comes associated with the ribosomes for polypep-
tide synthesis. The changes in the level of mRNA 
in our experiments were not reflected in corres- 
ponding protein changes. Only 72 hours after 
stimulation, a small increase in ICAM-1 concentra- 
tion was observed by Western blotting. Appa- 
rently, Stx1 is impairing the translation process, al-
though the overall synthesis of protein was intact 
as proven by the leucine incorporation assay. The 
apparent discrepancy between mRNA and protein 
levels might be explained by post-transcriptional 
buffering mechanisms such as RNA interference 
effects. Such options should be addressed in future 
more detailed studies (180). The negligible increase 
in the surface expression of ICAM-1 is expected 
based on the data of the Western blotting. The in-
fluence of post-translational modification on the 
cell membrane trafficking can also not be excluded 
(181). The low mRNA concentration of ICAM-1 and 
interleukin-8 in the control situation precluded the 
evaluation of changes in mRNA degradation after 
transcriptional blockade. 
These results differ from those observed in the 
monocyte and macrophage. In a human monocytic 
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In this report a  
familial hetero-
zygous mutation 
of IF is described 
in a patient with  
atypical HUS.
the mutation had dire consequences for the trans-
planted kidney. Data about the other members of 
the family are provided. Finally, new therapeutic 
possibilities for patients with defective or deficient 
IF are proposed.
  Abstract
 A genetic predisposition involving complement 
regulatory genes has become evident in some pa- 
tients with atypical HUS. In this paper, a patient 
with a heterozygous missense mutation in factor 
I (IF) is described. Although the serum level of IF 
was normal, a mild functional defect in the alter- 
native pathway of complement could be demon- 
strated in the affected members of the family. 
After an episode of atypical HUS, chronic renal 
insufficiency started at the age of 15 months. Re-
currence of HUS, with loss of the renal transplant, 
occurred twice in this patient. The recurrence of 
HUS in the graft was not reflected by haemato-
logical abnormalities (haemolysis, thrombocyto- 
penia).  One additional transplant was lost due to 
arterial thrombosis of the renal artery. This report 
confirms the gloomy outcome of renal transplants 
in patients with a IF deficiency. New therapies 
should be evaluated in these patients.
 Introduction
 Atypical haemolytic uraemic syndrome (HUS) 
should be separated from typical or shiga-like tox-
in induced HUS. In typical HUS, the classical fea-
tures (haemolytic anaemia, thrombocytopenia and 
renal failure) are mostly preceded by diarrhoea. 
The atypical forms of HUS can be sporadic, famil-
ial and relapsing. A genetic predisposition involving 
complement regulatory genes has become evident 
in some patients with atypical HUS (reviewed in 
reference 183). Mutations in the plasma comple-
ment regulator factor H (HF1) and, the transmem- 
brane complement regulator membrane cofactor 
protein (MCP) and patients with anti-HF1 auto-anti- 
bodies have been described as causes of atypical 
HUS (183). Both proteins are acting as cofactors 
for complement IF. This is a soluble regulatory 
serine protease of the complement system. It me-
diates the cleavage of the α-chain of C3b leading 
to the formation of iC3b, followed by its further 
degradation into C3dg and C3c. Furthermore, 
IF cleaves C4b to yield C4c and C4d. This will lead 
to an inhibition of the complement system and acts 
to protect host surfaces against complement acti-
vation. Also CR1 receptor (CD35) can function as a 
cofactor for IF.
The gene encoding for IF is located on chromosome 
4q25. It spans 63 KB and comprises 13 exons. It has 
a molecular weight of 88.800 Da and is composed 
of two polypeptide chains (MW 50.000 and 38.000 
Da), which are linked by disulfide bounds. The differ-
ent structural protein domains of IF are well estab-
lished. The first exon is a leader sequence, which is 
not present in the mature protein. The second exon 
encodes a module only found in complement C6 and 
C7, the so-called IF membrane attack complex mo-
dule. A scavenger receptor domain is encoded by the 
third and fourth exon. The fifth and sixth exon each 
encode a low-density lipoprotein receptor module. 
Two small exons separate the first six exons from 
the last five that encode the serine protease domain 
of IF, forming the light chain (184). This serine pro-
tease domain is occupied with the cleavage of the 
above mentioned complement factors.  In this report 
a familial heterozygous mutation of IF is described 
in a patient with atypical HUS. This patient showed 
a normal concentration of IF in serum. However, 
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late and recent signs of intravascular coagulation 
probably due to recurrence of HUS.
At the age of seven years, he received a second 
renal transplant. He received cyclosporine and pred-
nisone as immune-suppressive treatment together 
with thrombosis prophylaxis (low molecular weight 
heparins). A renal arterial thrombosis occurred at 
the first day and led to a transplantectomy. 
At the age of 10 years he received a third renal trans- 
plant with a cadaver kidney, under the usually immu-
nosuppressive and anti-coagulant treatment (cyclo- 
sporine, prednisone, low molecular weight hepa- 
rins). Diuresis occurred rapidly and serum creati-
nine declined. However, at the sixth day postopera-
tively serum creatinine rose till 230 μmol/l. Due to 
a bleeding tendency, no biopsy could be performed. 
Despite treatment with anti-thymocyte immuno-
globulin (ATG) followed by high doses of prednisone, 
renal function further deteriorated. Haemodialysis 
treatment had to be started again and transplan-
tectomy was performed six weeks after transplanta-
tion. During the post-transplantation period, a de-
creasing number of platelets and haemoglobin was 
not observed. Pathology report of this third renal 
transplant showed significant fibrosis and prolifera-
tion of the intima of the arterioles with infiltration 
of monocytes and some granulocytes. Most of the 
glomeruli were ischaemic. Others show swollen en-
dothelial cells with monocytes and granulocytes. In 
some arterioles thrombosis was seen. Focal staining 
for C4d of peritubular capillaries was present. Swol-
len podocytes and broadening of the subendothelial 
space with fluffy material were observed by elec-
tron microscopy. Extensive fibrin and C3 deposition 
were present along the glomerular capillary walls. 
Based on these pathological findings, the diagnosis 
of HUS was made. 
 Case report
 Our patient is the third child in a non-consan-
guineous family with three children. The pregnancy 
and neonatal period were undisturbed. A relative in 
the paternal lineage (daughter of his father’s sister) 
died of HUS at the age of 25. The diagnosis was 
made at autopsy, while she was abroad.
At the age of 15 months the patient was referred 
to our paediatric nephrology ward by the local 
paediatrician. One week before admission he de-
veloped a sore throat, otitis, coughing and a gene- 
ral malaise. Diarrhoea was not present. The child 
became gradually pale and icteric and started vom-
iting. Laboratory values demonstrated haemolytic 
anaemia with burr-cells and renal dysfunction. The 
diagnosis of HUS was made. Initially, the renal func-
tion recovered, followed by a second phase of renal 
impairment ending in permanent damage. Perito-
neal dialysis had to be started. Six months later he 
had a relapse of HUS, accompanied by diarrhoea, 
which remitted spontaneously. Severe hypertension 
required bilateral nephrectomy. 
The first renal transplantation, with a cadaver kid- 
ney, occurred when the patient was 3,5 years old. 
Prednisone and cyclosporine were the immuno-
suppressive treatment modalities at that time. 
After a delayed start of the graft function, his se- 
rum creatinine became normal. Five months after 
renal transplantation, a rise in serum creatinine 
(200-250 μmol/l) was noted. Renal biopsy demon-
strated in some glomeruli swollen endothelial cells 
with infiltration of monocytes and granulocytes. 
The arterioles demonstrated swollen endothe-
lium. Some diffuse fibrosis, edema and influx of 
monocytes were found in the interstitium. Some 
mesangial C3 staining was observed.  Peritubular 
capillaries did not stain for C4d. Recurrence of HUS 
was suspected. The rejection was classified as IA. 
On the day preceding the biopsy thrombocytope-
nia, fragmentocytes and decreasing haemoglobin 
were absent. High dose prednisone was given and 
cyclosporine was switched to azathioprine. Un-
controllable hypertension (205/110 mmHg) with 
further deterioration of the renal function prompted 
transplantectomy, eight months after transplanta-
tion. The conclusion of the pathology report of the 
renal transplant was chronic vascular rejection with 
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 Subjects & Methods
 Molecular genetic studies
 Genomic DNA from our patient, his two sisters and 
his parents was prepared from whole blood using 
the method first described by Miller et al (183). The 
IF gene was amplified in 11 fragments (exon 1, 2, 3, 
4, 5-6, 7, 8, 9-10, 11, 12 and 13) by the polymerase 
chain reaction (PCR). Fragments included both 
DNA sequences of the individual exons, the splice 
donor and splice acceptor sites. The sequences 
of the primers and the reaction conditions are 
available upon request. The amplimers thus obtain- 
ed were subjected to DNA sequence analysis of 
the coding and non-coding strands (NM_000204). 
PCR products were purified with alkaline phospha- 
tase and exonuclease (Amersham, The Netherlands). 
Subsequently a sequence reaction was performed 
using the Ready reaction sequence mix (Applied 
Biosystems). After precipitation the fragments were 
dissolved in Hi-Ditm Formamide (Applied Biosys-
tems) and sequenced by the ABI Prism 3130 Genetic 
Analyzer. Sequence analyses were performed using 
Sequencer 4.2 software. Also, all exons of the gene 
encoding for MCP and exon 23 of the HF1 gene were 
subjected to DNA analyses.
 Complement assays
 Serum levels of C3 and C4 were measured by 
nephelometry. C3d was measured by ELISA after 
a precipitation step with 22% PEG 6000. Radial 
immunodiffusion was performed to determine the 
level of IF. For this measurement, a goat antibody 
against human IF was used (produced by the De-
partment of Nephrology, Leiden, The Netherlands). 
The functional analysis of the alternative pathway, 
as well as the classical pathway was measured 
with ELISA (COMPL300 Total Complement Func- 
tional Screen Kit, Euro-Diagnostica, Arnhem, The 
Netherlands). In short, wells were coated with either 
lipopolysaccharide (alternative pathway) or IgM 
(classical pathway) and patient serum was added 
for binding and activation of the specific routes. 
The formed end product of the complement cas-
cade, C5b-9, was determined with an alkaline 
phosphatase-conjugated antihuman C5b-9 (184). 
The classical and alternative pathways were also 
assessed by the haemolytic assay (184). All assays 
were performed in serum from the patient and his 
family members.
 Table 1 Analysis of the complement system 
 ND: not determined
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  Figure 1 Mutation in factor I 
(A) Forward sequence of wild type and patient. 
In the patient, there is a T (ATT for isoleucine) to 
C (ACT for threonine) transition at position 1019, 
which results in an amino acid change in the serine 
protease domain of factor I. (B) Reverse sequence 
of wild type and patient at the region of the muta-
tion. The mutation is indicated with an arrow.
  Figure 2 Schematic representation of the 
domain structure of factor I
 Leader peptide
 IF Membrane Attack Complex
 Scavenger Receptor
 Low-density Lipoprotein Receptor
 Unknown
 Serine protease
IF is composed of a heavy (amino acids 19-335) 
and a light (amino acids 340-583) chain, which 
are linked by a disulfi de bound. The leader peptide 
(amino acids 1-18) and the cleavage site (amino 
acids 336-339) are lost from the mature protein. 
The mutation found in the patient is indicated with 
an arrow. It is detected in the fi rst amino acid of a 
structurally conserved region of the catalytically 
active domain.
 Results
 After screening the genomic DNA encoding for 
IF, one heterozygous 1019T > C mutation in the fac-
tor I gene was observed in our patient with atypi-
cal relapsing HUS (fi gure 1). This missense mutation 
(Ile322Thr) is located at the start of the serine pro-
tease domain (fi gure 2). Isoleucine is the fi rst amino 
acid of a structurally conserved region of the cata-
lytically active domain (187). The 1019 T > C muta-
tion was absent in 112 Dutch control alleles. The pa-
tient inherited the mutation via the paternal allele. 
The mutation was also present in the two sisters. No 
mutations were found in the genes encoding MCP 
or HF1. 
To investigate whether this mutation had an effect 
on the level and activity of the protein, a quantita-
tive assay of IF in combination with a functional 
analysis of the alternative and classical pathway of 
complement was performed. The serum level of IF 
and HF1 were normal in the patient and his father. 
The alternative pathway of the complement system 
tested by ELISA or haemolysis had in the affected 
members of the family a slightly decreased or low 
normal functional activity, while the activity of the 
classical pathway remained normal. Only in the re-
ported patient an increased serum concentration of 
C3d was found. Serum C3 was slightly lowered or in 
the low normal range in the affected members of 
the family (table 1).
Amino acid
1 19 335
S - S
heavy chain light chain
340 583
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 Discussion 
 A heterozygous mutation in IF, a regulatory pro-
tein of the complement system, was detected in our 
patient, his father, and his two sisters. This mutation 
resulted in an amino acid change in the serine pro-
tease domain. The IF concentrations in the serum of 
our patient and his father were found normal. The 
antigenic C3 levels were slightly decreased. 
In all affected members of the family the function-
al activity of the alternative pathway was at least 
once lowered, while the activity of the classical 
pathway remained normal. Heterozygous persons 
in families with FI deficiency had a normal acti- 
vity of the classical pathway (188). Further study 
is required to explain the discrepancy in functional 
activity in both pathways. The increased concentra-
tion of C3d in our patient is due to his disturbed 
renal function and some stimulating effects of the 
haemodialysis (189, 190).
The homozygous deficiency of IF is well studied. 
It results in an increased turnover of C3 and thereby 
in a defect in opsonification. The deficiency is clini-
cally associated with increased susceptibility to se-
vere infections. Particularly infections with encap-
sulated bacteria such as Streptococcus pneumoniae 
and Neisserial bacteria can be found (191). Also im-
mune complex- mediated diseases due to defective 
immune complex clearances are associated with IF 
deficiency (192).
Fremeaux-Bacchi et al, Kavanagh et al, Esparza-Gor-
dillo et al and Capioli et al  have recently described 
heterozygous mutations of FI that predispose to the 
development of HUS (86, 94, 95, 104). Striking was 
the first occurrence of the disease at adult age, which 
was frequently observed. Pregnancy could have a fa-
vourable role. Even when the first symptoms of HUS 
appear at adult age, a defect in the regulatory path-
way should be considered. 
In contrast to patients who have a mutation in MCP, 
the results of transplantation in HUS patients due 
to a heterozygous IF-mutation are gloomy. Patients 
with mutations in MCP are not prone to a recur- 
rence after transplantation. This is due to the fact 
that normal MCP will be present in the renal al-
lograft, being a transmembrane protein. Conside-
ring mutations in IF, one of the patients reported by 
Fremeaux-Bacchi et al had a recurrence of HUS in 
two transplants. The first patient of Kavanagh et al 
had initially an excellent renal function after trans- 
plantation, but a recurrence and deterioration of 
the function occurred after two months. The se- 
cond patient had a recurrence of HUS, which was 
noted twenty months after the transplantation. 
The sister of this second patient had two trans- 
plants that failed early. In one transplanted pa-
tient, reported by Caprioli et al, two grafts were 
lost because of the recurrence of HUS within 
the first year after transplantation. Our patient had 
a possible recurrence after the first graft, and a 
proven recurrence after the third graft.
Can transplantation still be recommended in pa- 
tients with HUS due to a heterozygous mutation 
in IF? Recurrence of HUS can be expected during 
periods of complement activation after renal trans-
plants. Dangerous predictable situations are ischae-
mia/reperfusion early after transplantation and 
during acute rejection (193, 194). 
New therapeutic possibilities should be considered. 
The effect of treatment with plasma in patients with 
deficient IF has been studied. The half-life of IF is 
24-45 hours, but with a more pronounced effect on 
the C3 and C4 level (195). After a plasma infusion 
(20 ml/kg) in our patient, the functional activity of 
the alternative pathway remained above 40% dur-
ing at least three days (the activity before the infu-
sion was 26%). Another possibility is treatment with 
Eculizimab, a humanized antibody that specifically 
targets the complement protein C5 and prevents 
its cleavage. Complement inhibition at the C5 level 
blocks the formation of C5b-9 while preserving ear-
ly components critical for the clearance of bacteria 
and immune-complexes (196). Experimental work 
in mice is encouraging. Prevention of C5 activation 
ameliorated spontaneous and experimental glom-
erulonephritis in factor H deficient mice (197). The 
availability of recombinant IF will be the ultimate 
solution.
New treatment protocols for patients with deficient 
or defective IF are unavoidable in order to improve 
the outcome of renal transplantations in these pa-
tients. Renal transplantation is prone to failure in 
patients with a heterozygous mutation in IF. 
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The secret recipe of HUS
hemolysin demonstrated to be cytotoxic in a dose- 
and time-dependent manner to human endothe- 
lial cells. Furthermore, hemolysin is capable of ac-
tivating monocytes to release cyto-kines which in- 
crease the presence of Gb3-receptors on endo- 
thelial cells (201). However, it remains to be elucida- 
ted if hemolysin is able to reach the circulation 
and induce a systemic effect. Paton et al discover- 
ed a new AB5 toxin called subtilase cytotoxin 
(24). This toxin is capable of cleavage of an essen-
tial endoplasmic reticulum chaperone which will 
induce cell death (202). This toxin was present in 
32 out of 68 different Stx-producing Escherichia coli 
strains (24). 
Since all three toxins demonstrated to have a 
direct and damaging effect on endothelial cells in 
vitro, a combined role in the pathogenesis could be 
possible. 
 The pathogenesis of HUS involves elements of ma- 
ny different systems of the human body which 
maintain its homeostasis. Examples are the coagu-
lation cascade, and the innate immunity with the 
complement system. All these different parts result 
in a complex disease mechanism with many inter-
actions between the involved systems. A complete 
picture of the pathogenesis is lacking. And last but 
not least, also the individual genetic profile will con-
tribute to this complex disease. Although research-
ers over the years revealed small parts to provide 
a better understanding, the pathogenesis is still ‘a 
secret recipe’. 
The purpose of this thesis was to identify ingre-
dients that contribute to the development of this 
multi-factorial disease. Since specific treatment is 
still missing, a better understanding of the disease 
mechanism will ultimately lead to new treatment 
strategies. 
 5.1 The toxin
 An important question concerning HUS is it Stx 
is still the central factor in HUS? Especially since 
Stx was never detected in serum of patients with 
HUS. Why are we so interested in this protein? The 
presence of only endotoxin from the Escherichia 
coli bacteria, called lipopolysaccharide (LPS) will 
not induce HUS in experimental models of ani-
mals (198). Findings that support the key role of 
Stx in HUS is the detection of Stx in renal biopsies 
of patients with HUS and the presence of Stx-an-
ti-bodies in the serum of patients (19, 107). How-
ever, also other Escherichia coli-secreted proteins 
can be involved in the pathogenesis. Cytolethal 
disten-ding toxin was identified in different strains 
of Escherichia coli and caused direct damage of 
DNA resulting in cell death in human endothelial 
cells (22, 199). The gene cluster for this protein 
was detected in 4.9% of E coli O157:H7 (200). This 
toxin also proved to have a cytotoxic effect on 
human glomerular endothelial cells (own prelimin- 
ary data). An additional detected protein is the 
pore-forming hemolysin. This protein was detected 
in EHEC-strains which did not produce Stx, although 
the loss of Stx-genes before analysis remains a 
plausible option (23). In this work, recombinant 
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tory response with attraction of PMN and increased 
permeability leading to (bloody) diarrhea. This will 
lead to a more pronounced access of Stx into the 
circulation.
It is assumed that Stx will bind specifically to a 
transporter in order to reach the renal endothelium. 
Especially since the toxin was never detected in the 
acute phase of HUS in serum of patients with HUS. 
Many blood cells have been studied, but until now 
none proved to be capable of this task. Our group 
suggested a transport-pathway by PMN (38). How-
ever, in chapter 2.2 we came to an opposite conclu-
sion; PMN are not the transporters of Stx. Different 
techniques were performed to analyse a possible 
binding. In vitro experiments with both full blood and 
freshly isolated PMN did not result in a binding of 
Stx to the PMN. Also in vivo experiments with injec-
tion of the B-subunit from Stx in mice, demonstrat-
ed a rapid clearance from the blood without binding 
to PMN. When we studied Stx-binding to PMN iso-
lated from HUS-patients, there were variable results 
with one patient demonstrating binding of a Stx-an-
tibody to the PMN during active disease. However, 
this antibody did also bind to PMN from patients on 
haemodialysis in contrast to patients on peritoneal 
dialysis and healthy controls. This indicates that this 
antibody was not specific and probably binds to ac-
tivated granulocytes present in patients on haemo-
dialysis and during HUS.  Furthermore, Stx was not 
capable of activating PMN, which suggests that no 
specific binding was present. Our data was recently 
confirmed by Flagler et al (207). This work demon-
strated that Stx was not able to induce apoptosis 
of PMN. Furthermore, after addition of Stx to hu-
man whole blood, the highest concentration could 
be detected in the cell-free plasma fraction. Neither 
Stx1 nor Stx2 was found to be associated with iso-
lated PMN. Also in their hands, the injection of Stx 
into mice did not result in binding to blood cells. 
This indicates that other possible carriers have to 
be explored. The binding of Stx to peripheral blood 
monocytes carrying a specific receptor for Stx was 
already demonstrated (52, 53, 54). This indicates 
that monocytes could be an interesting option to 
transport Stx to the renal endothelium. But, al-
though monocytes contribute to the pathogenesis 
by producing pro-inflammatory cytokines after in-
ternalising the toxin, it could not be demonstrated 
  5.2 Transport of Stx
 Stx is the most extensively studied protein in the 
research of HUS. Research was especially focussed 
on the transport route to its main target, the renal 
endothelium. Interfering in this pathway will pre-
vent Stx from damaging the kidney.
Different animal models have been tested. Siegler 
et al demonstrated a primate model of HUS (203). 
It was demonstrated that baboons also carry 
Gb3-receptors in the gut and kidney. After an in-
travenous injection with Stx1, they developed a 
biochemical picture similar to HUS. Keepers et al 
recently described a murine model in which a intra- 
peritoneal co-injection of Stx2 and LPS is given 
(204). This resulted in thrombocytopenia, haemo- 
lytic anemia and renal failure. Also a canine model 
has been presented by Raife et al (205). An intra- 
venous injection of Stx1 resulted in bloody diarrhoea 
and procoagulant changes similar to human. Since 
the animal models remain controversial concer-
ning the presence of Gb3-receptors and their cel-
lular sensitivity for Stx (the receptor is absent on 
glomerular endothelia from mice and rats), many in 
vitro studies are still performed.
More insight has been gained in understanding how 
Stx is transported from the intestinal tract into the 
circulation. Especially, since Schuller et al demon-
strated the binding of Stx to Paneth-cells in the small 
intestines (33). Before, no receptor for Stx was de-
tected in human primary intestinal epithelial cells in 
contrast to human cell lines.  
After crossing trans-or paracellular the intestinal 
wall, Stx has to reach the circulation in order to 
damage the renal endothelium. When we consider 
that below the intestinal epithelial lining there is an 
underlying gut-associated lymphoid tissue (GALT) 
filled with macrophages, dendritic cells and T-lym-
phocytes, it is intriguing to realize that Stx can still 
reach the circulation (206). The effect of Stx on 
monocytes has been well-described, but the inter-
action between the toxin and dendritic cells is still 
to be evaluated. 
Probably, the architecture of the intestinal wall is 
disturbed by the adherence of EHEC. This adhe- 
rence combined with the passage of Stx will in-
crease the expression of chemokine IL-8 on the cell 
surface (31). This results in initiation of an inflamma-
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to be the transporter (see chapter 2.1). Furthermore, 
it shows that one needs to be cautious with the in-
terpretation of binding experiments performed at 
4˚C since binding properties change at 37˚C. 
It could be hypothetically possible that Stx travels 
unbound in the circulation, and is directed towards 
Gb3-receptors present on various endothelia with 
its final effect dependent on the intracellular path-
way of the toxin. Or should other serum proteins 
be tested for a role as transporter. Kimura et al 
demonstrated that protein serum amyloid P (SAP) 
is able to bind and neutralize Stx2 (57). This se-
rum protein does not exist in other species. Arm-
strong et al have performed in vivo experiments to 
demonstrate a protective role of this protein (58). 
After intraperitoneal injection of SAP in mice, it pro-
tected them from a lethal challenge with Stx2. Also 
human SAP-transgenic mice were protected from 
Stx2. The accumulation of Stx2 in target organs 
(kidney and brain) was diminished in the presence 
of SAP in the circulation. This group also studied 
the presence of SAP in persons with pathogenic 
Escherichia coli infections. There was no clear dif-
ference in serum level of SAP between patients 
developing HUS and those without it. However, the 
clearly diminished accumulation in target organs 
indicates a possible new approach for preventing 
damage in HUS.
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stress possibly increases the up-regulation of intra-
cellular calcium and thereby the stimulating effect 
of Stx.  Also in chapter 3.3, shear stress is applied to 
the endothelial cells. In this chapter, a subtoxic dose 
of Stx results in the firm adhesion of leukocytes. 
HSPG play a crucial role in this effect, since cleav-
age of HSPG reduces the amount of adherent cells. 
For the first time, the role of HSPG in the pathogen-
esis was evaluated. Since no direct effect of Stx on 
the HSPG could be demonstrated, an indirect effect 
through release and binding of chemokines to HSPG 
could be a plausible explanation. 
But how is this activating effect initiated? How is 
it possible that this cytotoxic protein also has an 
activating effect? The results presented in chap-
ter 3.4 demonstrate the increase of mRNA of IL-8 
and ICAM-1 after incubation with a subtoxic dose 
of the toxin. This effect was also demonstrated by 
Matussek et al (149). But, the transcription of mRNA 
is not being properly followed by efficient transla-
tion, since only small amounts of protein can be 
detected after more than 48 hours. This indicates 
that instead of only disabling ribosomes, Stx is also 
able to activate endothelial cells, however not very 
efficiently. The exact mechanism is yet unclear, but 
up-regulation of transcription factors like NF-κB and 
AP-1, and also a higher level of phosphorylation of 
intracellular kinases JNK1 and -2 and P38 have been 
described in a monocytic cell line (56, 177). This may 
also occur in endothelial cells. Groups of Thorpe and 
Tesh, working with intestinal epithelial and mono-
cytic cell lines, suggested a ribotoxic stress model 
occurring after incubation with a subtoxic dose of 
Stx (56, 117). This indicates that after damaging the 
ribosome, it will send a signal to stress-activated pro-
tein kinase pathways. This results in new biogenesis 
of ribosomes and an enhanced cytokine expression. 
This model may also be applicable in our endothe-
lial cells. We hypothesize that the endothelial cell 
becomes activated after internalising Stx, resulting 
in production of mRNA-transcripts and release of 
WPbs content. This effect is enforced by application 
of shear stress. After internalising, part of the toxin 
is retrogradely transported to the ribosome, which 
is dependent on the position of the Gb3-receptor in 
the outer cell membrane. The other part is targeted 
to the lysosome and is degraded. The Gb3-receptor 
will be recycled and appear again on the cell surface 
 5.3 Effect of Stx toxin on
 endothelium
 Since the retrograde transport route of Stx was 
described by Sandvig et al (14), many research 
groups have used the toxin as a model for this in-
tracellular trafficking pathway. Chapter 3.1 demon-
strates that this pathway is also followed by Stx 
in its main target; the renal endothelium and in 
mesangial cells. This was a missing chapter in the 
knowledge on HUS. The ribosomes of the renal en-
dothelium will be attacked by Stx after retrograde 
transport. The increase of sensitivity of renal en-
dothelium by cytokine TNF-α, resulted from an 
increased amount of Stx in the endoplasmic reti-
culum instead of a different transport-route. This 
transport-route is of crucial importance for the bio-
logical activity of Stx. Cells insensitive for the cy-
totoxic effect of Stx, like monocytes demonstrated 
a different pathway with direction of the toxin to 
the lysosome instead of the endoplasmic reticulum 
(54). The presence of the receptor in specific areas 
of the cell membrane (so-called detergent-resistant 
membranes), directs the toxin into the retrograde 
pathway. Probably the sensitivity of the cell type 
is relying on the location of the majority of Gb3-
receptors. Since foreskin endothelial cells express 
many Gb3-receptors without cytotoxicity of Stx, 
it would be interesting to study the location of these 
receptors in the cell membrane. When a threshold of 
active A-subunit reaches the cytoplasma, cytotoxi-
city occurs. The ribosomes will be damaged and the 
protein synthesis will arrest, leading to cell death. 
But what occurs with a subtoxic dose of Stx? This 
will not result in an overall inhibition of the protein 
synthesis (132). Instead, activation of cells seems to 
take place. In chapters 3.2, 3.3, 3.4 subtoxic doses 
of Stx were used. This probably approaches the in 
vivo situation, since Stx was never found in the cir-
culation. In chapter 3.2 a subtoxic dose of Stx was 
capable of releasing the content of WPbs from renal 
endothelial cells in flow. Two different mechanisms 
are possible; an increase in intracellular calcium or 
an increase cAMP is needed. Since Ikeda et al dem-
onstrated an increase of calcium by Stx in Stx-sen-
sitive Vero-cells (originating from the African green 
monkey); this could be the mechanism of release 
in our endothelial cells (153). Application of shear 
with effects on glomerular permeability (72). 
Another unanswered question is why specifi cally 
children are prone to develop HUS? The hypoth-
esis that paediatric renal endothelium would carry 
more Gb3-receptors proved not to be true (16). 
This indicates that other options need to be 
explored. Answers to the above formulated hypo-
theses, will direct the research in this fi eld. 
(208). The damaged ribosome will release a stress 
signal. When a subtoxic dose of Stx is applied, not 
every ribosome will be damaged, allowing transla-
tion of proteins. This mechanism will contribute to 
the pathogenesis of HUS. The proposed pathway is 
demonstrated in fi gure 1. 
  Figure 1 Intracellular traffi cking and effects of a 
subtoxic dose of Stx in the renal endothelium 
The fi lled arrows indicate a well-established tran-
sport-pathway or effect. The open arrow is hypo-
thetical. (G: Golgi-apparatus; ER: Endoplasmic Re-
ticulum; R: Ribosome; N: Nucleus; L: Lysosome)
One of the key question in the pathogenesis of HUS 
remains why specifi cally the renal endothelium is 
attacked. Possible explanations are: (a) the intracel-
lular traffi cking and sensitivity is specifi c in renal en-
dothelium compared to other endothelia dependent 
on the position of Gb3 in the outer cell membrane; 
(b) there is an decreased expression of membrane-
bound complement-regulatory proteins in renal 
endothelium resulting in an increased insertion of 
the membrane-attack complex thereby initiating 
the coagulation system; (c) an increased expression 
of HSPG compared to other endothelia resulting in 
more adhesion of leukocytes and infl ammation; (d) 
the presence of mesangial cells which release less 
NO after internalising Stx resulting in vasoconstric-
tion and thereby aggravating damage of the renal 
endothelium (209); (e) the presence of podocytes 
which release endothelin-1 after internalising Stx 
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with lepirudin, a thrombin-blocker, which improved 
the clinical outcome in a canine model of HUS (203).
Supportive care and prevention of further damage 
by optimising above described approaches remain 
the best possible options of treatment at this mo-
ment. 
  5.4 Treatment of infection-induced 
HUS
 Garg et al performed a systemic review describing 
a total of 49 studies including 3476 patients with 
infection-induced HUS (210). 12% died or devel-
oped end-stage renal disease and 25% of survivors 
demonstrated long-term renal sequelae. Especially 
the occurrence of central nervous system symp-
toms and need for initial dialysis is associated 
with a worse long-term prognosis. A better treat-
ment is still needed. Since Stx is the leading ele-
ment in damaging the kidney, attempts have to be 
made to capture it before it reaches its goal. Differ-
ent agents have been developed to bind and inacti-
vate Stx. The fi rst agent which was tested double-
blind, randomized and placebo-controlled in children 
with infection-induced HUS was a synthetic Stx-
binder, called Synsorb-Pk (211). Unfortunately, this 
product did not show any signifi cant improvement 
in the course of disease. The administration was 
probably too late and could not infl uence the course 
of the disease. Another possibility is the use of Stx-
binding enteral bacteria. Pinyon et al engineered a 
recombinant bacterium based on a non-pathogenic 
Escherichia coli  strain which successfully binds Stx 
and protects mice from lethal doses of Escherichia 
coli  O157:H7 (212). But again, these bacteria have to 
be given very early to prevent renal damage. Until 
now, different synthetic compounds with greater af-
fi nity for Stx have been developed. Human studies 
have to be awaited. Recently, Gu et al reported that 
heparin was able to block the adhesion of Escheri-
chia coli O157:H7 to human colonic epithelial cells by 
blocking binding of the bacteria to immobilized epi-
thelial beta-1 integrins (213). If this will result in ther-
apeutic options, needs to be further investigated. 
Another interesting option to bind Stx is the use of 
monoclonal antibodies. Mukherjee et al developed 
human monoclonal antibodies which prevented Stx-
cytotoxicity in both Stx-sensitive mice and piglets 
(214). Phase 1 trials in humans are being performed. 
The most important problem in these therapeu-
tic options is the amount of renal damage already 
present at the moment of presentation. Initiated 
damage can not be restored, although progression 
of damage can be possibly prevented. 
Raife et al described the possibility of prevention 
screened for mutations in the complement control 
proteins. 
The best therapeutic options in this type of HUS 
would be to add the recombinant form of the protein 
to patients with mutations. Since patients with HF1 
is the largest and therefore most interesting group 
for the pharmaceutical industry, recombinant HF1 
is being prepared for therapeutic treatment. This is 
not the case for recombinant IF. In these patients, 
plasmapheresis is the preferred therapeutic option. 
This will lead to an addition of intact IF, preventing 
the occurrence of HUS.
 5.5 HUS caused by disorders of  
 complement regulation
 The obtained insight in the pathogenesis of this 
specific form of HUS is enormous. Specific muta-
tions have been described in complement regula-
tory proteins like HF1, IF, MCP and BF. Most of the 
mutations result in a loss of function, but the lat-
ter being a gain-of-function mutation. To carry a 
mutation in these proteins does not always result 
in developing HUS. Like in chapter 4.1, a mutation 
in Factor I predisposed the patient to develop HUS 
whereas his healthy father and sisters also carry the 
mutation. This chapter also described that a normal 
level of the protein cannot exclude the involvement 
of this protein. Kavanagh et al demonstrated that 
the mutation described in chapter 4.1 results in a 
secreted protein that lack C3b and C4b cofactor ac-
tivity (215).
Recently, Pickering et al developed the first mouse 
model of non-Stx HUS (216). This model provided 
the knowledge that heterozygous mutations in HF1 
resulting in an effective plasma C3 regulation com-
bined with a defective regulation on the renal en-
dothelium, will lead to a spontaneous development 
of HUS. If there is a complete deficiency of HF1, 
membranoproliferative glomerulonephritis type II 
will occur.
Until now, in around 50% of patients with non-Stx 
HUS, the genetic cause of the disease is still un-
known. This stimulates investigators to find other 
possible involved complement proteins. Also, com-
binations of polymorphisms need to be considered.
The knowledge of which complement protein is in-
volved is important for optimising the treatment 
of patients with non-Stx HUS. Since complement 
factors are membrane-bound or circulating, this 
can predict whether kidney transplantation can be 
successful. Patients with mutations in membrane-
bound proteins like MCP can be transplanted. How-
ever, circulating mutated complement proteins tend 
to initiate a relapse after transplantation. Combined 
liver and renal transplantation is a possibility, but 
remains controversial (217). Live-related donations 
should not take place until the underlying defect 
in the patient and occurrence in the donor is ex-
amined. Also patients, who develop a first occur-
rence of HUS after renal transplantation, should be 
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this chapter explains how after promising first re-
sults, it was concluded that also the monocyte is 
not capable of transport. After a necessary change 
of temperature after binding Stx to monocytes and 
before incubation with the target cells, the toxin 
became released. This indicates how careful data 
from in vitro experiments performed below body 
temperature needs to be interpretated. When ex-
periments were performed without any change of 
temperature, no transfer of Stx from monocytes to 
target cells could be detected
In chapter 3 the effect of Stx on endothelial cells 
was evaluated. Next to cytotoxicity at a high dose, a 
subtoxic dose of the toxin proved to have a stimula-
ting effect. 
In chapter 3.1 the intracellular pathway of Stx in 
primary glomerular endothelial and mesangial cells 
are evaluated. This missing knowledge is important 
for interpretation of the effect of Stx on its main tar-
get, the kidney. After internalising, the toxin follows 
the retrograde pathway in both cell types. This en-
ables the toxin to reach and damage the ribosome. 
Incubation with TNF-α upregulated the receptor for 
the toxin (Gb3), thereby increasing the quantity of 
transported toxin. Not the transport pathway itself 
changed. 
Chapter 3.2 describes the effect of Stx on WPbs. 
These endothelium-specific storage vesicles con-
tain many important proteins for inflammation 
(IL-8) and coagulation (VWF). These evidently play 
a role in the pathogenesis of HUS. To approach the 
in vivo situation, shear stress was applied to the en-
dothelial cells. When GMVEC was exposed to Stx in 
flow conditions, exocytosis of WPbs could be de-
tected with confocal microscopy. Since GMVEC is 
the primary target for Stx, this could contribute to 
the pathogenesis of HUS.
In chapter 3.3 the effect of Stx on the adhesion of 
leukocytes to the endothelium was evaluated. It was 
already described that Stx increased the amount of 
adherent leukocytes, but the role of HSPG in this 
process was yet unknown. When HSPG was cleaved 
from the endothelial cells after incubation with Stx, 
a decrease of adhering leukocytes was detected. An 
increase of chemokines attached to HSPG is an ac-
ceptable hypothesis.
In chapter 3.4 the apparent stimulating effect of 
Stx on endothelial cells was explored. An increase 
 Summary
 English
 HUS consists of haemolytic anaemia, thrombo-
cytopenia and acute renal failure. There are many 
different forms of which infection-induced and dis-
orders of complement regulation are the most fre-
quent diagnosed ones. 
The purpose of this thesis was to identify new in-
gredients in the pathogenesis of HUS. Until now, the 
disease mechanism of HUS is a secret recipe. A bet-
ter understanding of the underlying mechanism of 
disease can lead to improved treatment strategies.  
Chapter 1 is an introduction to the experimental 
work of this thesis, with a general overview of cur-
rent knowledge on HUS. The most recent knowledge 
on the two above mentioned forms of HUS will be 
presented. Concerning infection-induced HUS, the 
knowledge on the journey of Stx including passage 
from the intestinal tract into the circulation and its 
passage to the renal endothelium will be presented. 
Disorders of complement regulation can also cause 
HUS; the involved proteins and their mutations are 
also described in chapter 1. 
Chapter 2 presents the work on the transport of Stx 
in the circulation. For many years now, researchers 
are longing to find a specific transporter to explain 
how Stx is specifically targeted to the renal endothe-
lium. In chapter 2.1, the PMN as a possible carrier 
was evaluated. Although former experiments de-
monstrated that PMN could be the transporter for 
Stx in patients with HUS, new experiments resulted 
in the opposite. The possible interaction was stud-
ied with different techniques. It was not possible to 
bind Stx to human PMN in vitro or to PMN originat-
ing from mice in vivo. The binding of Stx-antibodies 
to PMN appeared to lack specificity. PMN from pa-
tients after haemodialysis were able to bind the an-
tibodies. This could indicate that the antibody also 
binds to a specific structure on membranes of acti-
vated PMN. Using these antibodies for a diagnostic 
purpose in HUS is not permitted. 
Chapter 2.2 presents the experiments which inves-
tigated whether the monocyte could be the carrier 
for Stx in the circulation. Monocytes have a specific 
receptor for Stx and are not sensitive for its cyto-
toxic effect. Instead, they become activated and 
produce pro-inflammatory cytokines. The work in 
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aangetoond dat  er geen specifieke binding was van 
een Stx-antilichaam. Alhoewel er binding plaats-
vond van het antilichaam aan PMN van een patiënt 
met acute HUS, werd ook  binding gezien aan PMN 
van patiënten met hemodialyse. Dit betekent dat 
het antilichaam kan binden aan specifieke struc-
turen op het membraan van een geactiveerde PMN. 
Kortom, het detecteren van Stx op PMN met behulp 
van antilichamen is geen goede diagnostische test 
voor HUS.  
Hoofdstuk 2.2. presenteert experimenten waarin de 
monocyt als transporter voor Stx wordt bestudeerd. 
Monocyten hebben een specifieke receptor voor Stx 
en zijn niet gevoelig voor het cytotoxische effect. Ze 
raken zelfs geactiveerd en produceren vervolgens 
pro-inflammatoire cytokines. Dit hoofdstuk begint 
met veelbelovende data, maar uiteindelijk wordt 
geconcludeerd dat ook de monocyt niet in staat is 
om Stx te transporteren naar net nierendotheel. Na 
een benodigde temperatuurswisseling, liet het tox-
ine los van de monocyt. Dit betekent dat men altijd 
voorzichtig moet zijn om de data van experimenten 
uitgevoerd onder 37˚C te implementeren naar de 
humane situatie. Echter, wanneer de experimenten 
werden uitgevoerd zonder temperatuurswisseling, 
werd geen transfer van Stx vanaf de monocyten 
naar de doelwitcellen gezien. Maar, buiten kijf staat 
dat monocyten een belangrijke rol spelen in de 
pathogenese van HUS. 
In hoofdstuk 3 wordt het effect van Stx op en-
dotheelcelen geevalueerd. Naast cytotoxiciteit, kan 
een subtoxische dosis ook een stimulerend effect 
hebben. Na internalisatie van het toxine, wacht de 
endotheelcel niet passief totdat de eiwitsynthese 
wordt geblokkeerd. Echter, het doet een poging om 
zichzelf te beschermen tegen ernstige schade. 
Hoofdstuk 3.1 toont de intracellulaire route van Stx 
in primaire glomerulaire endotheliale en mesangiale 
cellen. Deze ontbrekende kennis is belangrijk voor 
de interpretatie van het effect van het toxine op zijn 
belangrijkste doel, de nier. Na internalisatie van het 
toxine, volgt het de retrograde route. Dit stelt het 
toxine in staat om het cytoplasma en dus de ribo-
soom te bereiken. Pre-incubatie met TNF-α, wat de 
gevoeligheid van beide celtypes voor Stx vergroot, 
verhoogde de kwantiteit van getransporteerd tox-
ine door een toename van Gb3-receptoren en niet 
door een aanpassing van de route. Bovendien, was 
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 De naam HUS omvat een complexe multi-fac- 
toriele aandoening. Het bestaat uit hemolytische 
anemie, thrombocytopenie en acuut nierfalen. Er 
zijn verschillende vormen van HUS beschreven, 
waarvan infectie-gerelateerd en stoornissen in de 
complement-regulatie de oorzaken zijn die het 
meest frequent worden gediagnosticeerd. 
Het doel van dit proefschrift was om nieuwe in-
grediënten in de pathogenese van HUS te identifi-
ceren. Tot op de dag van vandaag is het exacte ziek-
temechanisme een geheim recept. Een beter begrip 
van het ontstaan van HUS kan leiden tot nieuwe 
behandelingsstrategieën. Vooral voor de infectie-
gerelateerde HUS is dit belangrijk, omdat slechts 
ondersteunende behandeling kan worden gegeven. 
De oorzaak wordt nog steeds niet aangepakt. 
Hoofdstuk 1 is een inleiding op het experimentele 
werk van dit proefschrift. Het is een algemeen over-
zicht van de huidige kennis over HUS. De nieuwste 
inzichten zullen worden beschreven. Wat betreft de 
infectie-gerelateerde HUS wordt de route van Stx 
van de darm via de circulatie naar het nierendotheel 
uitvoerig beschreven. Recent zijn nieuwe inzichten 
verworven in de kennis over het transport van Stx 
over de darm. Het transport van Stx in de circulatie 
is nog steeds onduidelijk en zal worden behandeld 
in dit proefschrift. Tevens zal de huidige kennis over 
de intracellulaire route worden beschreven. Dit leidt 
tot een beter begrip van de gevoeligheid van de cel 
voor Stx en de celbiologische aspecten. Wat betreft 
de HUS door stoornissen in complement-regulatie, 
zullen de betrokken eiwitten en de bekende muta-
ties worden beschreven.
Hoofdstuk 2 omvat het experimentele werk over 
transport van Stx in de circulatie. Al gedurende 
lange tijd zijn onderzoekers op zoek naar een speci-
fieke transporter van Stx. Dit om te begrijpen hoe 
Stx specifiek naar het nierendotheel wordt ge-
transporteerd. In hoofdstuk 2.1 wordt geëvalueerd 
of de PMN een mogelijke transporter voor Stx is. 
Alhoewel eerdere experimenten aantoonden dat 
PMN in staat waren om Stx te transporteren, toon-
den de nieuwe experimenten dit niet aan. Er werd 
geen binding gevonden tussen Stx en humane PMN 
in vitro of PMN van muizen in vivo. Bovendien werd 
in mRNA of ICAM-1 and IL-8 could be detected. How-
ever, translation of this mRNA occurred very ineffi-
ciently. Small amounts of protein could be detected 
only after 72 hours. A subtoxic dose of Stx is able 
to both activate the cell and inhibit the translation 
process of new proteins.  
Chapter 4.1 demonstrates a novel heterozygous mu-
tation in IF in a patient with non-Stx HUS. Although, 
the serum level of IF was normal, a mild functional 
defect could be detected. Interestingly, two siblings 
and the father also carried the mutation, but did not 
experience any clinical problems. This indicates that 
the defect forces a predisposition.
HUS consists  
of haemolytic 
anemia throm-
bocytopenia  
and acute renal  
failure.
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nemen dat zowel de vader als de twee zussen ook 
drager zijn van de mutatie, zonder kliniek hiervan. 
Dit impliceert dat ook deze vorm van HUS multifac-
torieel is. 
TNF-α niet in staat om de positie van Gb3 in het 
celmembraan te veranderen. Er was geen toename 
van Gb3 in de DRM, wat zou resulteren in een sterk-
ere toxiciteit. 
Hoofdstuk 3.2 beschrijft het effect van Stx op 
WPbs. Deze endotheel-specifieke opslagvesikels be-
vatten belangrijke componenten voor inflammatie 
(IL-8) en coagulatie (VWF). Deze eiwitten spelen 
een evidente rol in de pathogenese van HUS. Om de 
in vivo situatie zo goed als mogelijk te benaderen, 
werd ‘shear stress’ toegepast aan de endotheel cel-
len. Wanneer GMVEC werd blootgesteld aan Stx ‘in 
flow’, kon exocytose van de WPb worden gedetect-
eerd met behulp van confocale microscopie. HUVEC 
reageerde niet ‘in flow’, maar toonde een klein ef-
fect in statische condities. Aangezien GMVEC het 
primaire doel is voor Stx, kan dit effect een bijdrage 
leveren aan de pathogenese van HUS.
In hoofdstuk 3.3  werd het effect van Stx op de ad-
hesie van leukocyten aan endotheel bestudeerd. 
Het was reeds bekend dat Stx in staat was om de 
adhesie van leukocyten aan het endotheel te doen 
toenemen. Dit effect werd toegeschreven aan toe-
name van cytokines. Echter, de rol van HSPG in dit 
proces was niet bekend. Wanneer HSPG werd ver-
wijderd van endotheelcellen na incubatie met Stx, 
werd een afname van het aantal adhererende leu-
kocyten gezien. Dit kan twee verschillende mecha-
nismes hebben: een toename in de expressie van 
HSPG of een toename in chemokines gebonden aan 
de HSPG. Deze laatste mogelijkheid is het meest 
waarschijnlijk. 
In hoofdstuk 3.4 wordt het stimulerende effect van 
Stx op endotheelcellen nader onder de loep genom-
en. Een toename van mRNA van ICAM-1 en IL-8 kon 
worden gemeten. Echter, de translatie van dit mRNA 
vond zeer inefficiënt plaats. Slechts kleine hoeveel-
heden eiwit konden worden gemeten na meer dan 
48 uur incubatie. Dit suggereert dat naast het cyto-
toxische effect van het toxine, een subtoxische dosis 
in staat is om de cel te activeren. Het is nog niet du-
idelijk wanneer tijdens het intracellulaire transport 
dit plaats vindt. Dit behoeft verder onderzoek. 
Hoofdstuk 4.1 beschrijft een nieuwe heterozygote 
mutatie in IF in een patiënt met non-Stx HUS. Al-
hoewel de waarde in het serum als normaal werd 
beschouwd, kon een mild functioneel defect worden 
gedetecteerd. Het is interessant om in achting te 
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Nadat de bacterie is verankerd aan de darm kan het 
een toxine (=gifstof) gaan produceren. Deze wordt 
door de bacterie uitgescheiden en komt in het bloed 
terecht. Vanaf hier wordt het specifiek vervoerd 
naar de nier. Cellen in de bloedvaten van de nier 
zijn extra gevoelig voor dit toxine en gaan dood. 
Hierdoor ontstaat stolling in de nier en een mas-
sale ontstekingsreactie. Dit leidt ertoe dat de nier 
niet meer functioneert en hierdoor afvalstoffen niet 
meer uitgescheiden kunnen worden. Dit heet acuut 
nierfalen en behoeft snel handelen door middel van 
nierdialyse. 
Zo omschreven lijkt het een duidelijk mechanisme, 
maar er zijn nog steeds veel vragen niet opgelost. 
In dit proefschift wordt ondermeer gekeken hoe het 
toxine zich kan verplaatsen in het bloed. Nog nooit 
is het toxine gevonden in het bloed van mensen met 
HUS. Hieruit kan geconcludeerd worden dat het er-
gens aan moet binden. Twee verschillende bloedcel-
types zijn bestudeerd op een mogelijke functie als 
transporter. Ten eerste werd de neutrofiel bekeken. 
Dit is een witte bloedcel en betrokken bij de afweer. 
Deze cel bleek echter niet in staat om het toxine te 
binden en was ook niet gevoelig voor het effect van 
het toxine. Alle experimenten werden buiten het 
lichaam op gekweekte cellen (=in vitro) uitgevoerd. 
Hierbij moet dan altijd worden afgevraagd of dat 
betrouwbaar is om te vergelijken met de situatie in 
het lichaam (=in vivo). Omdat het niet verantwoord 
is om het toxine aan mensen te geven, werd het 
geïnjecteerd bij muizen. Maar ook bij deze experi-
menten konden we het toxine niet terugvinden aan 
de neutrofiel.
Een ander type witte bloedcel is de monocyt. Deze 
cel is wel in staat om het toxine te binden. Het is 
verder interessant om te vermelden dat deze cel 
niet doodgaat door het toxine, maar zelfs wordt ge-
activeerd. Maar ook deze cel bleek na meerdere ex-
perimenten niet geschikt om het toxine in het bloed 
te transporteren. De zoektocht naar deze vraag zal 
dus moeten worden gecontinueerd. Bovendien zit-
ten er in het bloed naast bloedcellen ook allerlei ei-
witten die een poging tot bestuderen waard zijn.
Een ander onderdeel van dit proefschrift beschrijft 
het exacte effect van het toxine op de gevoelige 
vaatwandcellen. Ook deze cellen zijn net als de mo- 
nocyt, in staat om het toxine te binden en  op te ne- 
men. In dit proefschrift beschrijven we de exacte 
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 Het hemolytisch-uremisch syndroom (HUS) is een 
nieraandoening welke vooral op jonge leeftijd kan 
ontstaan. Het heeft verschillende oorzaken zoals 
het doormaken van een infectie met een specifieke 
bacterie of ten gevolge van een aangeboren defect 
in het afweersysteem. De verschillende vormen 
geven wel dezelfde kenmerken: (1) een tekort aan 
rode bloedcellen door beschadiging, (2) een tekort 
aan bloedplaatjes en (3) plotseling optredende uit-
val van de nieren. Het is echter niet geheel duidelijk 
hoe deze aandoening nu ontstaat en daardoor is 
een goede behandeling niet mogelijk. Alleen de con-
sequenties van HUS kunnen nu worden bestreden 
door middel van bijvoorbeeld transfusies van bloed-
producten, nierdialyse en in ernstige gevallen een 
niertransplantatie. Om dit te kunnen verbeteren en 
de ziekte directer aan te kunnen pakken voordat 
de nier wordt beschadigt, moet meer onderzoek 
worden gedaan naar het exacte mechanisme van 
ontstaan. Omdat dit nog steeds niet duidelijk is, 
kan het ziektemechanisme worden gezien als een 
‘secret recipe’. In dit proefschrift wordt daarom ge-
zocht naar nieuwe ingrediënten van het geheime 
recept van HUS.
 Infectie-gerelateerde HUS
HUS wordt vaak veroorzaakt door een bacterie, 
genaamd Escherichia coli O157:H7. Deze bacterie 
komt voor in het darmstelsel van vee, zoals koeien 
en schapen. Deze dieren hebben er geen last van, 
maar kunnen de bacterie uitscheiden in hun ontlast-
ing. Op deze wijze komt het bij de mens terecht: via 
besmetting van vlees in het slachthuis, via biologis-
che voedingsmiddelen of via slechte handenhygiëne 
na bezoek aan dieren. Het meest voorkomend is be-
smetting via niet goed-doorbakken gehakt. Daarom 
wordt het ook wel de ‘hamburger-ziekte’ genoemd. 
De bacterie komt dus via voedsel in de darm van 
de mens en bindt hier aan de darm wand. Hiervoor 
gebruikt het een ingenieus mechanisme, waarbij 
het een eigengemaakt anker in de cel plaatst. Dit 
geeft een ontsteking van de darm waardoor diarree 
ontstaat. Deze kan bloederig zijn. Dat is een alarm-
signaal waarbij altijd contact moet worden gezocht 
met een arts! 
Dit suggereert 
dat naast het  
cytotoxische  
effect van het 
toxine, een sub-
toxische dosis in 
staat is om de cel 
te activeren.
Samenvatting niet-medici
143142
  HUS door aangeboren defecten van het  
immuunsysteem
 Het immuunsysteem van de mens is een zeer 
complex geheel. Een deel ervan is aangeboren en de 
rest moet worden gevormd gedurende het leven ten 
gevolge van het doormaken van verschillende infec-
ties. Een onderdeel van het aangeboren systeem is 
het complementsysteem. Dit is een cascade van ei-
witten die worden geactiveerd als een bacterie het 
lichaam binnendringt. Het complementsysteem is in 
staat om deze te doden door het maken van een 
gat in de wand van de bacterie. Het complementsys-
teem heeft een nauwe regulatie om te voorkomen 
dat het eigen lichaam wordt beschadigd. Deze regu-
latie bestaat uit eiwitten die gebonden zitten aan 
vaatwandcellen of circuleren in het bloed. Wanneer 
het systeem geactiveerd wordt door een bacterie 
en zich per ongeluk bindt aan een vaatwandcel, zijn 
deze regulerende eiwitten in staat om het fatale 
vervolg te stoppen. Echter, wanneer deze eiwitten 
niet goed functioneren, ontstaat er een beschadig-
ing aan de vaatwandcellen specifiek in de nier. Dit 
leidt vervolgens tot het ontstaan van HUS. 
Deze inzichten in het ontstaan van deze erfelijke 
vorm van HUS zijn zeer recent. In verschillende 
regulerende eiwitten van het complementsysteem 
zijn defecten gevonden. In dit proefschrift staat een 
nieuwe defect beschreven bij een patiënt met HUS, 
wat recidiveerde in zijn transplantatienier. Er bleek 
wel voldoende eiwit aanwezig te zijn, maar deze 
functioneerde niet naar behoren. 
Door deze nieuwe inzichten is men nu in staat om te 
behandeling te optimaliseren. Er kan worden voor-
speld op basis van het aangedane eiwit of er kans is 
van slagen van een niertransplantatie. Ook kunnen 
de defecte eiwitten in goede vorm worden toege-
diend aan de patiënt.
 Figuur 1 Het ontstaansmechanisme van HUS route van het toxine in cellen van de humane nier. 
Deze route heeft tot gevolg dat het toxine een 
specifieke celstructuur, namelijk de ribosoom, kan 
beschadigen. Hierdoor gaat de cel dood. Maar waar 
eerst werd gedacht dat dit het enige effect van het 
toxine was, is door onze experimenten gebleken dat 
ook nog andere mechanismes plaatsvinden. Als het 
toxine binnendringt in de cel, is er een snelle re-
spons door het uitscheiden van opslagblaasjes (ge-
naamd Weibel-Palade bodies). Deze zijn gevuld met 
belangrijke stoffen die eerste hulp kunnen verlenen 
aan de cel door middel van het aantrekken van ont-
stekingscellen en het reguleren van stolling. Voor 
het aantrekken van de ontstekingscellen spelen de 
heparan sulfaat proteoglycanen (HSPG) een belan-
grijke rol. Dit zijn varen-achtige structuren die aan 
de buitenkant van de vaatwandcellen zitten. Wan-
neer HSPG worden verwijderd van de vaatwand-
cellen, zijn minder witte bloedcellen in staat om te 
binden. Dit betekent dat deze celstructuren een rol 
spelen in het ziektemechanisme.
Bovendien wordt de cel door het toxine geactiveerd 
tot het produceren van eiwitten die betrokken zijn 
bij de ontsteking en de stolling. Maar door de gelijk-
tijdige beschadiging van de cel, is het erg moeilijk 
voor de cel om ze daadwerkelijk te maken. Bij een 
hoge dosis van het toxine gaan de cellen dood. Bij 
een lage dosis toxine, zullen na lange tijd deze eiwit-
ten geproduceerd kunnen worden.
Bovenstaande bevindingen geven een nieuwe im-
puls aan de inzichten in HUS. Onze bevindingen van 
dit proefschrift staan samengevat in figuur 1. Deze 
gegevens zullen moeten worden vertaald in een 
betere behandeling.
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